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ABSTRACT 
Yi-hsuan Tsai: Transcriptome-wide study of alternative splicing across multiple cancer types 
(Under the direction of Zefeng Wang and Shawn M. Gomez) 
 Alternative splicing (AS) is a very important cellular process in eukaryote, which 
contribute to both the proteome diversity and control of gene expression levels. It is tightly 
regulated in different tissues and developmental stages and dysregulation of splicing can lead 
to many human diseases. Cancer is one of the extreme examples where splicing is highly 
altered. However the underline mechanism responsible for such dysregulation is largely 
unclear. Moreover, identification of cancer specific AS events is complicated by the large 
noise of different tissues-specific splicing. In the chapters that follow, we first explore the 
evolution and functionality of RNA binding proteins which is one of the key regulators of 
AS. We then use the RNA-seq data from TCGA (The Cancer Genome Atlas) to identify AS 
events that are significantly altered between tumor and normal samples across multiple 
cancer types. We also show that these cancer-specific AS events are highly conserved, more 
likely to maintain protein reading frame, and mainly function in cell cycle, cell 
adhesion/migration, and insulin signaling pathway. Furthermore, these events can serve as 
new molecular biomarkers to distinguish cancer from normal tissues, to separate cancer 
subtypes, and to predict patient survival. We also demonstrate that most genes whose 
expression is closely associated with cancer-specific splicing are key regulators of the cell 
cycle. Our study uncovers a common set of cancer-specific AS events altered across multiple 
cancers, providing mechanistic insight into how splicing is mis-regulated in cancers. Lastly 
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we show that kidney tumors harbor significantly higher intron retention than other tumor 
types and such increase of splicing alteration in kidney cancer is highly correlated with 
patient survival. Together our works have helped to better understand AS across multiple 
human cancers and how it might be regulated and its connection to some important cancer 
pathways.  
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CHAPTER 1  
 
INTRODUCTION 
With the very first draft of the human genome announced in 2000 [1, 2], and the 
following full completion in 2003, people have once believed that the human genetic blueprint, 
such a big progress in biology, will bring us to the next era of medicine. Decoding of the human 
genomic sequences indeed took us to the next level of biological research. Hypothesis-driven 
science has been largely replaced by discovery-driven research because of the large amount of 
data. However, this is just the beginning of post-genomic revolution. Although we have all the 
sequence code for building a human being, there are still lots of unknown. What regions are 
coded for functional genes, what sequences contain regulatory elements and what else are just 
merely random noises. Genome annotation has progressed very slowly after the completion of 
human genome. After more than a decade, people are still debating about what percentage of the 
human genome is actually doing something important. To our surprise, only less than 2 percent 
of the human genome contains protein-coding sequences. Even when counting the regulatory 
sequences, the fraction of functional DNA is estimated less than 10-20% [3, 4]. 
Although deciphering the human genome wasn’t as easy as we originally thought, many 
big advances in medical fields have been made. Predictive genetic tests for many human diseases 
are available now and personalized medicine is also on its way for future cancer therapy. All 
these would have not been possible without the first map of human genome.  
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1.1 Next-generation sequencing and RNA-seq  
The next revolution occurred when the ‘second-generation’ (or next-generation) 
sequencing was developed. The new high-throughput sequencing technology allows us to 
sequence DNA/RNA much more quickly and with much lower cost. According to National 
Human Genome Research Institute’s report, the cost of sequencing a genome was more than 
10M in early 2000 and it has dropped to below 10K in around 2011 [5]. Such a dramatically drop 
in price has outpaced Moore’s law since early 2008 when the next-generation sequencing 
technology took the place of the Sanger-based sequencing [5]. Because of the low cost, sequence 
data has been generated in a way that we cannot imagine and cannot finish analyzing them in 
time. Large consortium, such as ENCODE [6], 1000 genomes [7], and TCGA [8] all have 
accumulated large amount of data, and most of the data are public accessible. Even though some 
of these sequence data have been released for a while, we can still see new publications using the 
data every month. There are still a lot of treasures within these sequencing data waiting for us to 
discover.  
 The new technology has also made ‘RNA-seq’ (RNA sequencing) possible. The concept 
of RNA-seq is very simple. Short read sequences (typically about 25-50 nucleotides long) are 
obtained from random locations along RNA by either sequencing sheared double-stranded 
cDNA libraries (strandless RNA-seq) or sequencing directional cDNA libraries (stranded RNA-
seq) [9]. After hundreds of millions of short sequences have been generated, they are then 
mapped back to a reference genome allowing gaps between exon-exon junctions using 
bioinformatics algorithms. RNA-seq can be used to study the dynamic of eukaryotic 
transcriptomes, make it possible to redefine the transcriptome content in different cell types, 
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different tissues and different developmental stages, not only qualitatively but also 
quantitatively. 
 
1.2 Alternative splicing and its regulation  
Since human transcriptome has been deeply sequenced, it’s been shown that more than 
90% of human genes undergo alternative splicing (AS) process to produce more than one 
splicing isoforms containing different combinations of exons [10, 11]. This important cellular 
process can control the expression level of genes and contribute to the diversity of proteome. 
Through AS, same gene can have protein isoforms with totally different functions. For example, 
the Fas receptor gene has one soluble and one membrane-bound isoforms with opposing effects 
on apoptosis [12]. Another example is the Drosophila fruitless (fru) gene, which is spliced 
differently in males and females to control its sexual orientation [13]. Splicing process is also 
tightly regulated in different tissues and developmental stages [10, 11], and dysregulation of AS 
is closely associated with various human diseases [14, 15]. 
The specificity of splicing is mainly determined by the core splicing signals including the 
5’ or 3’ splice site (i.e. 5’ss or 3’ss) at each end of an intron and the branch point sequence (BPS) 
at the upstream of 3’ss. However, the core splice site motifs contain only about half of the 
information required to precisely define exon/intron boundaries [16]. In addition to these core 
splicing signals, splicing is regulated by multiple splicing regulatory elements (SREs) that 
specifically recruit trans-acting splicing factors to activate or repress the use of adjacent splice 
sites [17]. There are four types of SRE, two in the exonic region: exonic splicing enhancers 
(ESEs) or silencers (ESSs) that function to promote or inhibit inclusion of the exon they reside 
in, and two in the intronic region: intronic splicing enhancers (ISEs) or silencers (ISSs) that 
  
 
4 
  
 
enhance or inhibit usage of adjacent splice sites or exons (Figure. 1.1) [18]. It is known that the 
activities of SREs may depend on the relative locations of the elements in pre-mRNAs, e.g. G-
triplets could act as an ISE when it’s located in intronic locations, but also function as an ESS 
when located in exons [19]. This is commonly known as “context dependence” of SREs. Same 
effects also apply to splicing factors: the same splicing factor may either activate or inhibit 
splicing by binding to its cognate SREs in different pre-mRNA regions [18, 20, 21]. More details 
of splicing regulation can be found in some recent reviews [17, 22-25]. 
 
1.3 RNA binding proteins and its role in splicing regulation 
Many RNA-binding proteins (RBPs) facilitate splicesome assembly on pre-mRNA 
during splicing process. In addition to RNA splicing, specific interactions between RBPs and 
RNAs also play essential roles in many other mRNA metabolism, including RNA editing, 
translocation, and degradation [26]. Altering the expression of RBPs can have dramatic impact 
on in various RNA-related cellular functions, and aberrant RBP function can also lead to a wide 
range of human diseases including cancer [27] and neurodegenerative diseases [28, 29].  
The sequence-specific interaction of RBPs and RNAs are mediated through various RNA 
binding domains that contains 60-100 amino acids with α-helix and β-strand topology, including 
RNA Recognition Motif (RRM), K homology (KH) domain, Piwi/Argonaute/Zwille (PAZ) 
domain, and etc. With recent advances in RNA biology, many proteins have been identified that 
interacts with RNAs and at least more than 40 RNA biding domains (RBDs) have been 
categorized [30]. Among them, RRM is the most frequent domains presented in >50% of RBPs 
[31]. In addition, many RBPs contain more than one RBD, and it is unclear how each RBD 
contributes to the binding specificity of the RBPs with multiple RBD and whether all RBDs are 
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required for target binding. Previous study has shown that multicellular organisms have more 
RBPs than single cell organisms and the number of RBD within a RBP has expanded 
significantly in mammal as well [32]. However, the mechanism by which the number of RBPs 
and RBDs increase during evolution and the functional implication of such expansion remain 
unclear. 
One of the most important cellular process RBPs regulate is AS which is the main subject 
of this study. Some RBPs that regulate splicing have been identified, however, many of them 
have different functions when binding to different sequence targets [18, 23], which makes the 
splicing regulation more complicated. For example, the CUGBP2 splicing factor can promote the 
inclusion of cTNT exon 5 via biding to its downstream intron region, while in the brain, it can 
silence the N1 exon of the NMDA R1 receptor through binding to its upstream intron region [33, 
34]. Some of the splicing regulation proteins can compete with each other for the binding sites. 
For example, in HIV tat exon 3, both hnRNPA1 and SF2 can bind to the exon to inhibit or to 
enhance the splicing respectively [35]. A1 binds to an ESS to repress the splicing but the SF2 can 
also bind to the ESEs located in the same exon to promote the splicing. When SF2 presents, it 
blocks the A1 repression and allow the exon inclusion. Another example is the regulation of 
exon 11 of the insulin receptor gene, where hnRNP F and SRSF1 compete with the hnRNP A1 
for the binding site to promote or inhibit exon 11 inclusion [36]. Some of the splicing regulation 
proteins are dosage depend. For example, the relative ratio of A1 to ASF/SF2 can regulate 
splicing patterns differently [37] [38]. 
Although it’s believed that many more proteins can regulate RNA splicing, the four 
major groups of known splicing regulators are: the heterogeneous nuclear riboncleoprotein 
(hnRNP), serine-argine (SR) proteins, embryonic lethal, abnormal vision (ELAV)-like proteins 
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and CUG-BP and ETR-like factor (CELF) proteins [39]. Review of these proteins can be found 
in [40-43]. 
 
1.4 Splicing in cancers 
The mis-regulation of splicing is a common cause of various human diseases including 
cancer. Hundreds of genes are mis-spliced in a typical cancer cell, and many cancer-specific 
splicing isoforms play key roles in pathogenesis and growth of tumors. For example, in 
glioblastoma, a tumor-specific α-exon skipping isoform, FDFR1β is overexpressed in the tumor 
cells and the overexpression is regulated by the increase in expression of a splicing inhibitory, 
PTB (hnRNPI) [44]. As one of the molecular hallmarks of human cancer, the splicing mis-
regulation is thought to be controlled by the changes of expression levels and/or activity of 
certain splicing factors. Several splicing factors, including SRSF1 and hnRNP A2, were found to 
act as a proto-oncogene to induce malignant transformation of normal cells [45-47], while other 
splicing factors, such as RBM5 [48] and RBM4 [49], can serve as tumor suppressor genes to 
inhibit cancer growth. Therefore the relationship between splicing factors and the cancer-specific 
splicing profile is a very important research subject. 
Another mis-regulation of cancer splicing pathway is through the cis-acting SREs. Since 
AS regulation is through the sequence-specific interaction of splicing factors and its binding 
targets, mutations of the cis-elements can disrupt such specific interaction and lead to splicing 
mis-regulation. For example a missense mutation in BRCA1 gene increase the binding affinity of 
splicing repressors, hnRNP A1 and hnRNP H/F, which can increase exon skipping in breast 
cancer [50].  
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It has been shown that the changes of alternative splicing can be used as a powerful 
biomarker to diagnose cancer or to predict the response to therapy [51, 52]. In the past, several 
studies were designed to perturb each splicing factor and further determine how an individual 
splicing factor affected splicing of specific genes or entire transcriptome. However the TCGA 
consortium presented a unique dataset that mimic the perturbance of various splicing factors at 
same time in a large number of clinical samples. Therefore we can study the splicing regulation 
in cancer by measuring the correlation of splicing changes with levels of all known and putative 
splicing factors across all samples. Through investigating the correlation between splicing and 
gene expression, we aim to identify key splicing factors that responsible for the splicing mis-
regulation in cancers. Furthermore, these findings can provide novel anti-cancer therapeutic 
targets based on the cancer specific RNA-RBP interactions. 
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Figure 1.1 Schematic diagram of splicing regulation. 
Open boxes represent exons and jagged lines are introns. The brackets represent splice sites. The 
adenosine in branch point is also indicated. Splicing is regulated by trans-acting splicing factors 
(SR protein, hnRNP or unknown factors) that recognize cis-elements (classified as ESE, ESS, 
ISS and ISE). Figure adapted from [18]. 
 
 
  
  
 
9 
  
 
 
 
 
CHAPTER 2  
 
IDENTIFICATION OF PREVALENT RNA RECOGNITION MOTIF DUPLICATION IN 
THE HUMAN GENOME.1 
 
2.1 Overview 
The sequence-specific recognition of RNA by proteins is mediated through various RNA 
binding domains, with the RNA recognition motif (RRM) being the most frequent and present in 
>50% of RNA-binding proteins (RBPs). Many RBPs contain multiple RRMs, and it is unclear 
how each RRM contributes to the binding specificity of the entire protein. We found that RRMs 
within the same RBP (i.e., sibling RRMs) tend to have significantly higher similarity than 
expected by chance. Sibling RRM pairs from RBPs shared by multiple species tend to have 
lower similarity than those found only in a single species, suggesting that multiple RRMs within 
the same protein might arise from domain duplication followed by divergence through random 
mutations. This finding is exemplified by a recent RRM domain duplication in DAZ proteins and 
an ancient duplication in PABP proteins. Additionally, we found that different similarities 
between sibling RRMs are associated with distinct functions of an RBP and that the RBPs tend 
to contain repetitive sequences with low complexity. Taken together, this study suggests that the 
                                                
1 This chapter previously appeared as an article in the Journal of RNA. The original citation is as 
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number of RBPs with multiple RRMs has expanded in mammals and that the multiple sibling 
RRMs may recognize similar target motifs in a cooperative manner. 
 
2.2 Introduction 
Specific interactions between RNAs and proteins play an essential role in regulating 
mRNA processing, including RNA splicing, polyadenylation, translocation, and degradation 
[26]. Altering the level or activity of RNA-binding proteins (RBPs) has a dramatic impact on 
various RNA-related cellular functions, with aberrant RBP function leading to human diseases 
[27]. For example, many RBPs specifically recognize regulatory cis-elements in pre-mRNA and 
thereby inhibit or promote use of nearby splicing sites [17, 18]. The binding between these 
splicing factors and their RNA target is crucial to many cellular processes, as most human genes 
undergo alternative splicing to produce multiple isoforms with distinct functions. Therefore, 
examining the interactions between different RBPs and their RNA targets is an important 
component in understanding various gene regulation pathways. 
The sequence-specific interaction between RBPs and single-stranded RNAs is usually 
mediated through various RNA binding domains (RBDs) including the RNA recognition motif 
(RRM), the pentatricopeptide repeat (PPR), the K homology (KH), the zinc-finger, the 
Pumilio/FBF (PUF), and the cold-shock (CSD) domains [53]. Although protein sequence 
elements outside of the RBD may contact RNA and affect RNA binding [54, 55], the RBD is the 
key determinant of RNA binding specificity [56]. Among them, the RRM is the most abundant 
and present in over 50% of RBPs in humans [31]. A typical RRM contains 80–90 aa that fold 
into a β1α1β2β3α2β4 topology, where the four anti-parallel β-sheets and the two additional α 
helices create ample surface that interacts with RNA [31, 57]. The most conserved region of the 
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RRM consists of two short sites (6–8 aa) in β1 and β3 (named RNP-2 and RNP-1, respectively) 
that are crucial for RNA interaction [57-59]. However, recent structures of various RRMs bound 
by their cognate RNA show that RRMs may interact with RNA through diverse mechanisms [60-
62]. For example, hnRNP I (poly-pyrimidine tract binding protein or PTB) has four RRMs with 
similar specificities. The β3 of each RRM contributes only weakly to RNA binding, whereas the 
hydrophobic side chains in β2 are responsible for binding to RNA bases through hydrophobic 
interactions [60]. In other cases, like hnRNP F, interactions between the RNA target and the 
RRM were found mainly in the loop region rather than in the β-sheet of the RRM [63, 64]. 
RRMs usually recognize a short RNA element of 2–5 nt (nucleotide), and some RBPs 
contain multiple RRMs. The tandem RRMs in the same RBP can either bind to similar RNA 
sequences and function cooperatively [62, 64] or have very different RNA binding 
activities/specificities [65], or only one/some of the RRMs are functional while the others do not 
exhibit RNA binding [66]. Therefore, for RBPs with multiple RRMs, the general rules for how 
each RRM contributes to binding specificity are largely unclear. 
We conducted a detailed sequence analysis of the RRM-containing RBPs in humans and 
other organisms. Surprisingly, we found a strong trend indicating that RRMs within the same 
protein (hereafter referred to as “sibling RRMs”) have higher sequence similarity to each other 
than the RRM pairs from different proteins. In addition, sibling RRMs within the RBPs specific 
to a single species have higher similarity than those shared by multiple species. Together, these 
findings suggest that prevalent domain duplications of RRMs have occurred within many RBPs 
during evolution. This result is further illustrated by cases of both a recent and an ancient RRM 
duplication. In addition, we found that the RBPs with similar sibling RRMs are more likely to 
bind to the 3′ UTR than those proteins having more divergent sibling RRMs and that the RBP 
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sequence regions outside RRMs have a strong bias for low complexity and/or repetitive 
sequences. Altogether, these analyses reveal important implications regarding RBP evolution. 
 
2.3 Results 
 
2.3.1 Increased numbers of RBPs in mammals.  
The number of proteins with canonical RBDs has expanded significantly in mammals. In 
Table 2.1, we list the common RBDs and the number of proteins containing common RNA-
binding domains from five different organisms whose proteomes are thoroughly annotated. 
Humans have the most RBPs among all species examined, and there is a large expansion in the 
number of RBPs in mammals with the exception of PAZ domain-containing proteins. In 
addition, we found that the number of RRMs within a single RBP has increased in mammals 
compared to other low-complexity organisms when examining the RRM-containing RBPs across 
different species (Supplemental Figure S2.1). These observations lead to intriguing fundamental 
questions such as why do humans need so many RBPs and why is it that many RBPs contain 
multiple RBDs? One possible explanation could be that multiple RBDs allow RBPs to bind RNA 
with higher sequence specificity and/or affinity than those with a single binding domain. Another 
possible reason is that multiple domains may help RBPs to bind to longer RNA sequences. On 
average, a single RBD binds to 4–6 nt; thus, multiple RBDs may have provided some selective 
advantage for increased binding specificity and affinity and/or also facilitate binding to longer 
RNA targets. 
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2.3.2 Sibling RRMs are more similar to each other  
To study these questions, we analyzed RRM-containing RBPs at a proteome-wide scale 
across multiple species. We applied a series of filters to obtain unique human RBPs that have 
well-defined RRM domains and extracted the sequence of each RRM using the consensus 
annotation from three domain annotation databases (Figure 2.1A). This process was repeated for 
three other species (Mus musculus, Drosophila melanogaster, Caenorhabditis elegans), and both 
the species-specific and conserved RBPs were extracted by the same set of filters for further 
analyses (see Materials and Methods). After filtering for gene duplication and database 
redundancy, we extracted 453 unique RRMs from human RBPs. 
We aligned each of the 453 unique human RRMs to all others to calculate sequence 
similarity scores and plotted the mean score ± standard deviation (1 × SD) as vertical gray bars 
(Figure 2.1B), obtaining an average similarity score of ∼23. However, similarity scores between 
sibling RRMs appear to be skewed toward higher similarity (denoted by red circles in Figure 
2.1B), indicating that the sibling RRMs within the same RBPs have significantly higher 
sequence similarity to each other than what is expected by chance (P = 2.4 × 10−20 by 
Kolmogorov-Smirnov test, or P = 2.4 × 10−17 by t-test if assuming normal distribution) (Figure 
2.1B). In particular, among the 1186 sibling RRM pairs, 467 pairs (39.4%) had similarity scores 
higher than the mean plus 1 × SD, whereas 38 pairs (3.2%) scored below mean −1 × SD. This 
skewed distribution was not dependent on the score system that we used in measuring similarity, 
as we observed similar results using additional score methods and matrices (Supplemental Figure 
S2.2). Further analysis suggested that the increased similarity between sibling RRMs was 
unrelated to the length of the peptide between these domains, as we did not find any correlation 
between the RRM similarities and their distances (Supplemental Figure S2.3). This increased 
  
 
14 
  
 
similarity is not limited to a single species, as the same results were obtained when we analyzed 
the sibling RRMs in the D. melanogaster genome (Supplemental Figure S2.4A). In addition to 
RRM, we also analyzed KH and C2H2 zinc finger domains, both of which are commonly found 
in human RBPs. While comparing the similarity scores of sibling domain pairs to those of all 
other pairs (i.e., nonsibling pairs), we again found a higher sequence similarity in sibling pairs in 
both sibling KH and zinc finger domains (Supplemental Figure S2.4B), suggesting the increased 
similarity between sibling RNA binding domains is a common feature for different types of 
RBPs. 
There is a possibility that some proteins are under a global selection to preserve certain 
sequence bias, resulting in the increased sequence similarity between sibling RRM pairs within a 
single protein compared to random pairs. To measure the potential sequence bias, we calculated 
the average frequency of each amino acid in RRMs for different RBP groups with 2, 3, 4, and 5 
RRM domains (Supplemental Figure S2.5A). These groups include 112 proteins with two RRMs 
(112 sibling pairs), 44 proteins with three RRMs (132 sibling pairs), 11 proteins with four RRMs 
(66 sibling pairs), and one protein with five RRMs (10 sibling pairs). Overall, we found that the 
RRMs from different groups or within the same group have similar sequence composition. Five 
out of 20 aa have significant differences in mean of frequency between groups as judged by the 
ANOVA F-statistic (P-value < 0.01). Nevertheless, to better control the subtle sequence bias, we 
generated control groups of RRM pairs with matched composition distance to the real sibling 
RRM pairs for the rest of our analyses (see Materials and Methods section for details and 
Supplemental Figure S2.5B). 
We further analyzed the RBPs containing multiple RRMs and compared the cumulative 
distributions of RRM similarity scores in proteins with different numbers of RRMs. When 
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compared to a control set of 1000 randomly selected RRM pairings, we found that the different 
sets of RBPs all have higher similarity between their sibling RRMs than the randomly chosen 
RRM controls (except the 5-domain RBP set that contains a single member), as judged by the 
right shifts of plots (P = 6.3 × 10−13, 4 × 10−12, 2.2 × 10−14, and 0.8 for control vs. 2-, 3-, 4-, 
and 5-domain RBPs, respectively, by the Kolmogorov–Smirnov test) (Figure 2.1C). This result 
suggests that the higher similarity between sibling RRMs (Figure 2.1B) is a common property 
for all RBPs with different numbers of RRMs. 
A potential explanation of these observations is that the sibling RRMs resulted from 
domain duplication during evolution [67]. However, there is an alternative explanation that all 
the RRMs in proteins with multiple RRMs might be more conserved (i.e., similar to each other) 
regardless of whether they coexist in the same protein. To address this possibility, we selected 
the set of RBPs with two or three RRMs and shuffled the sibling relationship of these RRMs 
within each set. This shuffling of sibling relationships was conducted by randomly selecting two 
or three RRMs to form a simulated RBP (112 proteins with two RRMs and 44 proteins with 
three RRMs were generated in each shuffle), and this simulation was repeated 1000 times. We 
found that the mean similarity scores for shuffled RRM pairs were significantly less than the real 
sibling pairs (P = 0.001 by a rank test) (Figure 2.1D,E), suggesting that the higher similarity 
observed is, indeed, due to a sibling (duplication) relationship rather than the natural sequence 
bias between the sets of the “singleton RRMs” and the RRMs with siblings. Consistently, the 
similarity scores of random pairs of RRMs with siblings (mean = 22 for RBPs with two or three 
RRMs) (Figure 2.1D,E) are similar to those of random pairs of all RRMs (mean = 23) (Figure 
2.1B). 
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2.3.3 Sibling RRM pairs in species-specific RBPs are more similar to each other 
We further examined the sequence conservation of sibling RRM pairs from different 
species whose proteomes are well annotated. For each of four species (human, mouse, fruit fly, 
and worm), we selected the RBPs shared among all species and the RBPs found only in one 
species (see Materials and Methods) and compared the similarity between sibling RRMs within 
the same protein. We found that, in all species except worms, the similarity between sibling 
RRMs is significantly higher in the species-specific RBPs as compared to that of sibling RRMs 
in RBPs shared across all four species. Generally, genes conserved across multiple species are 
more ancient, as they appeared before speciation, whereas genes unique to certain species are 
more recently evolved. According to this simple assumption, our finding suggests that the RRM 
sibling pairs in “younger” (i.e., species-specific) proteins have higher sequence similarities than 
those in “older” proteins (i.e., conserved across distant species). A simple explanation is again 
that most sibling RRMs arose from domain duplication during evolution, which was then 
followed by sequence drift in each species through random mutations. The sibling RRMs in 
older proteins resulted from more ancient duplication and, therefore, would be expected to have 
higher sequence divergence. In particular, such increased similarity was more obvious between 
the sibling RRMs specific to human and mouse (Figure 2.2A,B), suggesting an extensive RRM 
duplication in mammals. We are aware that our explanation is based on a usual assumption in 
gene evolution; however, there is an alternative but less likely scenario that the unique genes 
could have existed in the common ancestor but were subsequently lost in all species except one. 
 
2.3.4 Recent RRM duplication in DAZ proteins.  
We observed an outlier with similarity score of 100 between RRMs of human DAZ 
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proteins (i.e., completely identical). The DAZ proteins have four paralogs on the Y chromosome: 
DAZ1 (3 RRMs), DAZ2 (1 RRM), DAZ3 (1 RRM), and DAZ4 (2 RRMs); one paralog on 
chromosome 3: DAZL (DAZ like) (1 RRM), and one on chromosome 2: BOLL (1 RRM) (Figure 
2.3A). Among these six proteins, the RRMs in four DAZ proteins and DAZL are completely 
identical, whereas the RRM in BOLL has 53% identity with the others. Previous sequence 
analyses suggests that at least two gene duplication events were required to generate this protein 
family: The first duplication gave rise to DAZL and BOLL, which was followed by a second 
duplication of DAZL to generate Y chromosome-specific DAZ proteins [68-70]. The second 
duplication could either be a single duplication that generated four DAZ proteins, or 
alternatively, several sequential duplications that happened within a short time window so as to 
produce four proteins. 
Among the six proteins within the DAZ family, only human DAZ1 and DAZ4 have 
multiple RRMs. To improve the annotation of this family, the sequences of the six human DAZ 
family proteins were compared against the genomes of chimpanzee, macaque, gorilla, chicken, 
frog, and zebra fish (Figure 2.3A). Such reannotation is necessary, since the nomenclature does 
not necessarily reflect the real evolutionary route of these proteins in some species (e.g., Dazl in 
worm is the ortholog of human Boll). The single RRM proteins DAZL and BOLL can be found 
in all species tested, whereas DAZ proteins with multiple RRMs can only be identified in certain 
primates (human, chimpanzee, and macaque, but not in gorilla) (Figure 2.3A). This result 
suggests that there was an RRM domain duplication following the second gene duplication on 
the Y chromosome, generating new DAZ family members with multiple RRMs. This domain 
duplication appears to be a recent event that happened only in a subgroup of primates including 
humans. It is also possible that such domain duplication happens in multiple steps, as the DAZ 
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proteins with multiple RRMs were detected in macaque but not gorilla. Alternatively, assembly 
errors in this repetitive region of the Y chromosome could also prevent the detection of DAZ 
proteins with multiple RRMs in gorilla. 
To examine their evolution over a more recent time frame, we further determined the 
SNP density within the DAZ protein family (Figure 2.3B). We calculated the SNP density 
(number of SNPs/gene length) for each DAZ gene, as well as the average SNP density of 100 
genes randomly selected from the same chromosome (gray bars). The SNP density of BOLL is 
similar to that of other genes randomly selected from chromosome 2, while the SNP density of 
DAZL is slightly lower than that of the randomly selected genes on chromosome 3. However, 
the SNP densities of the four DAZ genes are two orders of magnitude less than the densities of 
other randomly selected genes on the Y chromosome. Since the majority of gene variation 
observed in a population is due to random drift of neutral (or nearly neutral) mutations, as 
proposed by the neutral theory of molecular evolution [71], the SNP density is correlated with 
the functional importance and evolution time of the gene [72]. Our observation of SNP densities 
is consistent with the hypothesis that there has been at least one very recent RRM domain 
duplication event that generated DAZ1 with multiple RRMs. 
2.3.5 Ancient RRM duplications in PABPs 
 In addition to recent domain duplication, we also found a case of ancient duplication of 
RRMs in the human genome. Human polyadenylate-binding proteins (PABPs) belong to a 
conserved protein family that binds to the poly(A) tail of mRNA through RRMs [73]. Six PABP 
paralogs in humans (PABP1, PABP3, PABP4, PABP5, PAP1L, and PAP4L) contain four RRM 
domains, with some members containing an additional C-terminal domain called PABC. In 
addition, the human PABP2 and EPAB2 (embryonic PABP2) contain a single RRM, and 
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PAP1M contains two RRMs (Figure 2.4A). The family of PABP proteins in other species (M. 
musculus, D. melanogaster, C. elegans, and Schizosaccharomyces pombe) contains members 
with one RRM or four RRMs, with the exception of a yeast protein (PABX) that contains three 
RRMs. Through multiple sequence alignments of all 21 RRMs in different species, we clustered 
these RRMs according to similarity and found that these RRMs clustered predominantly by the 
relative locations in a protein rather than by the species (Figure 2.4B). For example, the first of 
the four RRMs in all PABPs across five species has higher similarity to each other than to its 
sibling RRMs, thus forming a monophyletic clade. The same observation is also valid for the 
second, third, and fourth RRM in different proteins across all species. This relationship was 
clearly demonstrated in Figure 2.4B, where we color-coded the RRMs by different positions and 
observed that the RRMs of the same color were mostly clustered together (forming a 
monophyletic clade) in the phylogenetic tree (Figure 2.4B). The proteins with single RRMs are 
also clustered with each other across different species, and this clade is more similar to the first 
of the four RRMs in other proteins. This conservation pattern suggests that the domain 
duplication generating four sibling RRMs had most likely happened in the common ancestor of 
all these species (additional duplications might also occur in human and nematode), producing a 
larger family of PABPs. We speculate that there may be additional ancient domain duplications 
similar to PABPs, but such events are difficult to identify due to the lack of reliable measurement 
to distinguish ancient duplication vs. nonduplicated RRMs. For the future work, we may be able 
to compare the ages of all genes vs. all potentially duplicated RRM domains (with a correct 
background model for age of the individual domain and entire protein) and thus to determine if 
there is a correlation between the similarity score of sibling RRMs and the approximate age of 
the duplication. 
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These two specific examples in DAZ and PABP families represent both a recent and an 
ancient RRM duplication, strongly supporting our finding in analyzing all sibling RRMs (Figure 
2.1B). Taken together, our results suggest a model wherein RRM duplication has happened 
frequently during evolution, followed by random evolutionary drift that introduces additional 
sequence variation. This simple model is consistent with the finding that the number of proteins 
with multiple RRMs has expanded in humans and other mammals (Supplemental Figure S2.1). 
2.3.6 Similarity between sibling RRMs is associated with RBP functions 
In addition to the time since duplication, other features might also contribute to the 
similarities between sibling RRMs. For example, evolutionary constraints can also affect how 
fast the sequence drifts through random mutations after domain duplication. To study if the 
similarities between sibling RRMs are associated with certain functional preferences of RBPs, 
we conducted a survey of functional differences in the RBPs with multiple RRMs. We observed 
a general trend that the proteins that bind to polyadenylated RNA in the 3′ UTR tend to have 
more similar sibling RRM pairs, whereas the proteins that bind to the 5′ UTR tend to have 
dissimilar sibling RRMs (Figure 2.5A), suggesting there may be some association between the 
similarity of sibling RRM and the RBP function. 
To further study this potential relationship, we conducted a gene ontology analysis on all 
human RBPs having multiple RRMs. According to the similarity scores between each RRM pair, 
we divided all pairs into six groups, each containing ∼100 RRM pairs. The corresponding 
proteins in each group were subjected to functional enrichment analysis by he DAVID 
annotation tool (http://david.abcc.ncifcrf.gov/) [74], and the results were compared across all 
groups (Figure 2.5B). As expected, the function of “singlestranded RNA binding” and “mRNA 
binding” are significantly enriched across all groups (Figure 2.5B, bottom), serving as a positive 
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control. Consistent with the earlier observation, we also found a significant enrichment of 
“mRNA 5′-UTR binding” (P = 1.8 × 10−5, fold enrichment = 406) in proteins with dissimilar 
sibling RRMs (group 1: similarity score = 1–20). In contrast, enrichment of “polyadenylated 
RNA binding” (P = 5.1 × 10−5, fold enrichment = 256) occurred in proteins having sibling RRM 
pairs with the highest similarity (group 6: similarity score = 42–100). In addition, the RBPs with 
similar sibling RRMs were also found to be enriched in poly(U) RNA binding, poly-pyrimidine 
track binding, and poly-purine track binding, suggesting that these RRMs are more likely to bind 
repetitive RNA elements (groups 4–6) (Figure 2.5B). This finding is consistent with the notion 
that the requirement of binding to repetitive targets may impose additional selective pressure on 
these RBPs after RRM duplication. Individual RRMs are known to specifically recognize short 
sequences (usually 2–5 nt), and thus, RBPs with similar sibling RRMs could be expected to 
facilitate the binding to longer RNA targets containing repetitive elements. 
Compared to other regions of mRNA, the 5′-UTR region usually contains binding sites 
for factors that affect the translation efficiency of mRNA [75]. On the other hand, the 3′ UTR 
usually contains more repetitive sequences used to control RNA stability (e.g., AU-rich 
elements) [76, 77]. As expected, the RBPs with dissimilar sibling RRMs (group 1) are enriched 
only in 5′-UTR binding and translation regulation (Figure 2.5B). Conversely, proteins with 
similar sibling RRMs have a small bias toward binding to the 3′ UTR. Recently, a 
comprehensive identification of the binding motifs for RBPs suggested that the RBDs with 
higher protein similarity are more likely to bind to similar RNA motifs [53]. Our data raise an 
interesting prediction that mRNA metabolism is controlled by more diverse elements in the 5′ 
UTR but by more repetitive elements in the 3′ UTR. This hypothesis seems to be true for 
translation control and RNA degradation through AU-rich elements, but its generality remains to 
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be examined. 
2.3.7 RRM-containing RBPs are enriched with repetitive motifs  
In addition to the RRMs, other sequence motifs may also contribute to RRM-containing 
RBP function or even RNA binding affinity/specificity [78]. Thus, we analyzed the non-RRM 
fragments of RBPs to determine their characteristics that may contribute to function. We 
removed RRM sequences from the RBPs and calculated the frequency of each amino acid in the 
remaining fragments. To estimate the enrichment of each amino acid, we computed logarithm 
value for the ratio of amino acid frequency in these fragments vs. that in all human proteins and 
found that amino acids A, G, P, Q, R, S, and Y were highly enriched (Figure 2.6A). We further 
searched for the frequent words flanking these enriched amino acids (five residues up- and 
down- stream) (Figure 2.6B). As expected, we found that RS di-peptides were highly enriched in 
this data set because the Ser/Arg-rich proteins (SR proteins) are a major class of splicing factors 
that recognize RNA targets through RRMs. In addition, we found a high frequency of GY di-
peptides as well as many other low-complexity poly-G and poly-P sequences. These repetitive 
motifs were represented by a word cloud plot (Figure 2.6C), where the occurrences of all 
possible di-, tri- (with arbitrary second amino acid), and tetra-peptides (the second and third 
amino acids could be any amino acid) were computed after removing the RRM from the RBP 
sequences. We found that the Gly-rich, Pro-rich, Ser-rich, and Ala-rich sequences often co-
occurred with the RRMs (Figure 2.6C); some of these repetitive motifs were also reported in an 
unbiased identification of all mammalian RBPs [32]. To determine whether these repetitive 
sequences are specific to RRM-containing proteins, we analyzed sequences of RBPs containing 
the KH or zinc finger C2H2 domain (Supplemental Figs. S2.6, S2.7). All RBPs with RRM, KH, 
and zinc finger C2H2 domains have low complexity poly-G and poly-P motifs. Furthermore, we 
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found the RS di-peptide repeats were only found in RRM-containing proteins, whereas the poly-
S was found to be enriched in RBPs with the KH and zinc finger C2H2 domain (cf. Figure 2.6B 
and Supplemental Figures S2.6B, S2.7B).  
 
2.4 Discussion 
 
Proteins that specifically bind to single-stranded RNA play critical roles in regulating 
various RNA processing pathways; thus a detailed sequence analysis of these RBPs will provide 
key insights into gene regulation at the RNA level. This study suggests extensive domain 
duplications of RRM. Such duplications are probably followed by random evolutionary drift that 
introduces additional sequence variation, leading to the observed higher degree of sequence 
divergence in old proteins with ancient RRM duplications (Figures 2.2, 2.4). This domain 
duplication may play a significant role in the function of RBPs. One possible consequence could 
be that multiple RRMs allow a protein to bind RNA with higher sequence specificity and/or 
affinity than those RBPs with a single binding domain. Another consequence could be that 
multiple RRM domains may help RBPs to bind to longer RNA sequences. Typically a single 
RRM recognizes 2–5 nt; thus tandem RRMs may provide some selective advantage to increase 
binding specificity and bind to longer RNA targets. Consistent with this notion, the sibling 
RRMs in several RBPs, for example, PTB [60], were found to recognize similar RNA motifs. 
The domain duplication of RRMs might provide a possible explanation of why the RRM-
containing proteins are so abundant in the human genome. 
The extensive RRM duplication during evolution raises some fundamental questions in 
RNA biology. The human genome (or mammals, in general) has the highest number of RBPs 
with RRM duplications, and this RRM expansion probably contributed to the increased 
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complexity of RNA processing pathways in mammals. For example, the majority of human 
genes undergo alternative splicing, and a predominant fraction of splicing factors are RBPs with 
multiple RRM domains. In fact, we observed that the RBPs with different similarities in their 
sibling RRMs are functionally separated from each other (Figure 2.5). The proteins with very 
similar sibling RRMs tend to bind the 3′ end of mRNA and might function in RNA 
polyadenylation, whereas the RBPs with more divergent sibling RRMs tend to bind the 5′ UTR 
of mRNA and might affect the RNA translation. We speculate that RRM duplication, together 
with their diverging RNA binding targets in the transcriptome, allows the mutual selection in 
RNA–protein interaction and eventually leads to the functional divergence of RBPs. 
We also found that, compared to all other human proteins, the RRM-containing RBPs are 
more likely to have repetitive sequences in the regions outside the RRMs. These repetitive 
sequences frequently mediate protein–protein interactions, as RBPs with low-complexity 
domains tend to aggregate to form protein fibers [79]. The association of RRM-containing 
proteins with repetitive sequences (encoded by low complexity DNAs) raises an interesting 
possibility that these sequences may provide a mechanism for domain duplication, as the 
repetitive DNA sequences are less stable during replication and tend to cause local DNA 
duplication/expansions [80, 81]. Alternatively, such repetitive sequences could be a result of 
RRM duplication that is caused by local DNA duplication; however, the RBPs with a single 
RRM also contain low-complexity sequences. Nevertheless, the mechanism of domain 
duplication is an interesting question emerging from our study. 
We described a systematic analysis of RBPs, focusing on the proteins with the RRM as 
their RNA-recognition domain. Surprisingly, we found an increase in the number of RBPs 
containing multiple RRMs in mammals (Supplemental Figure S2.1) and that the sibling RRMs 
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within these proteins are more similar to each other than what would be predicted by controls 
(Figure 2.1). In addition, the sibling RRM pairs are more similar to each other in the species-
specific RBPs when compared to the ancient RBPs shared by multiple species, suggesting a 
general RRM duplication in many genes of the mammalian genome. Such domain duplication is 
further supported by two extreme examples: In the case of the DAZ protein family, a very recent 
RRM duplication appears to have happened in humans and several primate species, generating 
multiple RBPs containing identical sibling RRMs (Figure 2.3). In another case, the RRM 
duplications within the PABP proteins probably happened in the common ancestor of all 
eukaryotes, as similar duplication was found from yeast to human (Figure 2.4). Taken together, 
these results suggested a new and simple model wherein RRM duplication happened frequently 
during evolution, resulting in increased numbers of RBPs with multiple RRMs. 
 
2.5 Materials and Methods 
2.5.1 RNA binding proteins and RNA recognition motifs  
We extracted the RRM sequences according to the scheme in Figure 2.1A. First, the 
RRM sequences were downloaded from InterPro Biomart (http://www.ebi.ac.uk/interpro/biomart 
/martview/) with the following configuration: DATABASE: “InterPro BioMart,” DATASET: 
“InterPro Entry Annotation,” Filters: “InterPro,” Entry ID: “IPR000504,” and Source Signature 
Database: “Pfam, SMART, and Prosite.” We selected Pfam annotation if there was inconsistency 
between Source Signature Databases. Unless specified, both SwissProt and TrEMBL proteins 
were included, but only unique sequences were used. As a result, 453 unique RRMs with peptide 
sequence length ≥45 amino acids were included (Supplemental Table S2.1). Data of three other 
species, M. musculus, D. melanogaster, and C. elegans were also downloaded for ortholog 
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analysis (Supplemental Tables S2.2, S2.3). Other protein attributes, such as Gene Ontology 
(GO), Gene Orthologs, and Gene IDs, used in other databases, were downloaded from Ensembl 
Biomart (www.ensembl.org/biomart/martview). Because protein IDs are not standardized 
between or even within some databases, we performed a protein ID conversion as well as manual 
curation to combine our data sources. 
2.5.2 Sequence similarity score calculation  
ClustalW2 was used to compute all the pairwise alignment scores for every RRM pair. 
The similarity score was calculated by calibrating the number of identities between the two 
sequences with the length of alignment, and it is represented as a percentage, i.e., 0–100. The 
default protein weight matrix (Gonnet 250) was used for all the pairwise alignments in the main 
text. However, we also compared the similarity scores generated by using Gonnet 250 with 
BLOSUM30 (Supplemental Figure S2.2A) and PAM350 (Supplemental Figure S2.2B). We also 
repeated Figure 2.1B by using BLOSUM 30 as the weight matrix and obtained similar results 
(Supplemental Figure S2.2C). 
2.5.3 Sequence composition and composition distance 
We calculated the sequence composition as the frequency of the 20 amino acids in each 
RRM sequence. Therefore, a sequence composition for an RRM is a vector with 20 dimensions. 
To measure the similarity of sequence compositions between two RRMs, we used the city block 
distance between two vectors (i.e., sum of the frequency difference of each amino acid). We 
named such measurement the “composition distance,” which ranges from 0 to 2. 
To control for the sequence bias when choosing random RRM pairs, we use those with 
the composition distance matched to the real sibling pairs. For example, in Figure 2.1C, the 1000 
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control RRM pairs were randomly picked from all RRM pairs with composition distances within 
the 0.37–0.60 range (i.e., mean ± 1 SD of the composition distance from real sibling pairs) (see 
Supplemental Figure S2.5B). In Figure 2.1, D and E, all control RRM-pairs have a composition 
distance within 0.41–0.62 and 0.34–0.57, respectively. 
2.5.4 RBP orthologs 
H. sapiens, M. musculus, D. melanogaster, and C. elegans ortholog data were 
downloaded from the inparanoid database (http://inparanoid.sbc.su.se/download/current/ 
sqltables/) [82]. We downloaded six files, each containing orthologs between two species. We 
combined all the files and gathered more than 3000 proteins with orthologs found in all four 
species and thousands of species-specific proteins. These protein sequences were submitted to 
Pfam for domain analysis with an E-value cutoff of 0.1 (http://pfam.sanger.ac.uk/search#tabview 
=tab1). Only proteins with more than one predicted RRM were used to calculate the sequence 
similarity scores. Among the >3000 orthologs between the four species, 80 are RNA-binding 
proteins, among which 41 human RBPs, 41 mouse RBPs, 34 fly RBPs and 33 worm RBPs 
contain more than one RRM. We then extracted RBPs that are unique to the individual species 
and obtained 9, 12, 19, and 12 species-specific RBPs for human, mouse, fly, and worm, 
respectively. For the sequence similarity score calculation, the sequence pair of RRM from the 
same RBP were aligned to each other using ClustaW2. All proteins used are listed in 
Supplementary Tables S2.2 and S2.3. The location of the RRM sequence and the sequence 
similarity score were also included in the table. 
2.5.5 Analyses of DAZ and PABP protein family 
To obtain orthologs of the human DAZ protein family, we used inparanoid version 8.0 
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(http://inparanoid.sbc.su.se/download/8.0_current/Orthologs/). Six species were examined: 
chimpanzee, macaque, gorilla, chicken, frog, and zebrafish. When no ortholog was annotated in 
the inparanoid database for selected species, we manually searched the protein sequence 
database by blast to identify potential orthologs. If there are one DAZ domain and multiple 
DAZ-like repeats, we classified it as an ortholog of either DAZ3 or DAZ2, since orthologs of 
these two proteins are hard to distinguish. When the occurrence of the RRM is two, we consider 
it as a DAZ4 ortholog. If the occurrence of RRM is three, we count it as a DAZ1 ortholog. All 
the orthologs identified by both inparanoid and manual searches are listed in Supplemental Table 
S2.4 with their scores and bootstrap probabilities. 
The protein sequences of polyadenylate-binding proteins of five species (H. sapiens, M. 
musculus, D. melanogaster, C. elegans, and S. pombe) were downloaded from uniprot, and their 
RRM sequences were extracted. We used ClustaW2 to build the phylogenetic tree according to 
multiple sequence alignments (default parameters were used, i.e., Protein Weight Matrix: gonnet, 
Clustering type: Neighbor-joining). The ClustaW2-generated guide tree file was then visualized 
via theTreeView program. 
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Table 2.1 Number of proteins containing different RBDs in five species as reported from 
Ensembl biomart 0n 07/09/13  
Domain name  
(Interpro ID) 
Number of proteins in different species 
H. 
sapiens 
M. 
musculus 
D. 
melanogaster 
C. 
elegans 
S. 
cerevisiae 
RNA recognition motif 
(IPR000504) 
242 248 139 105 54 
K Homology domain 
(IPR004087) 
39 39 29 28 9 
C2H2 Zinc finger 
(IPR007087) 
805 693 291 176 48 
CCCH Zinc finger 
(IPR000571) 
63 50 30 37 10 
S1 RNA-binding 
domain (IPR022967) 
9 9 11 6 7 
PAZ domain 
(IPR003100) 
10 9 7 29 NULL 
Pumilio RNA-binding 
repeat (IPR001313) 
4 4 3 12 7 
Total (without any 
filter) 
63,253 38,561 15,628 46,589 7,126 
Data set used: Homo sapiens (GRCh37.p11), Mus musculus (GRCm38.p1), Drosophila 
melanogaster (BDGP5), Caenorhabditis elegans (WBcel235), and Saccharomyces cerevisiae 
(EF4). The two Zn finger domains can bind to both RNA and DNA. 
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Figure 2.1 Elevated sequence similarity between sibling RRMs in human RBPs. 
(A) Workflowoftheanalyses.ThehumanproteinscontainingRRMs were obtained from the InterPro 
database, and the RRM sequences were extracted according to the consensus annotations from 
three different da- tabases. After filtering out the duplicated sequence, 453 RRMs from 391 
unique RBPs were analyzed through sequence comparison. (B) Similarity scores between all 
RRM pairs in human RBPs. Each RRM was aligned with all other 452 RRMs, where the 
distribution of similarity score is represented by a gray vertical line spanning the mean ± 1× 
standard derivation. The similarity score between sibling RRMs was represented as a red circle. 
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The order of RRMs along the x-axis is arbitrary. (C) The cumulative frequency of similarity 
scores between sibling RRM pairs in proteins with 2, 3, 4, or 5 RRMs. As a control, we 
randomly selected 1000 RRM pairs and computed the cumulative frequency of their similarity 
scores. (D) Sibling RRMs are more conserved than the shuffled pairs. The histograms of 
similarity scores between sibling RRM pairs from 112 RBPs that contain two RRMs were 
plotted (open boxes). As controls, we shuffled the order of these RRMs to generate a simulated 
set of 112 RBPs with matched sequence composition. The shuffle was repeated 1000 times with 
replacement, and the mean similarity scores of RRM pairs were plotted as filled boxes. (E) Same 
as panel D, except 44 RBPs with three RRMs were analyzed. 
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Figure 2.2 Sibling RRM pairs in species-specific proteins are more conserved. 
(A) HumanRBPs with multiple RRMs were divided into two classes: the proteins shared among 
four different species (H. sapiens, M. musculus, D. melanogaster, and C. elegans) and the 
proteins found only in human. The similarity scores between sibling RRMs were calculated for 
each class and represented as a box plot. The score distributions were compared by t-test with P 
value indicated. The same analyses were also carried out using RBPs from M. musculus (B), D. 
melanogaster (C), and C. elegans (D). 
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Figure 2.3 An RBP family with recent RRM duplications. 
(A) ThemembersinthehumanDAZ protein family contain one or more RRMs and DAZ-like 
domains. All RRMs in DAZ1, DAZ2, DAZ3, DAZ4, and DAZL are identical, whereas the RRM 
in BOLL has 53% sequence identity with the other RRM. The DAZ1 to DAZ4 are in the Y 
chromosome, while BOLL and DAZL are in chromosomes 2 and 3. The ortholog genes in other 
species were identified by a combination of inparanoid annotation and blast search, and species 
that contain various DAZ proteins were represented with different boxes. The DAZ proteins with 
multiple RRMs were only found in cer- tain primates. (B) The SNP density of each human DAZ 
protein was compared with the average density of other genes in the same chromosome. The 
SNP density ratios between DAZ genes relative to other genes in the same chromosome are 
indicated. The genes in the Y chromo- some encoding DAZ proteins have lower SNP density, 
suggesting that they are more recently di- verged genes. 
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Figure 2.4 An RBP family with ancient RRM duplications.  
 
(A) The diagram of PABP proteins from five species (H. sapiens, M. musculus, D. mel- 
anogaster, C. elegans, and S. pombe). The members in this protein family contain one to four 
RRMs, and some also contain a C-terminal PABC domain. Each RRM is colored according to 
their relative positions within the protein. (B) The phylogenetic tree of RRMs in the PABP 
family was visualized via TreeView. The RRMs are colored in the same scheme as in panel A, 
and the RRMs in the same position are more similar to each other across all species. 
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Figure 2.5 Gene Ontology analysis of human RBPs with multiple RRMs.  
 
(A) Sibling RRMs with different similarities tend to bind distinct regions of mRNA. The 
similarities between sibling RRM pairs are rep- resented with a histogram (gray), with the 
colored dots indicating the gene ontology (GO) terms enriched in the genes from different bins 
of the histogram. (B) According to the domain similarity score between sibling RRMs, all RBPs 
were divided into six groups as equally as possi- ble: 1–20 (108 pairs), 21–24 (92 pairs), 25–28 
(106 pairs), 29–33 (104 pairs), 34–41 (97 pairs), and 42–100 (93 pairs). The GO analyses were 
carried out, and the enriched functional terms in each bin are represented with a heat map to 
indicate the significance of enrichment. The func- tions common to all groups are marked. 
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Figure 2.6 Sequence motifs enriched in the RRM-containing RBPs.  
 
(A) We removed the RRM sequence from the RBPs and analyzed the re- maining sequence for 
amino acid propensities. For all 20 amino acids, their frequencies within non-RRM regions were 
compared to other pro- teins in the human proteome and the relative ratio is plotted. (B) 
Sequence logos around the most enriched amino acid residues in RBPs. The height of each 
single-letter amino acid code corresponds to the probability of occurrence at each position. (C) 
Repetitive sequence patterns that significantly co-occur with RRM in all human proteins. The 
size of each pattern corresponds to the number of occurrence. The word cloud was generated 
with the Wordle online tool. The top 80 motifs are shown. 
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2.6 Supplementary Material 
 
 
 
 
Figure S2.1 Increased numbers of RRMs within a single RBP in mammals.  
Cumulative frequency of RBP with different numbers of RRM was plotted in four species (H. 
sapien, M. musculus, D. melanogaster and C. elegans). 
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Figure S2.2 The similarity scores of RRMs measured with different scoring matrices. 
To control for possible variations in our scoring schemes, we used different scoring matrices 
(Gonnet250, BLOSUM30 and PAM350) to measure similarity scores between all 453 RRM 
pairs in RBPs. (A) Scatter plot of scores measured by Gonnet250 vs. BLOSUM30. (B) Scatter 
plot of scores measured by Gonnet250 vs. PAM350. (C) Similarity scores between all RRM 
pairs in human RBPs. The data is plotted like Figure 1B, except the BLOSUM30 was used as the 
scoring matrix instead of Gonnet250. 
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Figure S2.3 The lengths between sibling RRMs do not affect the similarity. 
The similarity scores between sibling RRMs is plotted against the length (i.e. number of amino 
acid) between sibling RRMs. No correlation is found between the length and similarity scores.  
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Figure S2.4 Similarity scores between RRM pairs in D. melanogaster RBPs and pairs of KH 
domain in human RBPs.  
(A) Each RRM was aligned with all other RRMs in D. melanogaster, where the distribution of 
similarity score is represented by a grey vertical line spanning the mean ± 1× standard derivation.  
For proteins with multiple RRMs, the similarity score between the sibling RRMs was 
represented as a red circle.  The order of RRM along the x-axis is arbitrary. (B) Boxplots of 
sequence similarities for both sibling domain pairs (gray box) and all other non-sibling domain 
pairs (white box) were shown in the three types of RNA binding domains.  The sequences of 
C2H2 Zinc finger, KH domains and RRMs were extracted from human proteins.   
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Figure S2.5 Amino acid composition frequency and composition distance in real RRM-
pairs.  
(A) Amino acid frequencies of each RRM were calculated. We plotted the mean ±1 S.D. for 
RRMs in each group and compare the difference between groups using ANOVA test. 
Compositions that are significantly different between groups are denoted with *. (B) 
Composition distances between real RRM-pairs were calculated in each group and box plot of 
the distribution were plotted. We also listed the mean and standard deviation (S.D.) of the 
distribution.  
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Figure S 2.6 Sequence motifs enriched in human RBPs containing KH domain(s). 
(A) We removed the KH sequences from the RBPs and analyzed the remaining sequence for 
amino acid propensities. For all 20 amino acids, their frequencies in non-KH regions were 
compared to other proteins in the human proteome and the relative ratio plotted. (B) Sequence 
logos around the most enriched amino acid residues in RBPs. The height of each single-letter 
amino acid code corresponds to the probability of occurrence at each position. (C) Repetitive 
sequence patterns that significantly co-occur with KH in all human proteins. The size of each 
pattern corresponds to the number of occurrence. The top 80 motifs are shown. 
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Figure S2.7 Sequence motifs enriched in human RBPs containing Zinc finger C2H2 
domain(s). 
(A) We removed the Zinc finger C2H2 sequences from the RBPs and analyzed the remaining 
sequence for amino acid propensities. For all 20 amino acids, their frequencies within non-Zinc 
finger C2H2 regions were compared to other proteins in the human proteome and the relative 
ratio plotted. (B) Sequence logos around the most enriched amino acid residues in RBPs. The 
height of each single-letter amino acid code corresponds to the probability of occurrence at each 
position. (C) Repetitive sequence patterns that significantly co-occur with Zinc finger C2H2 in 
all human proteins. The size of each pattern corresponds to the number of occurrence. The top 80 
motifs are shown. 
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Table S 2.1 Detailed information of RRM-containing RBPs in human	  
UniProt/	  SwissProt	  ID	  
Associated	  
Gene	  Name	  
No.	  of	  
RRM	   RRM	  position	   RRM	  align	  score(s)	   PFAM	  ID	  
SRSF9_HUMAN	   SRSF9	   2	   113-­‐174,	  16-­‐83	   16	   	   PF00076	  
RBM46_HUMAN	   RBM46	   3	   63-­‐126,	  143-­‐204,	  238-­‐301	   25	  14	  22	   	   PF00076	  
PM14_HUMAN	   AC008073.5	   1	   21-­‐87	   NULL	   PF00076	  
PPIL4_HUMAN	   PPIL4	   1	   242-­‐312	   NULL	   PF00160	  PF00076	  
RAVR1_HUMAN	   RAVER1	   2	   61-­‐123,	  135-­‐203	   25	   	   PF00076	  
U2AF2_HUMAN	   U2AF2	   3	   400-­‐459,	  151-­‐224,	  261-­‐330	   11	  18	  20	   	   PF00076	  
RBM4B_HUMAN	   RBM4B	   2	   4-­‐64,	  81-­‐141	   44	   	   PF00076	  PF00098	  
RBM23_HUMAN	   RBM23	   2	   168-­‐233,	  265-­‐334	   19	   	   PF00076	  
DAZ3_HUMAN	   DAZ2	   1	   42-­‐98	   NULL	   PF00076	  
CPEB2_HUMAN	   CPEB2	   1	   334-­‐395	   NULL	   PF00076	  
RBM11_HUMAN	   RBM11	   1	   12-­‐80	   NULL	   PF00076	  
RBY1D_HUMAN	   RBMY1D	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
RBM47_HUMAN	   RBM47	   3	   73-­‐137,	  153-­‐214,	  248-­‐311	   29	  17	  19	   	   PF00076	  
RBM18_HUMAN	   RBM18	   1	   27-­‐98	   NULL	   PF00076	  
FUS_HUMAN	   FUS	   1	   287-­‐365	   NULL	   PF00641	  PF00076	  
MK67I_HUMAN	   MKI67IP	   1	   47-­‐116	   NULL	   PF12196	  PF00076	  
IF2B1_HUMAN	   IGF2BP1	   2	   85-­‐150,	  4-­‐68	   3	   	   PF00013	  PF00076	  
RBY1A_HUMAN	   RBMY1A1	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
IF4H_HUMAN	   EIF4H	   1	   45-­‐112	   NULL	   PF00076	  
HNRH1_HUMAN	   HNRNPH1	   3	   15-­‐82,	  293-­‐355,	  115-­‐181	   31	  44	  41	   	   PF00076	  PF08080	  
RBMS3_HUMAN	   RBMS3	   2	   63-­‐123,	  142-­‐206	   27	   	   PF00076	  
RBMXL_HUMAN	   RBMXL1	   1	   10-­‐80	   NULL	   PF00076	  PF08081	  
PTBP2_HUMAN	   PTBP2	   3	   459-­‐518,	  183-­‐247,	  340-­‐405	   26	  21	  24	   	   PF00076	  
PRGC1_HUMAN	   PPARGC1A	   1	   679-­‐739	   NULL	   PF00076	  
PABP5_HUMAN	   PABPC5	   4	  
20-­‐88,	  108-­‐175,	  304-­‐372,	  201-­‐
269	   23	  23	  24	  36	  32	  39	   	   PF00076	  
SART3_HUMAN	   SART3	   2	   706-­‐774,	  803-­‐871	   27	   	   PF00076	  PF05391	  
RBM14_HUMAN	   RBM14	   2	   81-­‐142,	  3-­‐60	   50	   	   PF00076	  
REXON_HUMAN	   AC004381.6	   1	   510-­‐571	   NULL	   PF00929	  PF00076	  
SR140_HUMAN	   U2SURP	   1	   276-­‐348	   NULL	   PF01805	  PF00076	  
RBM5_HUMAN	   RBM5	   1	   100-­‐163	   NULL	  
PF01585	  PF00076	  
PF00641	  
HNRPR_HUMAN	   HNRNPR	   3	   167-­‐231,	  343-­‐404,	  248-­‐309	   25	  22	  22	   	   PF00076	  
SRS12_HUMAN	   SRSF12	   1	   12-­‐81	   NULL	   PF00076	  
ENOX1_HUMAN	   ENOX1	   1	   144-­‐199	   NULL	   PF00076	  
SREK1_HUMAN	   SREK1	   1	   68-­‐136	   NULL	   PF00076	  
RB12B_HUMAN	   RBM12B	   2	   402-­‐470,	  288-­‐353	   12	   	   PF00076	  
EPAB2_HUMAN	   PABPN1L	   1	   149-­‐218	   NULL	   PF00076	  
SLIRP_HUMAN	   SLIRP	   1	   22-­‐84	   NULL	   PF00076	  
EIF3G_HUMAN	   EIF3G	   1	   241-­‐303	   NULL	   PF12353	  PF00076	  
RBM45_HUMAN	   RBM45	   3	   34-­‐92,	  406-­‐457,	  127-­‐183	   26	  35	  13	   	   PF00076	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TDR10_HUMAN	   TDRD10	   1	   36-­‐100	   NULL	   PF00567	  PF00076	  
RFOX1_HUMAN	   RBFOX1	   1	   120-­‐187	   NULL	   PF12414	  PF00076	  
RBM34_HUMAN	   RBM34	   1	   289-­‐358	   NULL	   PF00076	  
DAZ2_HUMAN	   DAZ2	   1	   42-­‐98	   NULL	   PF00076	  
ROA1_HUMAN	   HNRNPA1	   2	   107-­‐175,	  16-­‐84	   33	   	   PF00076	  
PPRC1_HUMAN	   PPRC1	   1	   1545-­‐1604	   NULL	   PF00076	  
PABP1_HUMAN	   PABPC1	   4	  
101-­‐168,	  296-­‐363,	  193-­‐261,	  
13-­‐83	   41	  47	  33	  51	  36	  31	   	   PF00076	  PF00658	  
CELF4_HUMAN	   CELF4	   2	   154-­‐216,	  56-­‐123	   41	   	   PF00076	  
SET1A_HUMAN	   SETD1A	   1	   101-­‐165	   NULL	  
PF11764	  PF00856	  
PF00076	  
DAZP1_HUMAN	   DAZAP1	   2	   115-­‐183,	  12-­‐80	   31	   	   PF00076	  
TSAP1_HUMAN	   TRNAU1AP	   2	   5-­‐73,	  98-­‐161	   28	   	   PF00076	  
RBP56_HUMAN	   TAF15	   1	   236-­‐314	   NULL	   PF00076	  PF00641	  
CELF5_HUMAN	   CELF5	   3	   136-­‐198,	  402-­‐471,	  47-­‐113	   31	  42	  25	   	   PF00076	  
PAP1L_HUMAN	   PABPC1L	   4	  
101-­‐168,	  193-­‐261,	  296-­‐363,	  
13-­‐83	   50	  41	  29	  48	  33	  29	   	   PF00076	  PF00658	  
CPSF7_HUMAN	   CPSF7	   1	   84-­‐155	   NULL	   PF00076	  
CPEB4_HUMAN	   CPEB4	   1	   474-­‐535	   NULL	   PF00076	  
RBY1B_HUMAN	   RBMY1B	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
IF2B3_HUMAN	   IGF2BP3	   2	   85-­‐150,	  4-­‐68	   9	   	   PF00013	  PF00076	  
HNRDL_HUMAN	   HNRPDL	   2	   151-­‐218,	  235-­‐296	   40	   	   PF00076	  
U1SBP_HUMAN	   SNRNP35	   1	   53-­‐122	   NULL	   PF00076	  
G3BP2_HUMAN	   G3BP2	   1	   333-­‐390	   NULL	   PF02136	  PF00076	  
LARP7_HUMAN	   LARP7	   1	   127-­‐188	   NULL	  
PF08777	  PF05383	  
PF00076	  
HNRPC_HUMAN	   HNRNPC	   1	   18-­‐80	   NULL	   PF00076	  
SRS11_HUMAN	   SRSF11	   1	   37-­‐101	   NULL	   PF00076	  
CELF1_HUMAN	   CELF1	   3	   403-­‐472,	  19-­‐84,	  110-­‐175	   22	  25	  34	   	   PF00076	  
PSPC1_HUMAN	   PSPC1	   2	   84-­‐148,	  158-­‐216	   22	   	   PF00076	  PF08075	  
HTSF1_HUMAN	   HTATSF1	   2	   289-­‐343,	  135-­‐212	   5	   	   PF00076	  
MYEF2_HUMAN	   MYEF2	   3	   235-­‐303,	  525-­‐592,	  102-­‐171	   45	  28	  39	   	   PF00076	  
SRSF1_HUMAN	   SRSF1	   2	   18-­‐85,	  123-­‐184	   25	   	   PF00076	  
HNRPQ_HUMAN	   SYNCRIP	   3	   164-­‐229,	  245-­‐306,	  340-­‐401	   20	  22	  19	   	   PF00076	  
RBMS2_HUMAN	   RBMS2	   2	   137-­‐201,	  58-­‐118	   29	   	   PF00076	  
RBM38_HUMAN	   RBM38	   1	   36-­‐93	   NULL	   PF00076	  
CNOT4_HUMAN	   CNOT4	   1	   130-­‐187	   NULL	   PF00076	  
PPIE_HUMAN	   PPIE	   1	   8-­‐78	   NULL	   PF00160	  PF00076	  
RBM25_HUMAN	   RBM25	   1	   89-­‐157	   NULL	   PF01480	  PF00076	  
RDM1_HUMAN	   RDM1	   1	   32-­‐88	   NULL	   PF00076	  PF04098	  
RBMS1_HUMAN	   RBMS1	   2	   64-­‐124,	  143-­‐207	   27	   	   PF00076	  
CELF2_HUMAN	   CELF2	   3	   134-­‐198,	  425-­‐494,	  43-­‐111	   30	  33	  21	   	   PF00076	  
MTHSD_HUMAN	   MTHFSD	   1	   308-­‐372	   NULL	   PF01812	  PF00076	  
RBY1E_HUMAN	   RBMY1E	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
DAZL_HUMAN	   DAZL	   1	   42-­‐108	   NULL	   PF00076	  
SRSF6_HUMAN	   SRSF6	   2	   4-­‐64,	  112-­‐177	   24	   	   PF00076	  PF08777	  
RA1L2_HUMAN	   HNRNPA1L2	   2	   107-­‐175,	  16-­‐84	   33	   	   PF00076	  PF11627	  
SRSF7_HUMAN	   SRSF7	   1	   13-­‐77	   NULL	   PF00076	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NCB2L_HUMAN	   NCBP2L	   1	   43-­‐104	   NULL	   PF00076	  
ROA0_HUMAN	   HNRNPA0	   2	   9-­‐75,	  100-­‐168	   35	   	   PF00076	  
SRS10_HUMAN	  
BX511012.1	  
SRSF10	   1	   12-­‐81	   NULL	   PF00076	  
ROA3_HUMAN	   HNRNPA3	   2	   37-­‐105,	  128-­‐196	   34	   	   PF00076	  
SRSF2_HUMAN	   SRSF2	   1	   18-­‐86	   NULL	   PF00076	  
IF4B_HUMAN	   EIF4B	   1	   99-­‐167	   NULL	   PF00076	  
RBM41_HUMAN	   RBM41	   1	   311-­‐379	   NULL	   PF00076	  
SET1B_HUMAN	   SETD1B	   1	   110-­‐174	   NULL	  
PF11764	  PF00856	  
PF00076	  
NCBP2_HUMAN	   NCBP2	   1	   42-­‐112	   NULL	   PF00076	  
HNRH2_HUMAN	   HNRNPH2	   3	   15-­‐82,	  293-­‐355,	  115-­‐181	   33	  44	  41	   	   PF00076	  PF08080	  
CPEB3_HUMAN	   CPEB3	   1	   443-­‐504	   NULL	   PF00076	  
TADBP_HUMAN	   TARDBP	   2	   193-­‐241,	  106-­‐171	   28	   	   PF00076	  
RAVR2_HUMAN	   RAVER2	   3	   71-­‐132,	  235-­‐302,	  145-­‐209	   11	  8	  16	   	   PF00076	  
HNRGT_HUMAN	   RBMXL2	   1	   10-­‐80	   NULL	   PF00076	  PF08081	  
RBM44_HUMAN	   RBM44	   1	   833-­‐896	   NULL	   PF00076	  
ZCRB1_HUMAN	   ZCRB1	   1	   12-­‐82	   NULL	   PF00076	  PF00098	  
RBY1F_HUMAN	  
RBMY1F	  
RBMY1J	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
IF2B2_HUMAN	   IGF2BP2	   2	   5-­‐62,	  86-­‐148	   13	   	   PF00013	  PF00076	  
SCAF8_HUMAN	   SCAF8	   1	   479-­‐544	   NULL	   PF04818	  PF00076	  
MSI2H_HUMAN	   MSI2	   2	   24-­‐91,	  112-­‐178	   44	   	   PF00076	  
ENOX2_HUMAN	   ENOX2	   1	   130-­‐186	   NULL	   PF00076	  
RBM3_HUMAN	   RBM3	   1	   8-­‐78	   NULL	   PF00076	  
A1CF_HUMAN	   A1CF	   3	   233-­‐296,	  138-­‐199,	  58-­‐124	   24	  20	  22	   	   PF00076	  
ZN638_HUMAN	   ZNF638	   1	   679-­‐730	   NULL	   PF00076	  
U2AF4_HUMAN	   U2AF1L4	   1	   88-­‐140	   NULL	   PF00642	  PF00076	  
RBM8A_HUMAN	   RBM8A	   1	   75-­‐144	   NULL	   PF00076	  PF08777	  
SNRPA_HUMAN	   SNRPA	   2	   210-­‐272,	  12-­‐82	   14	   	   PF00076	  
HNRPL_HUMAN	   HNRNPL	   2	   106-­‐155,	  204-­‐257	   26	   	   PF00076	  
CPSF6_HUMAN	   CPSF6	   1	   83-­‐152	   NULL	   PF00076	  
RBM22_HUMAN	   RBM22	   1	   234-­‐298	   NULL	   PF00076	  
RU2B_HUMAN	   SNRPB2	   2	   153-­‐212,	  9-­‐79	   26	   	   PF00076	  
PABP3_HUMAN	   PABPC3	   4	  
101-­‐168,	  13-­‐83,	  296-­‐363,	  193-­‐
261	   32	  38	  44	  29	  28	  51	   	   PF00076	  PF00658	  
ROA2_HUMAN	   HNRNPA2B1	   2	   114-­‐181,	  23-­‐91	   39	   	   PF00076	  PF11627	  
EIF3B_HUMAN	   EIF3B	   1	   207-­‐257	   NULL	   PF08662	  PF00076	  
TRA2B_HUMAN	   TRA2B	   1	   122-­‐190	   NULL	   PF00076	  
RFOX2_HUMAN	   RBFOX2	   1	   124-­‐191	   NULL	   PF12414	  PF00076	  
ROAA_HUMAN	   HNRNPAB	   2	   72-­‐139,	  155-­‐224	   39	   	   PF00076	  PF08143	  
PUF60_HUMAN	   PUF60	   2	   131-­‐201,	  228-­‐297	   41	   	   PF00076	  
THOC4_HUMAN	   THOC4	   1	   108-­‐176	   NULL	   PF00076	  
ELAV3_HUMAN	   ELAVL3	   3	   127-­‐190,	  41-­‐111,	  286-­‐355	   39	  28	  30	   	   PF00076	  
U2AFL_HUMAN	   ZRSR1	   1	   246-­‐302	   NULL	   PF00642	  PF00076	  
SFR15_HUMAN	   SCAF4	   1	   510-­‐573	   NULL	   PF04818	  PF00076	  
RBM15_HUMAN	   RBM15	   1	   376-­‐444	   NULL	   PF07744	  PF00076	  
DND1_HUMAN	   DND1	   1	   60-­‐123	   NULL	   PF00076	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PTBP1_HUMAN	   PTBP1	   3	   339-­‐405,	  186-­‐250,	  458-­‐518	   24	  24	  24	   	   PF00076	  
SAFB1_HUMAN	   SAFB	   1	   409-­‐477	   NULL	   PF00076	  PF02037	  
CIRBP_HUMAN	   CIRBP	   1	   8-­‐78	   NULL	   PF00076	  
SFPQ_HUMAN	   SFPQ	   2	   374-­‐433,	  299-­‐363	   16	   	   PF00076	  PF08075	  
DJC17_HUMAN	   DNAJC17	   1	   189-­‐233	   NULL	   PF00226	  PF00076	  
G3BP1_HUMAN	   G3BP1	   1	   342-­‐396	   NULL	   PF02136	  PF00076	  
RU17_HUMAN	   SNRNP70	   1	   105-­‐174	   NULL	   PF12220	  PF00076	  
RNPS1_HUMAN	   RNPS1	   1	   165-­‐234	   NULL	   PF00076	  
SRSF5_HUMAN	   SRSF5	   2	   6-­‐67,	  110-­‐175	   25	   	   PF00076	  
MSI1H_HUMAN	   MSI1	   2	   111-­‐177,	  23-­‐90	   47	   	   PF00076	  
RALYL_HUMAN	   RALYL	   1	   23-­‐85	   NULL	   PF00076	  
HNRPF_HUMAN	   HNRNPF	   2	   115-­‐181,	  293-­‐356	   42	   	   PF00076	  PF08080	  
DAZ4_HUMAN	   DAZ1	   2	   207-­‐263,	  42-­‐98	   100	   	   PF00076	  
GRSF1_HUMAN	   GRSF1	   1	   254-­‐319	   NULL	   PF00076	  
DAZ1_HUMAN	   DAZ1	   3	   207-­‐263,	  372-­‐428,	  42-­‐98	   100	  100	  100	   	   PF00076	  
RBM12_HUMAN	   RBM12	   3	   432-­‐498,	  859-­‐928,	  548-­‐613	   22	  22	  22	   	   PF00076	  
NELFE_HUMAN	   RDBP	   1	   269-­‐323	   NULL	   PF00076	  
U2AFM_HUMAN	   ZRSR2	   1	   241-­‐297	   NULL	   PF00642	  PF00076	  
PABP4_HUMAN	   PABPC4	   4	  
13-­‐83,	  296-­‐363,	  101-­‐168,	  193-­‐
261	   32	  29	  34	  42	  50	  45	   	   PF00076	  PF00658	  
TIA1_HUMAN	   TIA1	   3	   108-­‐178,	  9-­‐77,	  216-­‐280	   27	  33	  36	   	   PF00076	  
ROD1_HUMAN	   ROD1	   3	   479-­‐539,	  184-­‐248,	  360-­‐426	   22	  18	  24	   	   PF00076	  
HNRPG_HUMAN	   RBMX	   1	   10-­‐80	   NULL	   PF00076	  PF08081	  
RBM39_HUMAN	   RBM39	   2	   155-­‐220,	  252-­‐322	   19	   	   PF00076	  
SRSF4_HUMAN	   SRSF4	   2	   106-­‐171,	  4-­‐64	   22	   	   PF00076	  
RBM19_HUMAN	   RBM19	   5	  
834-­‐904,	  4-­‐72,	  732-­‐804,	  404-­‐
473,	  302-­‐362	  
30	  25	  24	  22	  31	  28	  13	  
34	  19	  14	   	   PF00076	  
CSTF2_HUMAN	   CSTF2	   1	   18-­‐88	   NULL	   PF00076	  
EWS_HUMAN	   EWSR1	   1	   363-­‐441	   NULL	   PF00641	  PF00076	  
HNRPD_HUMAN	   HNRNPD	   2	   100-­‐167,	  184-­‐243	   46	   	   PF00076	  PF08143	  
HNRPM_HUMAN	   HNRNPM	   3	   74-­‐143,	  655-­‐722,	  206-­‐274	   42	  31	  42	   	   PF00076	  PF11532	  
RBM40_HUMAN	   RNPC3	   2	   422-­‐496,	  29-­‐95	   25	   	   PF00076	  
NUCL_HUMAN	   NCL	   4	  
574-­‐640,	  309-­‐377,	  398-­‐459,	  
488-­‐554	   28	  35	  38	  14	  11	  43	   	   PF00076	  
CELF6_HUMAN	   CELF6	   3	   136-­‐198,	  398-­‐467,	  48-­‐115	   28	  39	  25	   	   PF00076	  
U2AF1_HUMAN	   U2AF1	   1	   91-­‐141	   NULL	   PF00642	  PF00076	  
RBM28_HUMAN	   RBM28	   3	   337-­‐395,	  116-­‐184,	  6-­‐68	   37	  25	  28	   	   PF00076	  
TRA2A_HUMAN	   TRA2A	   1	   123-­‐191	   NULL	   PF00076	  
BOLL_HUMAN	   BOLL	   1	   35-­‐103	   NULL	   PF00076	  PF08777	  
LA_HUMAN	   SSB	   1	   113-­‐178	   NULL	  
PF08777	  PF05383	  
PF00076	  
PAP1M_HUMAN	  
PABPC1L2B	  
PABPC1L2A	   2	   92-­‐159,	  4-­‐74	   26	   	   PF00076	  
HNRH3_HUMAN	   HNRNPH3	   2	   199-­‐262,	  20-­‐86	   40	   	   PF00076	  
CELF3_HUMAN	   CELF3	   3	   382-­‐451,	  9-­‐76,	  97-­‐161	   20	  30	  38	   	   PF00076	  
PDIP3_HUMAN	   POLDIP3	   1	   284-­‐344	   NULL	   PF00076	  
RBM7_HUMAN	   RBM7	   1	   12-­‐81	   NULL	   PF00076	  
NOL8_HUMAN	   NOL8	   1	   10-­‐79	   NULL	   PF00076	  
PRGC2_HUMAN	   PPARGC1B	   1	   904-­‐955	   NULL	   PF00076	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TIAR_HUMAN	   TIAL1	   3	   99-­‐169,	  11-­‐79,	  207-­‐271	   27	  33	  35	   	   PF00076	  
RBM42_HUMAN	   RBM42	   1	   383-­‐453	   NULL	   PF00076	  
MINT_HUMAN	   SPEN	   4	  
339-­‐406,	  440-­‐507,	  8-­‐68,	  520-­‐
583	   14	  19	  20	  26	  25	  19	   	   PF00076	  PF07744	  
PABP2_HUMAN	   PABPN1	   1	   174-­‐243	   NULL	   PF00076	  
RBM24_HUMAN	   RBM24	   1	   13-­‐70	   NULL	   PF00076	  
ELAV2_HUMAN	   ELAVL2	   3	   41-­‐111,	  127-­‐193,	  278-­‐347	   40	  31	  26	   	   PF00076	  
STPAP_HUMAN	   TUT1	   1	   58-­‐121	   NULL	   PF03828	  PF00076	  
SAFB2_HUMAN	   SAFB2	   1	   409-­‐478	   NULL	   PF00076	  PF02037	  
RBM4_HUMAN	   RBM4	   2	   4-­‐64,	  81-­‐141	   42	   	   PF00076	  PF00098	  
RFOX3_HUMAN	   RBFOX3	   1	   102-­‐169	   NULL	   PF12414	  PF00076	  
RBMX2_HUMAN	   RBMX2	   1	   38-­‐108	   NULL	   PF00076	  
RB15B_HUMAN	   RBM15B	   2	   420-­‐480,	  339-­‐408	   29	   	   PF00076	  PF07744	  
ELAV4_HUMAN	   ELAVL4	   3	   48-­‐118,	  299-­‐368,	  134-­‐200	   31	  38	  28	   	   PF00076	  
ELAV1_HUMAN	   ELAVL1	   3	   22-­‐92,	  246-­‐314,	  108-­‐174	   33	  29	  28	   	   PF00076	  
RALY_HUMAN	   RALY	   1	   23-­‐85	   NULL	   PF00076	  
SRSF3_HUMAN	   SRSF3	   1	   12-­‐77	   NULL	   PF00076	  
RBM10_HUMAN	   RBM10	   1	   132-­‐194	   NULL	  
PF01585	  PF00076	  
PF00641	  
HNRLL_HUMAN	   HNRPLL	   2	   80-­‐128,	  180-­‐230	   20	   	   PF00076	  
SF3B4_HUMAN	   SF3B4	   2	   102-­‐173,	  15-­‐85	   35	   	   PF00076	  
SLTM_HUMAN	   SLTM	   1	   386-­‐455	   NULL	   PF00076	  PF02037	  
CSTFT_HUMAN	   CSTF2T	   1	   18-­‐88	   NULL	   PF00076	  
RBPS2_HUMAN	   RBPMS2	   1	   33-­‐94	   NULL	   PF00076	  
RBPMS_HUMAN	   RBPMS	   1	   26-­‐87	   NULL	   PF00076	  
UHMK1_HUMAN	   UHMK1	   1	   345-­‐398	   NULL	  
PF00069	  PF07714	  
PF00076	  
HNRCL_HUMAN	   HNRNPCL1	   1	   18-­‐79	   NULL	   PF00076	  
RMXL3_HUMAN	   RBMXL3	   1	   10-­‐79	   NULL	   PF00076	  
NONO_HUMAN	   NONO	   2	   150-­‐210,	  76-­‐140	   14	   	   PF00076	  PF08075	  
E7EX17_HUMAN	   E7EX17	   1	   99-­‐167	   NULL	   PF00076	  
B4E312_HUMAN	   B4E312	   1	   39-­‐117	   NULL	   PF00076	  PF00641	  
B4DMJ1_HUMAN	   B4DMJ1	   1	   18-­‐80	   NULL	   PF00076	  
Q4W5M7_HUMAN	   Q4W5M7	   1	   679-­‐739	   NULL	   PF00076	  
Q6IA98_HUMAN	   Q6IA98	   2	   152-­‐217,	  249-­‐318	   19	   	   PF00076	  
B4DDC7_HUMAN	   B4DDC7	   1	   131-­‐193	   NULL	   PF00076	  
Q5T760_HUMAN	   Q5T760	   1	   37-­‐101	   NULL	   PF00076	  
C9JAB2_HUMAN	   C9JAB2	   1	   13-­‐77	   NULL	   PF00076	  
Q05BU6_HUMAN	   Q05BU6	   1	   37-­‐102	   NULL	   PF00076	  
Q49AS9_HUMAN	   Q49AS9	   2	   2-­‐46,	  84-­‐148	   26	   	   PF00076	  
Q5QP71_HUMAN	   Q5QP71	   1	   429-­‐490	   NULL	   PF00076	  
B4DQI6_HUMAN	   B4DQI6	   1	   22-­‐90	   NULL	   PF00076	  
B7ZLP6_HUMAN	   B7ZLP6	   1	   409-­‐477	   NULL	   PF00076	  PF02037	  
B4E2U5_HUMAN	   B4E2U5	   3	   385-­‐454,	  2-­‐67,	  92-­‐157	   22	  25	  34	   	   PF00076	  
D6RF44_HUMAN	   D6RF44	   1	   2-­‐69	   NULL	   PF00076	  
F5H1L1_HUMAN	   F5H1L1	   1	   304-­‐372	   NULL	   PF00076	  PF02037	  
Q53FG6_HUMAN	   Q53FG6	   2	   15-­‐85,	  102-­‐173	   33	   	   PF00076	  
F5H656_HUMAN	   F5H656	   2	   24-­‐88,	  98-­‐156	   22	   	   PF00076	  PF08075	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Q5SZ64_HUMAN	   Q5SZ64	   1	   59-­‐130	   NULL	   PF00076	  
F5H6R1_HUMAN	   F5H6R1	   1	   38-­‐108	   NULL	   PF00076	  
F5H101_HUMAN	   F5H101	   1	   10-­‐79	   NULL	   PF00076	  
Q6ZP53_HUMAN	   Q6ZP53	   1	   183-­‐237	   NULL	   PF00076	  PF02136	  
Q59ES8_HUMAN	   Q59ES8	   2	   540-­‐607,	  106-­‐174	   42	   	   PF00076	  
E7EWT5_HUMAN	   E7EWT5	   1	   8-­‐70	   NULL	   PF00076	  
A8MY68_HUMAN	   A8MY68	   1	   32-­‐88	   NULL	   PF00076	  PF04098	  
E9PCZ6_HUMAN	   E9PCZ6	   1	   146-­‐211	   NULL	   PF00076	  
B7Z1U7_HUMAN	   B7Z1U7	   1	   163-­‐230	   NULL	   PF00076	  
B4DTA2_HUMAN	   B4DTA2	   2	   2-­‐69,	  86-­‐147	   40	   	   PF00076	  
Q5JRI3_HUMAN	   Q5JRI3	   1	   12-­‐81	   NULL	   PF00076	  
Q53TM1_HUMAN	   Q53TM1	   1	   21-­‐87	   NULL	   PF00076	  
B4DWI8_HUMAN	   B4DWI8	   2	   24-­‐88,	  98-­‐156	   22	   	   PF08075	  PF00076	  
B4DUN1_HUMAN	   B4DUN1	   1	   239-­‐293	   NULL	   PF00076	  
B5BUD8_HUMAN	   B5BUD8	   1	   6-­‐67	   NULL	   PF00076	  
B4DSS8_HUMAN	   B4DSS8	   3	   194-­‐258,	  475-­‐535,	  356-­‐421	   26	  24	  16	   	   PF00076	  
B3KY61_HUMAN	   B3KY61	   1	   561-­‐612	   NULL	  
PF00642	  PF01480	  
PF00076	  
A4D2F7_HUMAN	   A4D2F7	   1	   18-­‐86	   NULL	   PF00076	  
B4DSJ1_HUMAN	   B4DSJ1	   1	   23-­‐85	   NULL	   PF00076	  
B4DEH8_HUMAN	   B4DEH8	   1	   46-­‐115	   NULL	   PF00076	  
Q5T9T9_HUMAN	   Q5T9T9	   1	   10-­‐80	   NULL	   PF00076	  
Q5CZ65_HUMAN	   Q5CZ65	   1	   9-­‐73	   NULL	   PF00076	  
B5BU08_HUMAN	   B5BU08	   1	   91-­‐141	   NULL	   PF00642	  PF00076	  
E9PFS2_HUMAN	   E9PFS2	   1	   47-­‐116	   NULL	   PF00076	  
B7ZW38_HUMAN	   B7ZW38	   1	   18-­‐79	   NULL	   PF00076	  
Q6AI50_HUMAN	   Q6AI50	   1	   10-­‐79	   NULL	   PF00076	  
B4DSU5_HUMAN	   B4DSU5	   3	   191-­‐255,	  467-­‐527,	  348-­‐413	   26	  24	  16	   	   PF00076	  
B1ALY6_HUMAN	   B1ALY6	   3	   384-­‐444,	  89-­‐153,	  265-­‐331	   22	  18	  24	   	   PF00076	  
Q32P45_HUMAN	   Q32P45	   1	   342-­‐396	   NULL	   PF02136	  PF00076	  
F2Z2U1_HUMAN	   F2Z2U1	   1	   10-­‐73	   NULL	   PF00076	  
E7ENA6_HUMAN	   E7ENA6	   1	   42-­‐98	   NULL	   PF00076	  
B2RA86_HUMAN	   B2RA86	   3	   129-­‐193,	  426-­‐495,	  38-­‐106	   30	  33	  21	   	   PF00076	  
D6REZ6_HUMAN	   D6REZ6	   1	   73-­‐137	   NULL	   PF00076	  
B4DT28_HUMAN	   B4DT28	   3	   28-­‐92,	  204-­‐265,	  109-­‐170	   25	  22	  22	   	   PF00076	  
B4DFT9_HUMAN	   B4DFT9	   1	   16-­‐83	   NULL	   PF00076	  
B7Z4C2_HUMAN	   B7Z4C2	   2	   2-­‐51,	  61-­‐121	   6	   	   PF08075	  PF00076	  
D6RBS9_HUMAN	   D6RBS9	   2	   73-­‐137,	  153-­‐214	   29	   	   PF00076	  
C9J2Z9_HUMAN	   C9J2Z9	   1	   101-­‐165	   NULL	   PF00076	  
E9PC62_HUMAN	   E9PC62	   3	   141-­‐205,	  438-­‐507,	  50-­‐118	   30	  33	  21	   	   PF00076	  
Q6P392_HUMAN	   Q6P392	   1	   242-­‐312	   NULL	   PF00160	  PF00076	  
D6RIT2_HUMAN	   D6RIT2	   1	   15-­‐82	   NULL	   PF08080	  PF00076	  
Q6NTA2_HUMAN	   Q6NTA2	   2	   89-­‐138,	  187-­‐240	   26	   	   PF00076	  
B4DT00_HUMAN	   B4DT00	   3	   110-­‐174,	  401-­‐470,	  19-­‐87	   30	  33	  21	   	   PF00076	  
B7Z5E0_HUMAN	   B7Z5E0	   3	   14-­‐84,	  251-­‐320,	  100-­‐166	   31	  38	  28	   	   PF00076	  
C9JGD3_HUMAN	   C9JGD3	   3	   216-­‐279,	  121-­‐182,	  41-­‐107	   24	  20	  22	   	   PF00076	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B7Z2F6_HUMAN	   B7Z2F6	   1	   252-­‐320	   NULL	   PF00076	  
C9JBI6_HUMAN	   C9JBI6	   1	   679-­‐730	   NULL	   PF00076	  
B4DDB6_HUMAN	   B4DDB6	   2	   15-­‐83,	  106-­‐174	   34	   	   PF00076	  
B0QYK1_HUMAN	   B0QYK1	   1	   307-­‐385	   NULL	   PF00641	  PF00076	  
A8K6V7_HUMAN	   A8K6V7	   1	   300-­‐357	   NULL	   PF02136	  PF00076	  
B1ANR1_HUMAN	   B1ANR1	   1	   13-­‐83	   NULL	   PF00076	  
Q2TSD2_HUMAN	   Q2TSD2	   3	   99-­‐169,	  11-­‐79,	  207-­‐271	   27	  33	  35	   	   PF00076	  
E5RFU5_HUMAN	   E5RFU5	   2	   79-­‐139,	  158-­‐222	   27	   	   PF00076	  
C9IZZ3_HUMAN	   C9IZZ3	   1	   368-­‐437	   NULL	   PF00076	  PF02037	  
C9JTN7_HUMAN	   C9JTN7	   2	   97-­‐167,	  9-­‐77	   27	   	   PF00076	  
A4D2F6_HUMAN	   A4D2F6	   1	   274-­‐342	   NULL	   PF00076	  
Q5QP20_HUMAN	   Q5QP20	   1	   27-­‐92	   NULL	   PF00076	  
B4DZH7_HUMAN	   B4DZH7	   1	   259-­‐310	   NULL	   PF00076	  
E9PQU5_HUMAN	   E9PQU5	   1	   89-­‐157	   NULL	   PF00076	  
B7Z5X3_HUMAN	   B7Z5X3	   1	   316-­‐384	   NULL	   PF00076	  
A8K8A6_HUMAN	   A8K8A6	   1	   10-­‐80	   NULL	   PF00076	  PF08081	  
B4DZ74_HUMAN	   B4DZ74	   1	   10-­‐65	   NULL	   PF00076	  PF04098	  
B3KME7_HUMAN	   B3KME7	   3	   384-­‐444,	  89-­‐153,	  265-­‐331	   22	  18	  24	   	   PF00076	  
Q53GL6_HUMAN	   Q53GL6	   1	   23-­‐85	   NULL	   PF00076	  
A6NJK7_HUMAN	   A6NJK7	   1	   10-­‐79	   NULL	   PF00076	  
E9PHU9_HUMAN	   E9PHU9	   1	   269-­‐338	   NULL	   PF00076	  
C9JGE3_HUMAN	   C9JGE3	   1	   290-­‐368	   NULL	   PF00641	  PF00076	  
B4DK81_HUMAN	   B4DK81	   1	   276-­‐348	   NULL	   PF00076	  
B3KP14_HUMAN	   B3KP14	   3	   88-­‐152,	  337-­‐399,	  186-­‐251	   28	  35	  46	   	   PF00076	  
B4E3T4_HUMAN	   B4E3T4	   1	   26-­‐87	   NULL	   PF00076	  
B4DJ90_HUMAN	   B4DJ90	   2	   284-­‐342,	  63-­‐131	   37	   	   PF00076	  
Q6IPF2_HUMAN	   Q6IPF2	   2	   107-­‐175,	  16-­‐84	   33	   	   PF00076	  PF11627	  
E5RGH4_HUMAN	   E5RGH4	   1	   38-­‐95	   NULL	   PF00076	  
F5GZU3_HUMAN	   F5GZU3	   1	   239-­‐307	   NULL	   PF00076	  
B7Z7Q9_HUMAN	   B7Z7Q9	   1	   42-­‐98	   NULL	   PF00076	  
B4DZW4_HUMAN	   B4DZW4	   3	   251-­‐318,	  56-­‐123,	  148-­‐216	   41	  50	  47	   	   PF00658	  PF00076	  
B4DRW3_HUMAN	   B4DRW3	   2	   109-­‐157,	  22-­‐87	   30	   	   PF00076	  
B4DVF8_HUMAN	   B4DVF8	   1	   71-­‐124	   NULL	   PF00076	  
B7Z6E0_HUMAN	   B7Z6E0	   1	   5-­‐73	   NULL	   PF00076	  
A6NLN1_HUMAN	   A6NLN1	   2	   13-­‐71,	  124-­‐184	   27	   	   PF00076	  
B4DSC7_HUMAN	   B4DSC7	   2	   97-­‐143,	  9-­‐76	   40	   	   PF00076	  
E7ETU5_HUMAN	   E7ETU5	   2	   31-­‐91,	  110-­‐174	   27	   	   PF00076	  
B3KWE6_HUMAN	   B3KWE6	   2	   7-­‐59,	  259-­‐328	   28	   	   PF00076	  
E9PM61_HUMAN	   E9PM61	   2	   4-­‐64,	  81-­‐138	   46	   	   PF00076	  
B6RF28_HUMAN	   B6RF28	   1	   149-­‐218	   NULL	   PF00076	  
Q9C059_HUMAN	   Q9C059	   1	   37-­‐99	   NULL	   PF00076	  
E7EU98_HUMAN	   E7EU98	   1	   42-­‐98	   NULL	   PF00076	  
B4DTC3_HUMAN	   B4DTC3	   2	   48-­‐115,	  132-­‐191	   46	   	   PF00076	  PF08143	  
B7Z4L7_HUMAN	   B7Z4L7	   2	   6-­‐63,	  95-­‐165	   20	   	   PF00076	  
A8KAI7_HUMAN	   A8KAI7	   1	   13-­‐70	   NULL	   PF00076	  
B4DMB1_HUMAN	   B4DMB1	   3	   129-­‐193,	  305-­‐366,	  210-­‐271	   25	  22	  22	   	   PF00076	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E7EN82_HUMAN	   E7EN82	   1	   42-­‐98	   NULL	   PF00076	  
E7ETR3_HUMAN	   E7ETR3	   1	   42-­‐98	   NULL	   PF00076	  
E1P603_HUMAN	   E1P603	   1	   13-­‐70	   NULL	   PF00076	  
Q13344_HUMAN	   Q13344	   1	   290-­‐368	   NULL	   PF00641	  PF00076	  
E7EWR4_HUMAN	   E7EWR4	   1	   18-­‐88	   NULL	   PF00076	  
E7EQV3_HUMAN	   E7EQV3	   3	   56-­‐123,	  251-­‐318,	  148-­‐216	   41	  47	  51	   	   PF00658	  PF00076	  
B4DJM2_HUMAN	   B4DJM2	   1	   42-­‐112	   NULL	   PF00076	  
F5GYZ3_HUMAN	   F5GYZ3	   2	   2-­‐51,	  61-­‐121	   6	   	   PF08075	  PF00076	  
B4DMD1_HUMAN	   B4DMD1	   2	   88-­‐149,	  183-­‐244	   22	   	   PF00076	  
D6RDL0_HUMAN	   D6RDL0	   1	   14-­‐82	   NULL	   PF00076	  
Q53XX5_HUMAN	   Q53XX5	   1	   8-­‐78	   NULL	   PF00076	  
B4DHA8_HUMAN	   B4DHA8	   2	   143-­‐205,	  56-­‐123	   41	   	   PF00076	  
F5H669_HUMAN	   F5H669	   1	   84-­‐155	   NULL	   PF00076	  
B2RDQ3_HUMAN	   B2RDQ3	   1	   122-­‐190	   NULL	   PF00076	  
D6RAM1_HUMAN	   D6RAM1	   1	   15-­‐82	   NULL	   PF00076	  
F5GXV1_HUMAN	   F5GXV1	   1	   10-­‐57	   NULL	   PF00076	  
B4DRS4_HUMAN	   B4DRS4	   2	   289-­‐343,	  135-­‐212	   5	   	   PF00076	  
B4DI28_HUMAN	   B4DI28	   1	   152-­‐216	   NULL	   PF00076	  
Q32Q83_HUMAN	   Q32Q83	   1	   242-­‐312	   NULL	   PF00160	  PF00076	  
E9PAU2_HUMAN	   E9PAU2	   2	   78-­‐140,	  152-­‐220	   25	   	   PF00076	  
D6RJ04_HUMAN	   D6RJ04	   1	   15-­‐82	   NULL	   PF00076	  
Q8TER1_HUMAN	   Q8TER1	   1	   73-­‐136	   NULL	   PF00076	  
E7EVG6_HUMAN	   E7EVG6	   1	   1281-­‐1340	   NULL	   PF00076	  
E7ETC0_HUMAN	   E7ETC0	   1	   11-­‐79	   NULL	   PF00076	  
D3DU92_HUMAN	   D3DU92	   1	   165-­‐234	   NULL	   PF00076	  
B4DJP9_HUMAN	   B4DJP9	   1	   12-­‐81	   NULL	   PF00076	  
Q96G38_HUMAN	   Q96G38	   1	   16-­‐66	   NULL	   PF08662	  PF00076	  
Q5HYB4_HUMAN	   Q5HYB4	   1	   62-­‐128	   NULL	   PF00076	  
A8K644_HUMAN	   A8K644	   2	   106-­‐171,	  4-­‐64	   22	   	   PF00076	  
D6R9T0_HUMAN	   D6R9T0	   1	   15-­‐82	   NULL	   PF00076	  
Q9Y6G0_HUMAN	   Q9Y6G0	   1	   38-­‐108	   NULL	   PF00076	  
E9PBY2_HUMAN	   E9PBY2	   1	   42-­‐98	   NULL	   PF00076	  
B4DN17_HUMAN	   B4DN17	   1	   307-­‐371	   NULL	   PF01812	  PF00076	  
B4DHS3_HUMAN	   B4DHS3	   2	   2-­‐46,	  84-­‐148	   24	   	   PF00076	  
E5RG67_HUMAN	   E5RG67	   1	   9-­‐77	   NULL	   PF00076	  
Q59EQ8_HUMAN	   Q59EQ8	   1	   18-­‐87	   NULL	   PF00076	  
B4DMY3_HUMAN	   B4DMY3	   2	   64-­‐131,	  147-­‐215	   39	   	   PF00076	  PF08143	  
E5RFD8_HUMAN	   E5RFD8	   1	   13-­‐60	   NULL	   PF00076	  
Q75MU1_HUMAN	   Q75MU1	   1	   45-­‐112	   NULL	   PF00076	  
B4DPK8_HUMAN	   B4DPK8	   2	   34-­‐83,	  132-­‐185	   26	   	   PF00076	  
B3KXC1_HUMAN	   B3KXC1	   1	   135-­‐196	   NULL	   PF00076	  
Q68DG4_HUMAN	   Q68DG4	   1	   115-­‐177	   NULL	   PF08080	  PF00076	  
F5H532_HUMAN	   F5H532	   1	   10-­‐80	   NULL	   PF00076	  
B2RXH8_HUMAN	   B2RXH8	   1	   18-­‐77	   NULL	   PF00076	  
B7Z2Z1_HUMAN	   B7Z2Z1	   1	   304-­‐372	   NULL	   PF00076	  PF02037	  
B4DVB8_HUMAN	   B4DVB8	   3	   49-­‐119,	  273-­‐341,	  135-­‐201	   33	  29	  28	   	   PF00076	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A8K3M9_HUMAN	   A8K3M9	   2	   16-­‐83,	  113-­‐174	   16	   	   PF00076	  
B4DHY1_HUMAN	   B4DHY1	   1	   91-­‐154	   NULL	   PF00076	  
C9JQN2_HUMAN	   C9JQN2	   1	   50-­‐105	   NULL	   PF09004	  PF00076	  
Q9BQ02_HUMAN	   Q9BQ02	   2	   346-­‐412,	  260-­‐326	   38	   	   PF00076	  
D6RFF0_HUMAN	   D6RFF0	   1	   127-­‐188	   NULL	   PF05383	  PF00076	  
B4DR70_HUMAN	   B4DR70	   1	   216-­‐294	   NULL	   PF00641	  PF00076	  
D6RF41_HUMAN	   D6RF41	   1	   63-­‐126	   NULL	   PF00076	  
E9PSH0_HUMAN	   E9PSH0	   1	   19-­‐84	   NULL	   PF00076	  
C9JPX0_HUMAN	   C9JPX0	   1	   305-­‐374	   NULL	   PF00076	  PF02037	  
D6RGD8_HUMAN	   D6RGD8	   1	   3-­‐60	   NULL	   PF00076	  
C9JJZ7_HUMAN	   C9JJZ7	   1	   19-­‐67	   NULL	   PF00076	  
B3KUJ0_HUMAN	   B3KUJ0	   2	   102-­‐173,	  15-­‐85	   33	   	   PF00076	  
B4E241_HUMAN	   B4E241	   1	   12-­‐77	   NULL	   PF00076	  
Q59G45_HUMAN	   Q59G45	   2	   358-­‐427,	  73-­‐137	   30	   	   PF00076	  
F5H6R6_HUMAN	   F5H6R6	   1	   30-­‐90	   NULL	   PF00076	  
B7Z6T4_HUMAN	   B7Z6T4	   1	   269-­‐320	   NULL	   PF00076	  
F5GWQ7_HUMAN	   F5GWQ7	   1	   39-­‐117	   NULL	   PF00076	  PF00641	  
F5GXV8_HUMAN	   F5GXV8	   1	   12-­‐81	   NULL	   PF00076	  
B4E1E3_HUMAN	   B4E1E3	   3	   226-­‐289,	  131-­‐192,	  51-­‐117	   24	  20	  22	   	   PF00076	  
E9PFH8_HUMAN	   E9PFH8	   1	   113-­‐178	   NULL	  
PF08777	  PF05383	  
PF00076	  
E7EPC9_HUMAN	   E7EPC9	   1	   99-­‐167	   NULL	   PF00076	  
B4DHE8_HUMAN	   B4DHE8	   2	   2-­‐69,	  90-­‐156	   44	   	   PF00076	  
Q53F64_HUMAN	   Q53F64	   2	   73-­‐140,	  156-­‐224	   39	   	   PF08143	  PF00076	  
E5RI26_HUMAN	   E5RI26	   1	   13-­‐73	   NULL	   PF00076	  
E7ERQ6_HUMAN	   E7ERQ6	   1	   42-­‐98	   NULL	   PF00076	  
E7EN40_HUMAN	   E7EN40	   1	   15-­‐82	   NULL	   PF00076	  
C9JIJ9_HUMAN	   C9JIJ9	   2	   62-­‐122,	  141-­‐205	   27	   	   PF00076	  
B4DM91_HUMAN	   B4DM91	   1	   10-­‐79	   NULL	   PF00076	  
D6RFJ8_HUMAN	   D6RFJ8	   1	   275-­‐332	   NULL	   PF02136	  PF00076	  
B1APY8_HUMAN	   B1APY8	   3	   53-­‐123,	  304-­‐373,	  139-­‐205	   31	  38	  28	   	   PF00076	  
A8K5C4_HUMAN	   A8K5C4	   3	   11-­‐79,	  99-­‐169,	  207-­‐271	   26	  35	  32	   	   PF00076	  
F5H659_HUMAN	   F5H659	   1	   771-­‐832	   NULL	   PF00076	  
Q6ZS99_HUMAN	   Q6ZS99	   4	  
467-­‐533,	  202-­‐270,	  381-­‐447,	  
291-­‐352	   28	  38	  35	  11	  14	  41	   	   PF00076	  
O95652_HUMAN	   O95652	   1	   43-­‐87	   NULL	   PF00076	  
B2R603_HUMAN	   B2R603	   1	   18-­‐80	   NULL	   PF00076	  
F5H357_HUMAN	   F5H357	   1	   26-­‐87	   NULL	   PF00076	  
B4DM75_HUMAN	   B4DM75	   4	  
76-­‐143,	  272-­‐340,	  169-­‐237,	  2-­‐
56	   36	  32	  18	  39	  18	  27	   	   PF00076	  
Q59FM6_HUMAN	   Q59FM6	   1	   222-­‐291	   NULL	   PF00076	  
E9PQ56_HUMAN	   E9PQ56	   2	   113-­‐183,	  210-­‐279	   41	   	   PF00076	  
B1ALY5_HUMAN	   B1ALY5	   3	   451-­‐511,	  156-­‐220,	  332-­‐398	   22	  18	  24	   	   PF00076	  
B3V096_HUMAN	   B3V096	   1	   18-­‐88	   NULL	   PF00076	  
Q7Z3W9_HUMAN	   Q7Z3W9	   1	   61-­‐111	   NULL	   PF00076	  
B7ZMC0_HUMAN	   B7ZMC0	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
A6NEW5_HUMAN	   A6NEW5	   1	   101-­‐168	   NULL	   PF00076	  
C9JLZ0_HUMAN	   C9JLZ0	   1	   495-­‐558	   NULL	   PF04818	  PF00076	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B4DZ07_HUMAN	   B4DZ07	   1	   2-­‐49	   NULL	   PF00076	  
F5H0M7_HUMAN	   F5H0M7	   1	   145-­‐209	   NULL	   PF00076	  
B3KTP9_HUMAN	   B3KTP9	   4	  
497-­‐563,	  232-­‐300,	  321-­‐382,	  
411-­‐477	   28	  35	  38	  14	  11	  43	   	   PF00076	  
B1APY9_HUMAN	   B1APY9	   3	   53-­‐123,	  290-­‐359,	  139-­‐205	   31	  38	  28	   	   PF00076	  
E7EU39_HUMAN	   E7EU39	   1	   42-­‐98	   NULL	   PF00076	  
B2RUT9_HUMAN	   B2RUT9	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
C9J286_HUMAN	   C9J286	   1	   84-­‐143	   NULL	   PF00076	  
D6RIU0_HUMAN	   D6RIU0	   2	   15-­‐82,	  115-­‐168	   38	   	   PF00076	  
Q0VGM7_HUMAN	   Q0VGM7	   1	   38-­‐108	   NULL	   PF00076	  
A8K1C9_HUMAN	   A8K1C9	   2	   421-­‐495,	  29-­‐95	   25	   	   PF00076	  
D6RFL5_HUMAN	   D6RFL5	   1	   73-­‐136	   NULL	   PF00076	  
B4DXN6_HUMAN	   B4DXN6	   1	   54-­‐104	   NULL	   PF08662	  PF00076	  
E9PFP2_HUMAN	   E9PFP2	   2	   289-­‐343,	  135-­‐212	   5	   	   PF00076	  
B9ZVT1_HUMAN	   B9ZVT1	   2	   402-­‐470,	  288-­‐353	   12	   	   PF00076	  
Q6PJB9_HUMAN	   Q6PJB9	   1	   37-­‐101	   NULL	   PF00076	  
B4DFK9_HUMAN	   B4DFK9	   2	   15-­‐82,	  248-­‐310	   33	   	   PF08080	  PF00076	  
B4DSI2_HUMAN	   B4DSI2	   2	   131-­‐191,	  12-­‐77	   16	   	   PF00076	  
D6RFM3_HUMAN	   D6RFM3	   2	   115-­‐163,	  15-­‐82	   42	   	   PF00076	  
A8K583_HUMAN	   A8K583	   1	   679-­‐730	   NULL	   PF00076	  
Q5QP21_HUMAN	   Q5QP21	   1	   133-­‐198	   NULL	   PF00076	  
B7Z1C7_HUMAN	   B7Z1C7	   1	   208-­‐275	   NULL	   PF00076	  
B4DM66_HUMAN	   B4DM66	   1	   231-­‐300	   NULL	   PF00076	  
B7Z5B6_HUMAN	   B7Z5B6	   1	   340-­‐408	   NULL	   PF00076	  PF02037	  
Q701P4_HUMAN	   Q701P4	   1	   91-­‐141	   NULL	   PF00642	  PF00076	  
B4DSZ2_HUMAN	   B4DSZ2	   1	   19-­‐87	   NULL	   PF00076	  
B4E2A3_HUMAN	   B4E2A3	   1	   8-­‐70	   NULL	   PF00076	  
B3KSX3_HUMAN	   B3KSX3	   1	   23-­‐85	   NULL	   PF00076	  
Q68DD9_HUMAN	   Q68DD9	   2	   138-­‐203,	  235-­‐305	   19	   	   PF00076	  
Q5VVE3_HUMAN	   Q5VVE3	   1	   298-­‐365	   NULL	   PF00076	  
Q53HH4_HUMAN	   Q53HH4	   1	   342-­‐396	   NULL	   PF02136	  PF00076	  
B3KVY2_HUMAN	   B3KVY2	   1	   18-­‐86	   NULL	   PF00076	  
B0QYK0_HUMAN	   B0QYK0	   1	   325-­‐403	   NULL	   PF00641	  PF00076	  
B4E187_HUMAN	   B4E187	   1	   258-­‐309	   NULL	   PF00076	  
D6R9K7_HUMAN	   D6R9K7	   2	   81-­‐138,	  4-­‐64	   43	   	   PF00076	  
B4DU52_HUMAN	   B4DU52	   1	   196-­‐254	   NULL	   PF00076	  
B4DRM3_HUMAN	   B4DRM3	   1	   99-­‐167	   NULL	   PF00076	  
A8K5K5_HUMAN	   A8K5K5	   1	   241-­‐303	   NULL	   PF12353	  PF00076	  
B4DDE7_HUMAN	   B4DDE7	   3	   118-­‐182,	  413-­‐482,	  27-­‐95	   30	  33	  21	   	   PF00076	  
D6RIH9_HUMAN	   D6RIH9	   1	   15-­‐82	   NULL	   PF00076	  
Q59HD3_HUMAN	   Q59HD3	   1	   161-­‐228	   NULL	   PF00076	  
C9JE21_HUMAN	   C9JE21	   1	   150-­‐204	   NULL	   PF00076	  
Q05DU0_HUMAN	   Q05DU0	   1	   38-­‐108	   NULL	   PF00076	  
Q53GD7_HUMAN	   Q53GD7	   1	   12-­‐81	   NULL	   PF00076	  
B7ZKM0_HUMAN	   B7ZKM0	   2	   670-­‐738,	  767-­‐835	   27	   	   PF00076	  PF05391	  
E7EU28_HUMAN	   E7EU28	   2	   145-­‐210,	  242-­‐311	   19	   	   PF00076	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A4D210_HUMAN	   A4D210	   1	   168-­‐218	   NULL	   PF08662	  PF00076	  
Q59H49_HUMAN	   Q59H49	   1	   203-­‐267	   NULL	   PF00076	  
F5H0D8_HUMAN	   F5H0D8	   1	   46-­‐102	   NULL	   PF00076	  
Q0VAC0_HUMAN	   Q0VAC0	   2	   107-­‐175,	  16-­‐84	   33	   	   PF11627	  PF00076	  
Q6IBQ5_HUMAN	   Q6IBQ5	   1	   287-­‐365	   NULL	   PF00641	  PF00076	  
E7ERC4_HUMAN	   E7ERC4	   1	   113-­‐178	   NULL	   PF05383	  PF00076	  
D3DPB2_HUMAN	   D3DPB2	   2	   110-­‐174,	  31-­‐91	   27	   	   PF00076	  
Q5H919_HUMAN	   Q5H919	   1	   135-­‐212	   NULL	   PF00076	  
B4E2S3_HUMAN	   B4E2S3	   2	   62-­‐122,	  141-­‐205	   27	   	   PF00076	  
F5GWN9_HUMAN	   F5GWN9	   1	   10-­‐79	   NULL	   PF00076	  
C9J9B2_HUMAN	   C9J9B2	   2	   63-­‐123,	  142-­‐206	   27	   	   PF00076	  
B7Z213_HUMAN	   B7Z213	   1	   34-­‐95	   NULL	   PF00076	  
B7Z974_HUMAN	   B7Z974	   1	   12-­‐76	   NULL	   PF00076	  
Q8NAK9_HUMAN	   Q8NAK9	   1	   18-­‐86	   NULL	   PF00076	  
Q2VIP3_HUMAN	   Q2VIP3	   4	  
101-­‐168,	  13-­‐83,	  296-­‐363,	  193-­‐
261	   32	  38	  44	  29	  28	  51	   	   PF00658	  PF00076	  
Q59GY3_HUMAN	   Q59GY3	   2	   38-­‐98,	  146-­‐211	   24	   	   PF00076	  
A6NIT8_HUMAN	   A6NIT8	   1	   71-­‐124	   NULL	   PF00076	  
F2Z2G3_HUMAN	   F2Z2G3	   1	   35-­‐103	   NULL	   PF00076	  
B7WPG3_HUMAN	   B7WPG3	   1	   80-­‐128	   NULL	   PF00076	  
F5H718_HUMAN	   F5H718	   1	   101-­‐157	   NULL	   PF00076	  
A0PJ47_HUMAN	   A0PJ47	   1	   409-­‐478	   NULL	   PF00076	  PF02037	  
Q68DZ9_HUMAN	   Q68DZ9	   1	   110-­‐178	   NULL	   PF00076	  
B7ZM40_HUMAN	   B7ZM40	   1	   865-­‐916	   NULL	   PF00076	  
Q05CK9_HUMAN	   Q05CK9	   3	   200-­‐265,	  281-­‐342,	  376-­‐437	   20	  22	  19	   	   PF00076	  
Q6PKC9_HUMAN	   Q6PKC9	   1	   37-­‐101	   NULL	   PF00076	  
E5RGV0_HUMAN	   E5RGV0	   1	   63-­‐129	   NULL	   PF00076	  
C9J6C5_HUMAN	   C9J6C5	   1	   28-­‐84	   NULL	   PF00076	  
B7Z959_HUMAN	   B7Z959	   1	   159-­‐227	   NULL	   PF00076	  PF02037	  
F5GZT4_HUMAN	   F5GZT4	   1	   23-­‐85	   NULL	   PF08080	  PF00076	  
Q6IQ42_HUMAN	   Q6IQ42	   1	   12-­‐58	   NULL	   PF00076	  
B4DIB6_HUMAN	   B4DIB6	   2	   23-­‐87,	  320-­‐389	   30	   	   PF00076	  
A8K4H1_HUMAN	   A8K4H1	   1	   286-­‐364	   NULL	   PF00641	  PF00076	  
Q9BUQ0_HUMAN	   Q9BUQ0	   3	   365-­‐431,	  186-­‐250,	  484-­‐544	   24	  24	  24	   	   PF00076	  
B3KT61_HUMAN	   B3KT61	   1	   23-­‐85	   NULL	   PF00076	  
C9J9G0_HUMAN	   C9J9G0	   1	   75-­‐123	   NULL	   PF00076	  
B4E3U4_HUMAN	   B4E3U4	   1	   10-­‐74	   NULL	   PF00076	  
B5BUB5_HUMAN	   B5BUB5	   1	   113-­‐178	   NULL	  
PF08777	  PF05383	  
PF00076	  
Q86UM1_HUMAN	   Q86UM1	   1	   207-­‐257	   NULL	   PF00076	  
B7Z5Y7_HUMAN	   B7Z5Y7	   1	   58-­‐118	   NULL	   PF00076	  
Q5SZQ6_HUMAN	   Q5SZQ6	   3	   382-­‐451,	  15-­‐77,	  97-­‐161	   20	  30	  33	   	   PF00076	  
Q5QP23_HUMAN	   Q5QP23	   1	   154-­‐219	   NULL	   PF00076	  
D6RDU3_HUMAN	   D6RDU3	   1	   15-­‐82	   NULL	   PF00076	  
Q4VC03_HUMAN	   Q4VC03	   4	  
13-­‐83,	  296-­‐363,	  101-­‐168,	  193-­‐
261	   32	  29	  34	  42	  50	  45	   	   PF00658	  PF00076	  
Q86VW9_HUMAN	   Q86VW9	   1	   366-­‐434	   NULL	   PF07744	  PF00076	  
B4DEP6_HUMAN	   B4DEP6	   1	   99-­‐167	   NULL	   PF00076	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A8K5X9_HUMAN	   A8K5X9	   5	  
834-­‐904,	  4-­‐72,	  732-­‐804,	  404-­‐
473,	  302-­‐362	  
30	  25	  24	  22	  31	  28	  13	  
34	  19	  14	   	   PF00076	  
B0LM41_HUMAN	   B0LM41	   1	   3-­‐60	   NULL	   PF00076	  PF00098	  
E7EV40_HUMAN	   E7EV40	   1	   80-­‐146	   NULL	   PF00076	  
B4DJ45_HUMAN	   B4DJ45	   1	   77-­‐125	   NULL	   PF00076	  
Q6ZR81_HUMAN	   Q6ZR81	   1	   8-­‐70	   NULL	   PF00076	  
F5GY08_HUMAN	   F5GY08	   1	   12-­‐81	   NULL	   PF00076	  
Q569H2_HUMAN	   Q569H2	   1	   26-­‐87	   NULL	   PF00076	  
E7EQD1_HUMAN	   E7EQD1	   1	   86-­‐154	   NULL	   PF00076	  
B2RDP1_HUMAN	   B2RDP1	   2	   152-­‐217,	  249-­‐318	   19	   	   PF00076	  
E7EX81_HUMAN	   E7EX81	   4	  
466-­‐532,	  201-­‐269,	  290-­‐351,	  
380-­‐446	   28	  35	  38	  14	  11	  43	   	   PF00076	  
C9JAA9_HUMAN	   C9JAA9	   1	   6-­‐68	   NULL	   PF00076	  
B3KWX7_HUMAN	   B3KWX7	   2	   131-­‐196,	  228-­‐298	   19	   	   PF00076	  
Q65ZQ3_HUMAN	   Q65ZQ3	   2	   128-­‐196,	  37-­‐105	   30	   	   PF00076	  
B5BU25_HUMAN	   B5BU25	   3	   396-­‐455,	  151-­‐224,	  261-­‐330	   11	  18	  20	   	   PF00076	  
E7EQJ0_HUMAN	   E7EQJ0	   1	   15-­‐82	   NULL	   PF00076	  
E7ET38_HUMAN	   E7ET38	   1	   130-­‐187	   NULL	   PF00076	  
B5BTZ8_HUMAN	   B5BTZ8	   2	   153-­‐212,	  9-­‐79	   25	   	   PF00076	  
B7Z8K4_HUMAN	   B7Z8K4	   1	   160-­‐214	   NULL	   PF00076	  
B9EIP3_HUMAN	   B9EIP3	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
A8K4T9_HUMAN	   A8K4T9	   1	   23-­‐85	   NULL	   PF00076	  
Q59G98_HUMAN	   Q59G98	   3	   146-­‐216,	  47-­‐115,	  295-­‐359	   27	  33	  36	   	   PF00076	  
A8KAQ5_HUMAN	   A8KAQ5	   1	   105-­‐174	   NULL	   PF12220	  PF00076	  
F5H160_HUMAN	   F5H160	   1	   779-­‐840	   NULL	   PF00076	  
B4DLU6_HUMAN	   B4DLU6	   1	   13-­‐77	   NULL	   PF00076	  
A8K329_HUMAN	   A8K329	   1	   409-­‐477	   NULL	   PF00076	  PF02037	  
B4DEM8_HUMAN	   B4DEM8	   1	   4-­‐64	   NULL	   PF00076	  
B3KQH4_HUMAN	   B3KQH4	   3	   68-­‐135,	  495-­‐564,	  184-­‐249	   22	  22	  22	   	   PF00076	  
B1AM48_HUMAN	   B1AM48	   2	   41-­‐111,	  127-­‐189	   42	   	   PF00076	  
B4DWT1_HUMAN	   B4DWT1	   1	   37-­‐102	   NULL	   PF00076	  
Q2VIN3_HUMAN	   Q2VIN3	   1	   10-­‐80	   NULL	   PF08081	  PF00076	  
B7Z2D8_HUMAN	   B7Z2D8	   3	   38-­‐102,	  287-­‐349,	  136-­‐201	   28	  35	  46	   	   PF00076	  
A2RRD3_HUMAN	   A2RRD3	   2	   133-­‐198,	  230-­‐300	   19	   	   PF00076	  
E7ERJ4_HUMAN	   E7ERJ4	   2	   15-­‐83,	  106-­‐174	   34	   	   PF00076	  
Q59G49_HUMAN	   Q59G49	   2	   4-­‐48,	  86-­‐150	   26	   	   PF00076	  
B1AM49_HUMAN	   B1AM49	   3	   69-­‐139,	  155-­‐221,	  306-­‐375	   40	  31	  26	   	   PF00076	  
E7EPM3_HUMAN	   E7EPM3	   1	   752-­‐813	   NULL	   PF00076	  
B4DKS8_HUMAN	   B4DKS8	   2	   38-­‐104,	  216-­‐279	   42	   	   PF08080	  PF00076	  
B7Z4G7_HUMAN	   B7Z4G7	   3	   51-­‐121,	  288-­‐357,	  137-­‐203	   31	  38	  28	   	   PF00076	  
Q53FN0_HUMAN	   Q53FN0	   1	   18-­‐86	   NULL	   PF00076	  
Q6MZY7_HUMAN	   Q6MZY7	   2	   6-­‐63,	  95-­‐165	   20	   	   PF00076	  
D6R9P3_HUMAN	   D6R9P3	   2	   73-­‐140,	  156-­‐224	   39	   	   PF00076	  PF08143	  
D6RBM0_HUMAN	   D6RBM0	   2	   15-­‐82,	  115-­‐181	   44	   	   PF00076	  
B4DZ01_HUMAN	   B4DZ01	   1	   197-­‐266	   NULL	   PF00076	  
A2ABK1_HUMAN	   A2ABK1	   1	   264-­‐318	   NULL	   PF00076	  
C9J1W7_HUMAN	   C9J1W7	   1	   510-­‐573	   NULL	   PF04818	  PF00076	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A8K525_HUMAN	   A8K525	   2	   150-­‐210,	  76-­‐140	   14	   	   PF08075	  PF00076	  
Q6FGE0_HUMAN	   Q6FGE0	   1	   6-­‐67	   NULL	   PF00076	  
C9JYS8_HUMAN	   C9JYS8	   1	   76-­‐140	   NULL	   PF00076	  PF08075	  
E5RHG7_HUMAN	   E5RHG7	   1	   13-­‐73	   NULL	   PF00076	  
B4E3E6_HUMAN	   B4E3E6	   2	   106-­‐174,	  15-­‐83	   33	   	   PF00076	  
Q5H918_HUMAN	   Q5H918	   1	   135-­‐212	   NULL	   PF00076	  
Q2L7G6_HUMAN	   Q2L7G6	   3	   129-­‐193,	  305-­‐366,	  210-­‐271	   25	  22	  22	   	   PF00076	  
C9JZG1_HUMAN	   C9JZG1	   1	   168-­‐218	   NULL	   PF00076	  
Q59GZ7_HUMAN	   Q59GZ7	   1	   4-­‐61	   NULL	   PF00658	  PF00076	  
Q6PJY9_HUMAN	   Q6PJY9	   1	   37-­‐102	   NULL	   PF00076	  
Q7Z3L0_HUMAN	   Q7Z3L0	   2	   6-­‐63,	  95-­‐165	   20	   	   PF00076	  
B4E0L0_HUMAN	   B4E0L0	   1	   301-­‐361	   NULL	   PF00076	  
B4DG28_HUMAN	   B4DG28	   2	   21-­‐83,	  261-­‐330	   28	   	   PF00076	  
B4DJB6_HUMAN	   B4DJB6	   3	   136-­‐198,	  371-­‐440,	  48-­‐115	   28	  39	  25	   	   PF00076	  
E5RFV3_HUMAN	   E5RFV3	   1	   23-­‐86	   NULL	   PF00076	  
Q14730_HUMAN	   Q14730	   1	   1-­‐66	   NULL	   PF08777	  PF00076	  
A4QPE1_HUMAN	   A4QPE1	   1	   158-­‐214	   NULL	   PF00076	  
Q8N220_HUMAN	   Q8N220	   1	   18-­‐78	   NULL	   PF00076	  
C9IZL7_HUMAN	   C9IZL7	   2	   76-­‐140,	  150-­‐206	   15	   	   PF00076	  
B7Z6I4_HUMAN	   B7Z6I4	   1	   130-­‐187	   NULL	   PF00076	  
Q59H57_HUMAN	   Q59H57	   1	   61-­‐139	   NULL	   PF00641	  PF00076	  
E9PCL7_HUMAN	   E9PCL7	   1	   264-­‐318	   NULL	   PF00076	  
E9PEG6_HUMAN	   E9PEG6	   1	   2-­‐48	   NULL	   PF00076	  
A8MXT5_HUMAN	   A8MXT5	   1	   409-­‐478	   NULL	   PF00076	  PF02037	  
Q3S611_HUMAN	   Q3S611	   1	   8-­‐78	   NULL	   PF00160	  PF00076	  
Q0P607_HUMAN	   Q0P607	   1	   510-­‐573	   NULL	   PF04818	  PF00076	  
B3KUF7_HUMAN	   B3KUF7	   1	   18-­‐73	   NULL	   PF00076	  
A8K4L9_HUMAN	   A8K4L9	   3	   11-­‐96,	  116-­‐186,	  224-­‐288	   26	  35	  33	   	   PF00076	  
F5GYA8_HUMAN	   F5GYA8	   1	   2-­‐49	   NULL	   PF00076	  
Q71RF1_HUMAN	   Q71RF1	   1	   18-­‐68	   NULL	   PF00076	  PF00642	  
B4E2X2_HUMAN	   B4E2X2	   1	   8-­‐78	   NULL	   PF00076	  
Q86X94_HUMAN	   Q86X94	   1	   236-­‐314	   NULL	   PF00076	  PF00641	  
E9PAM1_HUMAN	   E9PAM1	   1	   308-­‐372	   NULL	   PF01812	  PF00076	  
F2Z2W2_HUMAN	   F2Z2W2	   1	   3-­‐60	   NULL	   PF00076	  
E7EQS3_HUMAN	   E7EQS3	   2	   4-­‐64,	  81-­‐139	   44	   	   PF00076	  
E9PDD9_HUMAN	   E9PDD9	   1	   196-­‐254	   NULL	   PF00076	  
Q59EF5_HUMAN	   Q59EF5	   1	   31-­‐96	   NULL	   PF00076	  
Q6MZS5_HUMAN	   Q6MZS5	   3	   144-­‐208,	  225-­‐289,	  323-­‐384	   20	  25	  22	   	   PF00076	  
Q53F48_HUMAN	   Q53F48	   2	   20-­‐86,	  199-­‐263	   41	   	   PF00076	  
F5H047_HUMAN	   F5H047	   1	   84-­‐155	   NULL	   PF00076	  
B4E1U0_HUMAN	   B4E1U0	   2	   81-­‐139,	  4-­‐64	   42	   	   PF00076	  
A8K588_HUMAN	   A8K588	   2	   4-­‐64,	  112-­‐177	   24	   	   PF00076	  
B2R802_HUMAN	   B2R802	   2	   210-­‐272,	  12-­‐82	   14	   	   PF00076	  
F5H0R1_HUMAN	   F5H0R1	   1	   96-­‐159	   NULL	   PF03828	  PF00076	  
Q8IWE6_HUMAN	   Q8IWE6	   1	   37-­‐101	   NULL	   PF00076	  
B4DZ27_HUMAN	   B4DZ27	   3	   63-­‐126,	  143-­‐204,	  238-­‐301	   25	  14	  22	   	   PF00076	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B4DRP9_HUMAN	   B4DRP9	   3	   231-­‐298,	  658-­‐727,	  347-­‐412	   22	  22	  22	   	   PF00076	  
D6W592_HUMAN	   D6W592	   1	   80-­‐128	   NULL	   PF00076	  
E7EPF2_HUMAN	   E7EPF2	   1	   31-­‐91	   NULL	   PF00076	  
E9PGX9_HUMAN	   E9PGX9	   1	   62-­‐118	   NULL	   PF00076	  
E7EMJ8_HUMAN	   E7EMJ8	   2	   106-­‐171,	  4-­‐64	   22	   	   PF00076	  
Q5VZZ6_HUMAN	   Q5VZZ6	   3	   110-­‐174,	  415-­‐484,	  19-­‐87	   30	  33	  21	   	   PF00076	  
D6W5H1_HUMAN	   D6W5H1	   1	   679-­‐730	   NULL	   PF00076	  
B3KUY1_HUMAN	   B3KUY1	   1	   6-­‐74	   NULL	   PF00076	  
B2R6F3_HUMAN	   B2R6F3	   1	   12-­‐77	   NULL	   PF00076	  
SRSF8_HUMAN	   Q9BRL6	   1	   18-­‐86	   NULL	   PF00076	  
E9PLB0_HUMAN	   E9PLB0	   2	   81-­‐141,	  4-­‐64	   44	   	   PF00076	  
B3KM80_HUMAN	   B3KM80	   4	  
400-­‐466,	  135-­‐203,	  224-­‐285,	  
314-­‐380	   28	  35	  38	  14	  11	  43	   	   PF00076	  
D3DQM9_HUMAN	   D3DQM9	   1	   486-­‐547	   NULL	   PF00076	  
E5RG71_HUMAN	   E5RG71	   1	   23-­‐84	   NULL	   PF00076	  
B7Z3R7_HUMAN	   B7Z3R7	   3	   124-­‐188,	  373-­‐435,	  222-­‐287	   28	  35	  46	   	   PF00076	  
E5RGH3_HUMAN	   E5RGH3	   1	   56-­‐108	   NULL	   PF00076	  
Q3B867_HUMAN	   Q3B867	   1	   46-­‐113	   NULL	   PF00076	  
Q6IQ30_HUMAN	   Q6IQ30	   4	  
13-­‐83,	  296-­‐363,	  101-­‐168,	  193-­‐
261	   32	  29	  34	  42	  50	  45	   	   PF00658	  PF00076	  
D6R9M7_HUMAN	   D6R9M7	   1	   73-­‐137	   NULL	   PF00076	  
E7EUX0_HUMAN	   E7EUX0	   1	   285-­‐363	   NULL	   PF00641	  PF00076	  
B7ZLC2_HUMAN	   B7ZLC2	   1	   308-­‐372	   NULL	   PF01812	  PF00076	  
Q5QPM2_HUMAN	   Q5QPM2	   1	   23-­‐85	   NULL	   PF00076	  
B4DEG4_HUMAN	   B4DEG4	   2	   74-­‐143,	  167-­‐235	   31	   	   PF11532	  PF00076	  
B4DQL3_HUMAN	   B4DQL3	   1	   177-­‐246	   NULL	   PF00076	  
Q1RMF9_HUMAN	   Q1RMF9	   3	   207-­‐263,	  372-­‐428,	  42-­‐98	   100	  100	  100	   	   PF00076	  
B4DJK0_HUMAN	   B4DJK0	   1	   6-­‐67	   NULL	   PF00076	  
B3KRR4_HUMAN	   B3KRR4	   1	   242-­‐312	   NULL	   PF00160	  PF00076	  
D3DQF6_HUMAN	   D3DQF6	   1	   304-­‐355	   NULL	   PF00076	  
B2R7W4_HUMAN	   B2R7W4	   3	   167-­‐231,	  343-­‐404,	  248-­‐309	   25	  22	  22	   	   PF00076	  
B7ZLP7_HUMAN	   B7ZLP7	   3	   73-­‐137,	  153-­‐214,	  248-­‐311	   29	  17	  19	   	   PF00076	  
E9PN18_HUMAN	   E9PN18	   1	   151-­‐221	   NULL	   PF00076	  
C9JZB7_HUMAN	   C9JZB7	   1	   110-­‐177	   NULL	   PF00076	  
Q2PYN1_HUMAN	   Q2PYN1	   1	   3-­‐60	   NULL	   PF00076	  
C9JT33_HUMAN	   C9JT33	   1	   4-­‐68	   NULL	   PF00013	  PF00076	  
E9PB61_HUMAN	   E9PB61	   1	   115-­‐183	   NULL	   PF00076	  
E9PCY7_HUMAN	   E9PCY7	   3	   15-­‐82,	  293-­‐355,	  115-­‐181	   31	  44	  41	   	   PF08080	  PF00076	  
B4DMV6_HUMAN	   B4DMV6	   1	   45-­‐112	   NULL	   PF00076	  
D3DSV0_HUMAN	   D3DSV0	   1	   26-­‐87	   NULL	   PF00076	  
F5H606_HUMAN	   F5H606	   1	   12-­‐81	   NULL	   PF00076	  
A8K9U0_HUMAN	   A8K9U0	   2	   81-­‐141,	  4-­‐64	   42	   	   PF00076	  PF00098	  
Q96DI9_HUMAN	   Q96DI9	   1	   280-­‐340	   NULL	   PF00076	  
B0QYV1_HUMAN	   B0QYV1	   1	   95-­‐162	   NULL	   PF00076	  
F5GXS4_HUMAN	   F5GXS4	   1	   160-­‐229	   NULL	   PF00076	  PF02037	  
B4DSM4_HUMAN	   B4DSM4	   1	   47-­‐116	   NULL	   PF00076	  
B2R959_HUMAN	   B2R959	   2	   75-­‐124,	  173-­‐226	   26	   	   PF00076	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E9PMU7_HUMAN	   E9PMU7	   1	   151-­‐221	   NULL	   PF00076	  
D6R9D6_HUMAN	   D6R9D6	   3	   73-­‐137,	  153-­‐214,	  248-­‐311	   29	  17	  19	   	   PF00076	  
B1ANR7_HUMAN	   B1ANR7	   1	   75-­‐142	   NULL	   PF00658	  PF00076	  
B7Z5F9_HUMAN	   B7Z5F9	   3	   69-­‐133,	  318-­‐380,	  167-­‐232	   28	  35	  46	   	   PF00076	  
E7EWI9_HUMAN	   E7EWI9	   2	   15-­‐83,	  106-­‐174	   34	   	   PF00076	  
B4DMM2_HUMAN	   B4DMM2	   1	   128-­‐185	   NULL	   PF00076	  
D6RD18_HUMAN	   D6RD18	   2	   73-­‐140,	  156-­‐224	   39	   	   PF00076	  PF08143	  
Q0VGD6_HUMAN	   Q0VGD6	   3	   141-­‐205,	  317-­‐378,	  222-­‐283	   25	  22	  22	   	   PF00076	  
B4DUD5_HUMAN	   B4DUD5	   1	   18-­‐88	   NULL	   PF00076	  
B7Z888_HUMAN	   B7Z888	   1	   545-­‐610	   NULL	   PF04818	  PF00076	  
F5H0I5_HUMAN	   F5H0I5	   1	   10-­‐80	   NULL	   PF00076	  
Q96MX4_HUMAN	   Q96MX4	   1	   368-­‐446	   NULL	   PF00641	  PF00076	  
Q5JRI1_HUMAN	   Q5JRI1	   1	   12-­‐81	   NULL	   PF00076	  
B3KW50_HUMAN	   B3KW50	   3	   135-­‐199,	  384-­‐446,	  233-­‐298	   28	  35	  46	   	   PF00076	  
B4DGF8_HUMAN	   B4DGF8	   1	   84-­‐155	   NULL	   PF00076	  
Q6PIX2_HUMAN	   Q6PIX2	   2	   374-­‐433,	  299-­‐363	   16	   	   PF08075	  PF00076	  
C9JB16_HUMAN	   C9JB16	   1	   1-­‐58	   NULL	   PF00076	  
Q5QPM1_HUMAN	   Q5QPM1	   1	   23-­‐85	   NULL	   PF00076	  
F5H330_HUMAN	   F5H330	   1	   785-­‐836	   NULL	   PF00076	  
Q75MU2_HUMAN	   Q75MU2	   1	   45-­‐112	   NULL	   PF00076	  
A8K894_HUMAN	   A8K894	   2	   75-­‐123,	  175-­‐225	   20	   	   PF00076	  
B4E1M7_HUMAN	   B4E1M7	   2	   146-­‐211,	  243-­‐313	   19	   	   PF00076	  
E5RJM0_HUMAN	   E5RJM0	   1	   449-­‐510	   NULL	   PF00076	  
Q6FI03_HUMAN	   Q6FI03	   1	   342-­‐396	   NULL	   PF02136	  PF00076	  
B7ZMD9_HUMAN	   B7ZMD9	   1	   10-­‐79	   NULL	   PF08081	  PF00076	  
Q6PKH5_HUMAN	   Q6PKH5	   1	   4-­‐66	   NULL	   PF00076	  PF00641	  
B7Z645_HUMAN	   B7Z645	   3	   66-­‐131,	  147-­‐208,	  242-­‐303	   20	  22	  19	   	   PF00076	  
Q96MN4_HUMAN	   Q96MN4	   1	   307-­‐385	   NULL	   PF00641	  PF00076	  
B4DRA0_HUMAN	   B4DRA0	   2	   133-­‐198,	  230-­‐300	   19	   	   PF00076	  
Q5VX58_HUMAN	   Q5VX58	   4	  
101-­‐168,	  13-­‐83,	  296-­‐363,	  193-­‐
261	   32	  38	  44	  29	  28	  51	   	   PF00658	  PF00076	  
B2R5W2_HUMAN	   B2R5W2	   1	   18-­‐80	   NULL	   PF00076	  
B4DYX9_HUMAN	   B4DYX9	   1	   276-­‐330	   NULL	   PF00076	  
Q9BSM5_HUMAN	   Q9BSM5	   2	   2-­‐62,	  85-­‐153	   32	   	   PF00076	  PF11627	  
A8K1L8_HUMAN	   A8K1L8	   2	   18-­‐85,	  123-­‐184	   25	   	   PF00076	  
Q5VVE2_HUMAN	   Q5VVE2	   2	   78-­‐145,	  179-­‐246	   14	   	   PF00076	  
B4DF29_HUMAN	   B4DF29	   1	   102-­‐169	   NULL	   PF00076	  
Q7KYM9_HUMAN	   Q7KYM9	   2	   495-­‐562,	  46-­‐114	   42	   	   PF00076	  
Q5TGA3_HUMAN	   Q5TGA3	   1	   8-­‐78	   NULL	   PF00160	  PF00076	  
E7ETM7_HUMAN	   E7ETM7	   2	   183-­‐244,	  88-­‐149	   22	   	   PF00076	  
F5H4Y5_HUMAN	   F5H4Y5	   1	   19-­‐79	   NULL	   PF00076	  
E5RGV5_HUMAN	   E5RGV5	   1	   9-­‐77	   NULL	   PF00076	  
E7ENA5_HUMAN	   E7ENA5	   1	   42-­‐98	   NULL	   PF00076	  
F5H5I6_HUMAN	   F5H5I6	   3	   38-­‐102,	  287-­‐349,	  136-­‐201	   28	  35	  46	   	   PF00076	  
C9IYN3_HUMAN	   C9IYN3	   1	   80-­‐128	   NULL	   PF00076	  
B3KPW0_HUMAN	   B3KPW0	   2	   243-­‐305,	  92-­‐157	   46	   	   PF00076	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Q59EK7_HUMAN	   Q59EK7	   2	   176-­‐229,	  9-­‐70	   29	   	   PF00076	  
B4DN89_HUMAN	   B4DN89	   1	   18-­‐86	   NULL	   PF00076	  
B0QYY4_HUMAN	   B0QYY4	   1	   94-­‐161	   NULL	   PF00076	  
B3KT93_HUMAN	   B3KT93	   4	  
101-­‐168,	  193-­‐261,	  296-­‐363,	  
13-­‐83	   47	  39	  33	  50	  30	  36	   	   PF00658	  PF00076	  
A4QPG7_HUMAN	   A4QPG7	   2	   93-­‐153,	  12-­‐81	   29	   	   PF07744	  PF00076	  
B4DF54_HUMAN	   B4DF54	   1	   785-­‐836	   NULL	   PF00076	  
C9JGC2_HUMAN	   C9JGC2	   1	   83-­‐152	   NULL	   PF00076	  
B7Z8Z7_HUMAN	   B7Z8Z7	   3	   35-­‐99,	  115-­‐176,	  210-­‐273	   29	  17	  19	   	   PF00076	  
A1A693_HUMAN	   A1A693	   1	   332-­‐400	   NULL	   PF07744	  PF00076	  
Q6IRX3_HUMAN	   Q6IRX3	   1	   12-­‐81	   NULL	   PF00076	  
Q59FA2_HUMAN	   Q59FA2	   2	   50-­‐117,	  155-­‐217	   25	   	   PF00076	  
F5H540_HUMAN	   F5H540	   1	   10-­‐80	   NULL	   PF00076	  
A0AV56_HUMAN	   A0AV56	   1	   409-­‐477	   NULL	   PF00076	  PF02037	  
B8ZZ74_HUMAN	   B8ZZ74	   1	   3-­‐60	   NULL	   PF00076	  
B4DLM0_HUMAN	   B4DLM0	   2	   128-­‐193,	  225-­‐295	   19	   	   PF00076	  
Q3ZCS4_HUMAN	   Q3ZCS4	   4	  
101-­‐168,	  13-­‐83,	  296-­‐363,	  193-­‐
261	   32	  38	  44	  29	  28	  51	   	   PF00658	  PF00076	  
Q32ND0_HUMAN	   Q32ND0	   1	   101-­‐157	   NULL	   PF00076	  
O15187_HUMAN	   O15187	   2	   60-­‐130,	  168-­‐232	   33	   	   PF00076	  
B4DUA4_HUMAN	   B4DUA4	   1	   6-­‐67	   NULL	   PF00076	  
F5GWK3_HUMAN	   F5GWK3	   1	   185-­‐249	   NULL	   PF00076	  
Q6IAM0_HUMAN	   Q6IAM0	   1	   241-­‐303	   NULL	   PF12353	  PF00076	  
D6RA49_HUMAN	   D6RA49	   1	   73-­‐123	   NULL	   PF00076	  
Q53F45_HUMAN	   Q53F45	   2	   106-­‐171,	  4-­‐64	   22	   	   PF00076	  
Q8NB80_HUMAN	   Q8NB80	   1	   13-­‐77	   NULL	   PF00076	  PF00098	  
Q5CZ66_HUMAN	   Q5CZ66	   1	   9-­‐73	   NULL	   PF00076	  
Q5SZQ7_HUMAN	   Q5SZQ7	   3	   332-­‐401,	  9-­‐76,	  97-­‐161	   20	  30	  38	   	   PF00076	  
Q8TCM0_HUMAN	   Q8TCM0	   1	   120-­‐187	   NULL	   PF00076	  
B4DSU6_HUMAN	   B4DSU6	   1	   18-­‐80	   NULL	   PF00076	  
Q6PKD2_HUMAN	   Q6PKD2	   1	   18-­‐79	   NULL	   PF00076	  
B4DP51_HUMAN	   B4DP51	   1	   23-­‐85	   NULL	   PF08080	  PF00076	  
B3KUB0_HUMAN	   B3KUB0	   1	   145-­‐209	   NULL	   PF00076	  
E5RFP2_HUMAN	   E5RFP2	   1	   84-­‐145	   NULL	   PF00076	  
Q5T0W7_HUMAN	   Q5T0W7	   2	   138-­‐199,	  58-­‐124	   22	   	   PF00076	  
Q5JB52_HUMAN	   Q5JB52	   1	   80-­‐128	   NULL	   PF00076	  
B7Z3A4_HUMAN	   B7Z3A4	   1	   557-­‐622	   NULL	   PF04818	  PF00076	  
B4DM51_HUMAN	   B4DM51	   1	   51-­‐117	   NULL	   PF00076	  
Q147Y3_HUMAN	   Q147Y3	   1	   46-­‐113	   NULL	   PF00076	  
PAB4L_HUMAN	   P0CB38	   4	  
12-­‐82,	  100-­‐167,	  192-­‐259,	  295-­‐
362	   29	  29	  26	  47	  39	  47	   	   PF00076	  
Q7Z780_HUMAN	   Q7Z780	   1	   19-­‐68	   NULL	   PF00642	  PF00076	  
B3KX96_HUMAN	   B3KX96	   1	   18-­‐80	   NULL	   PF00076	  
Q8N1H4_HUMAN	   Q8N1H4	   1	   86-­‐154	   NULL	   PF00076	  
B7ZLC0_HUMAN	   B7ZLC0	   1	   307-­‐371	   NULL	   PF01812	  PF00076	  
Q86VG2_HUMAN	   Q86VG2	   2	   374-­‐433,	  299-­‐363	   16	   	   PF08075	  PF00076	  
Q7Z2U9_HUMAN	   Q7Z2U9	   1	   58-­‐121	   NULL	   PF00076	  
Q8TBR3_HUMAN	   Q8TBR3	   1	   287-­‐365	   NULL	   PF00641	  PF00076	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E1P5S2_HUMAN	   E1P5S2	   2	   6-­‐63,	  95-­‐165	   20	   	   PF00076	  
Q8TAL0_HUMAN	   Q8TAL0	   1	   590-­‐641	   NULL	   PF00076	  
B4DEK2_HUMAN	   B4DEK2	   1	   13-­‐77	   NULL	   PF00076	  
E9PQK4_HUMAN	   E9PQK4	   1	   19-­‐84	   NULL	   PF00076	  
Q6N037_HUMAN	   Q6N037	   2	   6-­‐63,	  95-­‐165	   20	   	   PF00076	  
A8K9S4_HUMAN	   A8K9S4	   2	   63-­‐123,	  142-­‐206	   27	   	   PF00076	  
D6W5Y5_HUMAN	   D6W5Y5	   1	   8-­‐78	   NULL	   PF00076	  
F5H3W3_HUMAN	   F5H3W3	   1	   42-­‐98	   NULL	   PF00076	  
Q05DR1_HUMAN	   Q05DR1	   1	   12-­‐82	   NULL	   PF00076	  PF00098	  
Q53GL4_HUMAN	   Q53GL4	   1	   7-­‐74	   NULL	   PF00658	  PF00076	  
B3KWU8_HUMAN	   B3KWU8	   3	   63-­‐126,	  143-­‐204,	  238-­‐301	   25	  14	  22	   	   PF00076	  
F5H4D6_HUMAN	   F5H4D6	   1	   160-­‐214	   NULL	   PF00076	  
F5H7Z1_HUMAN	   F5H7Z1	   1	   212-­‐279	   NULL	   PF00076	  
B7Z570_HUMAN	   B7Z570	   1	   18-­‐79	   NULL	   PF00076	  
Q9BSV4_HUMAN	   Q9BSV4	   2	   301-­‐360,	  226-­‐290	   16	   	   PF08075	  PF00076	  
Q86YK2_HUMAN	   Q86YK2	   1	   9-­‐79	   NULL	   PF00076	  
C9J323_HUMAN	   C9J323	   1	   84-­‐143	   NULL	   PF00076	  
Q549U1_HUMAN	   Q549U1	   1	   123-­‐191	   NULL	   PF00076	  
Q3ZB86_HUMAN	   Q3ZB86	   1	   376-­‐444	   NULL	   PF07744	  PF00076	  
Q4VY17_HUMAN	   Q4VY17	   3	   101-­‐168,	  193-­‐261,	  13-­‐83	   50	  29	  33	   	   PF00076	  
D6RBZ0_HUMAN	   D6RBZ0	   2	   73-­‐140,	  156-­‐224	   39	   	   PF00076	  PF08143	  
Q8N8Y7_HUMAN	   Q8N8Y7	   1	   10-­‐67	   NULL	   PF08081	  PF00076	  
B4DSS0_HUMAN	   B4DSS0	   1	   1281-­‐1340	   NULL	   PF00076	  
E7EW00_HUMAN	   E7EW00	   1	   276-­‐348	   NULL	   PF00076	  
E9PL19_HUMAN	   E9PL19	   1	   168-­‐228	   NULL	   PF00076	  
Q59GA1_HUMAN	   Q59GA1	   1	   110-­‐178	   NULL	   PF00076	  
B4DFI3_HUMAN	   B4DFI3	   1	   22-­‐84	   NULL	   PF00076	  
E7ERJ7_HUMAN	   E7ERJ7	   3	   264-­‐331,	  161-­‐229,	  13-­‐83	   51	  36	  31	   	   PF00658	  PF00076	  
F5GYB8_HUMAN	   F5GYB8	   1	   18-­‐78	   NULL	   PF00076	  
F5H6M0_HUMAN	   F5H6M0	   1	   84-­‐155	   NULL	   PF00076	  
B2R8Z8_HUMAN	   B2R8Z8	   3	   164-­‐229,	  245-­‐306,	  340-­‐401	   20	  22	  19	   	   PF00076	  
E9PKU1_HUMAN	   E9PKU1	   1	   46-­‐111	   NULL	   PF00076	  
B7ZLH9_HUMAN	   B7ZLH9	   1	   140-­‐207	   NULL	   PF00076	  
B3KRJ9_HUMAN	   B3KRJ9	   2	   23-­‐85,	  184-­‐252	   23	   	   PF00076	  
Q5IRN2_HUMAN	   Q5IRN2	   2	   115-­‐159,	  12-­‐80	   35	   	   PF00076	  
B1AKF7_HUMAN	   B1AKF7	   1	   101-­‐157	   NULL	   PF00076	  
B4DV79_HUMAN	   B4DV79	   1	   131-­‐181	   NULL	   PF08662	  PF00076	  
A8KAM9_HUMAN	   A8KAM9	   1	   8-­‐78	   NULL	   PF00160	  PF00076	  
D6RAF8_HUMAN	   D6RAF8	   1	   100-­‐167	   NULL	   PF00076	  PF08143	  
F5H8B8_HUMAN	   F5H8B8	   1	   10-­‐80	   NULL	   PF00076	  
Q96J71_HUMAN	   Q96J71	   3	   78-­‐141,	  1-­‐62,	  237-­‐306	   33	  28	  30	   	   PF00076	  
B3KVW0_HUMAN	   B3KVW0	   1	   840-­‐891	   NULL	   PF00076	  
B3KWQ8_HUMAN	   B3KWQ8	   2	   265-­‐310,	  168-­‐233	   23	   	   PF00076	  
Q69YJ7_HUMAN	   Q69YJ7	   3	   454-­‐520,	  881-­‐950,	  570-­‐635	   22	  22	  22	   	   PF00076	  
B3KQ99_HUMAN	   B3KQ99	   1	   130-­‐187	   NULL	   PF00076	  
E9PB51_HUMAN	   E9PB51	   2	   4-­‐64,	  81-­‐141	   42	   	   PF00076	  
  
 
61 
  
 
F5H0H3_HUMAN	   F5H0H3	   1	   340-­‐408	   NULL	   PF00076	  PF02037	  
A6NNE8_HUMAN	   A6NNE8	   1	   13-­‐77	   NULL	   PF00076	  
C9JD39_HUMAN	   C9JD39	   1	   510-­‐573	   NULL	   PF04818	  PF00076	  
E5RH24_HUMAN	   E5RH24	   1	   13-­‐83	   NULL	   PF00076	  
D3DPI2_HUMAN	   D3DPI2	   1	   18-­‐80	   NULL	   PF00076	  
E9PK21_HUMAN	   E9PK21	   1	   8-­‐78	   NULL	   PF00076	  
Q6P2D7_HUMAN	   Q6P2D7	   1	   210-­‐277	   NULL	   PF00076	  
Q69YM5_HUMAN	   Q69YM5	   1	   68-­‐136	   NULL	   PF00076	  
B0QYY7_HUMAN	   B0QYY7	   1	   137-­‐200	   NULL	   PF00076	  
B5BU15_HUMAN	   B5BU15	   1	   4-­‐64	   NULL	   PF00076	  
D6RBQ9_HUMAN	   D6RBQ9	   1	   81-­‐148	   NULL	   PF00076	  PF08143	  
B4DY08_HUMAN	   B4DY08	   1	   18-­‐80	   NULL	   PF00076	  
E2PSN0_HUMAN	   E2PSN0	   1	   88-­‐139	   NULL	   PF00076	  
B4DUA9_HUMAN	   B4DUA9	   1	   22-­‐90	   NULL	   PF00076	  
B1AKP7_HUMAN	   B1AKP7	   2	   193-­‐241,	  106-­‐171	   28	   	   PF00076	  
Q9BTF3_HUMAN	   Q9BTF3	   2	   88-­‐153,	  6-­‐68	   34	   	   PF00076	  
Q5JPA7_HUMAN	   Q5JPA7	   1	   317-­‐370	   NULL	   PF00069	  PF00076	  
B4DP35_HUMAN	   B4DP35	   1	   16-­‐84	   NULL	   PF00076	  PF11627	  
B4DN88_HUMAN	   B4DN88	   2	   64-­‐124,	  143-­‐207	   27	   	   PF00076	  
B4DYA2_HUMAN	   B4DYA2	   2	   285-­‐339,	  367-­‐435	   25	   	   PF00076	  PF05391	  
Q5QPL9_HUMAN	   Q5QPL9	   1	   23-­‐85	   NULL	   PF00076	  
B4E0W4_HUMAN	   B4E0W4	   1	   30-­‐90	   NULL	   PF00076	  
B7Z8M4_HUMAN	   B7Z8M4	   2	   6-­‐63,	  95-­‐164	   20	   	   PF00076	  
Q7Z3D7_HUMAN	   Q7Z3D7	   1	   197-­‐259	   NULL	  
PF01585	  PF00076	  
PF00641	  
Q5U0Q1_HUMAN	   Q5U0Q1	   1	   342-­‐396	   NULL	   PF02136	  PF00076	  
A8K9A4_HUMAN	   A8K9A4	   1	   18-­‐80	   NULL	   PF00076	  
E7EU30_HUMAN	   E7EU30	   1	   42-­‐98	   NULL	   PF00076	  
B4E0B5_HUMAN	   B4E0B5	   1	   16-­‐84	   NULL	   PF00076	  PF11627	  
E7ET15_HUMAN	   E7ET15	   1	   275-­‐347	   NULL	  
PF01805	  PF00076	  
PF08312	  
B4DS31_HUMAN	   B4DS31	   3	   134-­‐198,	  431-­‐500,	  43-­‐111	   30	  33	  21	   	   PF00076	  
B4DQX0_HUMAN	   B4DQX0	   3	   264-­‐331,	  161-­‐229,	  13-­‐83	   51	  36	  31	   	   PF00658	  PF00076	  
E7EU33_HUMAN	   E7EU33	   1	   42-­‐98	   NULL	   PF00076	  
Q96B58_HUMAN	   Q96B58	   2	   108-­‐178,	  9-­‐77	   27	   	   PF00076	  
E9PID8_HUMAN	   E9PID8	   1	   18-­‐88	   NULL	   PF00076	  
Q15164_HUMAN	   Q15164	   2	   107-­‐174,	  4-­‐72	   50	   	   PF00076	  
B4DTC1_HUMAN	   B4DTC1	   1	   37-­‐102	   NULL	   PF00076	  
E7ERE4_HUMAN	   E7ERE4	   3	   167-­‐231,	  347-­‐408,	  248-­‐313	   25	  21	  22	   	   PF00076	  
B7ZLP5_HUMAN	   B7ZLP5	   1	   409-­‐477	   NULL	   PF00076	  PF02037	  
Q9Y655_HUMAN	   Q9Y655	   3	   182-­‐250,	  49-­‐118,	  472-­‐539	   24	  42	  39	   	   PF00076	  
B1ANR0_HUMAN	   B1ANR0	   4	  
13-­‐83,	  296-­‐363,	  101-­‐168,	  193-­‐
261	   32	  29	  34	  42	  50	  45	   	   PF00658	  PF00076	  
B4DRG9_HUMAN	   B4DRG9	   1	   592-­‐639	   NULL	   PF00076	  
B7ZLQ8_HUMAN	   B7ZLQ8	   1	   449-­‐510	   NULL	   PF00076	  
E7ETJ9_HUMAN	   E7ETJ9	   1	   60-­‐130	   NULL	   PF00076	  
E7EUF4_HUMAN	   E7EUF4	   1	   42-­‐98	   NULL	   PF00076	  
B4DP00_HUMAN	   B4DP00	   2	   199-­‐261,	  15-­‐74	   28	   	   PF08080	  PF00076	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B7ZW41_HUMAN	   B7ZW41	   1	   18-­‐77	   NULL	   PF00076	  
B7Z876_HUMAN	   B7Z876	   1	   524-­‐589	   NULL	   PF04818	  PF00076	  
Q6NXQ0_HUMAN	   Q6NXQ0	   1	   18-­‐78	   NULL	   PF00076	  
F5H0B8_HUMAN	   F5H0B8	   2	   286-­‐340,	  368-­‐436	   25	   	   PF00076	  PF05391	  
Q5JQF3_HUMAN	   Q5JQF3	   2	   140-­‐208,	  37-­‐105	   39	   	   PF00076	  
A4D198_HUMAN	   A4D198	   1	   111-­‐178	   NULL	   PF00076	  
E1CJT3_HUMAN	   E1CJT3	   1	   40-­‐101	   NULL	   PF00076	  
Q86VN0_HUMAN	   Q86VN0	   1	   241-­‐297	   NULL	   PF00642	  PF00076	  
A2A2V2_HUMAN	   A2A2V2	   1	   267-­‐336	   NULL	   PF00076	  
E5RJB9_HUMAN	   E5RJB9	   1	   13-­‐83	   NULL	   PF00076	  
Q12771_HUMAN	   Q12771	   2	   79-­‐146,	  163-­‐223	   45	   	   PF08143	  PF00076	  
Q59GL1_HUMAN	   Q59GL1	   3	   136-­‐201,	  217-­‐278,	  312-­‐373	   20	  22	  19	   	   PF00076	  
Q96FE8_HUMAN	   Q96FE8	   1	   362-­‐440	   NULL	   PF00641	  PF00076	  
B4E0E5_HUMAN	   B4E0E5	   1	   9-­‐77	   NULL	   PF00076	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Table S 2.2 RRM-containing RBPs unique to four species and their multiRRM scores 	  
HumUnique	   Hum	  RRM1	  vs	  RRM2	   Hum_Scores	   MouUnique	   Mou	  RRM1	  vs	  RRM2	   Mou_Scores	  
ENSP00000352440	   33-­‐80	   117-­‐184	   25	   ENSMUSP00000066639	   13-­‐83	   101-­‐168	   32	  
ENSP00000383344	   42-­‐98	   207-­‐263	   100	   ENSMUSP00000066639	   13-­‐83	   193-­‐261	   31	  
ENSP00000341285	   16-­‐84	   107-­‐175	   34	   ENSMUSP00000066639	   13-­‐83	   296-­‐363	   32	  
ENSP00000383298	   16-­‐84	   107-­‐175	   34	   ENSMUSP00000066639	   101-­‐168	   193-­‐261	   47	  
ENSP00000362618	   4-­‐74	   92-­‐159	   26	   ENSMUSP00000066639	   101-­‐168	   296-­‐363	   39	  
ENSP00000281589	   13-­‐83	   101-­‐168	   32	   ENSMUSP00000066639	   193-­‐261	   296-­‐363	   57	  
ENSP00000281589	   13-­‐83	   193-­‐261	   28	   ENSMUSP00000111809	   10-­‐78	   101-­‐169	   33	  
ENSP00000281589	   13-­‐83	   296-­‐363	   27	   ENSMUSP00000072775	   23-­‐92	   114-­‐182	   34	  
ENSP00000281589	   101-­‐168	   193-­‐261	   44	   ENSMUSP00000071646	   37-­‐106	   128-­‐196	   36	  
ENSP00000281589	   101-­‐168	   296-­‐363	   38	   ENSMUSP00000098682	   2-­‐69	   94-­‐162	   41	  
ENSP00000281589	   193-­‐261	   296-­‐363	   52	   ENSMUSP00000098682	   2-­‐69	   197-­‐264	   42	  
ENSP00000352956	   168-­‐233	   265-­‐334	   19	   ENSMUSP00000098682	   94-­‐162	   197-­‐264	   47	  
ENSP00000302745	   52-­‐108	   217-­‐273	   100	   ENSMUSP00000050792	   13-­‐83	   101-­‐168	   35	  
ENSP00000302745	   52-­‐108	   382-­‐438	   100	   ENSMUSP00000050792	   13-­‐83	   193-­‐261	   33	  
ENSP00000302745	   217-­‐273	   382-­‐438	   100	   ENSMUSP00000050792	   13-­‐83	   306-­‐373	   33	  
ENSP00000362621	   4-­‐74	   92-­‐159	   26	   ENSMUSP00000050792	   101-­‐168	   193-­‐261	   48	  
	   	   	   	  
ENSMUSP00000050792	   101-­‐168	   306-­‐373	   44	  
	   	   	   	  
ENSMUSP00000050792	   193-­‐261	   306-­‐373	   55	  
	   	   	   	  
ENSMUSP00000006628	   4-­‐64	   81-­‐141	   44	  
	   	   	   	  
ENSMUSP00000058811	   93-­‐162	   226-­‐294	   28	  
	   	   	   	  
ENSMUSP00000058811	   93-­‐162	   459-­‐484	   26	  
	   	   	   	  
ENSMUSP00000058811	   226-­‐294	   459-­‐484	   53	  
	   	   	   	  
ENSMUSP00000093293	   12-­‐61	   202-­‐262	   10	  
	   	   	   	  
ENSMUSP00000079967	   13-­‐83	   101-­‐168	   29	  
	   	   	   	  
ENSMUSP00000079967	   13-­‐83	   193-­‐261	   34	  
	   	   	   	  
ENSMUSP00000079967	   13-­‐83	   296-­‐363	   30	  
	   	   	   	  
ENSMUSP00000079967	   101-­‐168	   193-­‐261	   44	  
	   	   	   	  
ENSMUSP00000079967	   101-­‐168	   296-­‐363	   42	  
	   	   	   	  
ENSMUSP00000079967	   193-­‐261	   296-­‐363	   48	  
	   	   	   	  
ENSMUSP00000053555	   5-­‐69	   156-­‐223	   30	  
	   	   	   	  
ENSMUSP00000053555	   5-­‐69	   285-­‐351	   16	  
	   	   	   	  
ENSMUSP00000053555	   5-­‐69	   403-­‐458	   23	  
	   	   	   	  
ENSMUSP00000053555	   5-­‐69	   763-­‐831	   24	  
	   	   	   	  
ENSMUSP00000053555	   156-­‐223	   285-­‐351	   23	  
	   	   	   	  
ENSMUSP00000053555	   156-­‐223	   403-­‐458	   28	  
	   	   	   	  
ENSMUSP00000053555	   156-­‐223	   763-­‐831	   25	  
	   	   	   	  
ENSMUSP00000053555	   285-­‐351	   403-­‐458	   19	  
	   	   	   	  
ENSMUSP00000053555	   285-­‐351	   763-­‐831	   8	  
	   	   	   	  
ENSMUSP00000053555	   403-­‐458	   763-­‐831	   30	  
	   	   	   	  
ENSMUSP00000049830	   36-­‐103	   120-­‐178	   30	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FlyUnique	   Fly	  RRM1	  vs	  RRM2	   Fly_Scores	   WormUnique	   Worm	  RRM1	  vs	  RRM2	   Worm_Scores	  
FBpp0084255	   205-­‐273	   293-­‐361	   42	   CE14916	   19-­‐34	   42-­‐91	   18	  
FBpp0112339	   32-­‐99	   120-­‐186	   46	   CE26612	   11-­‐73	   98-­‐160	   9	  
FBpp0082602	   44-­‐113	   129-­‐195	   29	   CE21988	   42-­‐108	   134-­‐204	   29	  
FBpp0085233	   177-­‐243	   260-­‐324	   7	   CE21988	   42-­‐108	   258-­‐319	   12	  
FBpp0085233	   177-­‐243	   342-­‐408	   8	   CE21988	   134-­‐204	   258-­‐319	   30	  
FBpp0085233	   177-­‐243	   422-­‐482	   13	   CE18030	   579-­‐620	   640-­‐705	   14	  
FBpp0085233	   260-­‐324	   342-­‐408	   21	   CE34717	   90-­‐114	   289-­‐346	   24	  
FBpp0085233	   260-­‐324	   422-­‐482	   9	   CE02193	   59-­‐128	   147-­‐215	   24	  
FBpp0085233	   342-­‐408	   422-­‐482	   16	   CE02193	   59-­‐128	   240-­‐308	   20	  
FBpp0072253	   115-­‐183	   205-­‐272	   29	   CE02193	   59-­‐128	   345-­‐413	   30	  
FBpp0111476	   98-­‐168	   216-­‐271	   35	   CE02193	   147-­‐215	   240-­‐308	   37	  
FBpp0075370	   109-­‐163	   194-­‐237	   34	   CE02193	   147-­‐215	   345-­‐413	   37	  
FBpp0070086	   152-­‐234	   250-­‐316	   29	   CE02193	   240-­‐308	   345-­‐413	   42	  
FBpp0070086	   152-­‐234	   404-­‐473	   31	   CE43237	   227-­‐296	   329-­‐392	   32	  
FBpp0070086	   250-­‐316	   404-­‐473	   32	   CE03762	   4-­‐64	   114-­‐180	   14	  
FBpp0082318	   34-­‐96	   138-­‐195	   39	   CE40238	   70-­‐136	   160-­‐226	   17	  
FBpp0076141	   132-­‐155	   220-­‐276	   16	   CE42017	   5-­‐35	   99-­‐127	   6	  
FBpp0099744	   34-­‐102	   125-­‐186	   35	   CE42017	   5-­‐35	   157-­‐209	   19	  
FBpp0070207	   95-­‐165	   181-­‐244	   31	   CE42017	   99-­‐127	   157-­‐209	   17	  
FBpp0111494	   463-­‐533	   567-­‐633	   28	   CE30079	   72-­‐140	   183-­‐236	   22	  
FBpp0082785	   267-­‐331	   340-­‐403	   10	   CE42199	   821-­‐853	   891-­‐913	   13	  
FBpp0082959	   453-­‐518	   706-­‐730	   24	  
	   	   	   	  
FBpp0099578	   119-­‐189	   205-­‐267	   36	  
	   	   	   	  
FBpp0071961	   113-­‐192	   244-­‐313	   22	  
	   	   	   	  
FBpp0071961	   113-­‐192	   376-­‐431	   8	  
	   	   	   	  
FBpp0071961	   244-­‐313	   376-­‐431	   17	  
	   	   	   	  
FBpp0073543	   28-­‐62	   80-­‐116	   11	  
	   	   	   	  
FBpp0073543	   28-­‐62	   132-­‐198	   25	  
	   	   	   	  
FBpp0073543	   28-­‐62	   275-­‐344	   25	  
	   	   	   	  
FBpp0073543	   80-­‐116	   132-­‐198	   29	  
	   	   	   	  
FBpp0073543	   80-­‐116	   275-­‐344	   32	  
	   	   	   	  
FBpp0073543	   132-­‐198	   275-­‐344	   29	  
	   	   	   	  
FBpp0084669	   33-­‐101	   124-­‐190	   26	  
	   	   	   	   
  
  
 
65 
  
 
Table S 2.3 RRM-containing RBP orthologs in four species and their multiRRM scores 
 
HumShared	   Hum	  RRM1	  vs	  RRM2	   Hum_Scores	   MouShared	   Mou	  RRM1	  vs	  RRM2	   Mou_Scores	  
ENSP00000284073	   24-­‐91	   112-­‐178	   43	   ENSMUSP00000096222	   86-­‐140	   177-­‐234	   27	  
ENSP00000373277	   63-­‐123	   142-­‐206	   26	   ENSMUSP00000096222	   86-­‐140	   403-­‐457	   12	  
ENSP00000352612	   69-­‐139	   155-­‐221	   38	   ENSMUSP00000096222	   177-­‐234	   403-­‐457	   18	  
ENSP00000352612	   69-­‐139	   306-­‐375	   31	   ENSMUSP00000104945	   23-­‐85	   187-­‐255	   23	  
ENSP00000352612	   155-­‐221	   306-­‐375	   26	   ENSMUSP00000042658	   16-­‐84	   107-­‐175	   34	  
ENSP00000334538	   23-­‐85	   184-­‐252	   25	   ENSMUSP00000089958	   12-­‐80	   115-­‐183	   31	  
ENSP00000261741	   4-­‐72	   298-­‐363	   15	   ENSMUSP00000005041	   151-­‐225	   261-­‐330	   18	  
ENSP00000261741	   4-­‐72	   404-­‐473	   27	   ENSMUSP00000005041	   151-­‐225	   400-­‐459	   11	  
ENSP00000261741	   4-­‐72	   589-­‐642	   20	   ENSMUSP00000005041	   261-­‐330	   400-­‐459	   18	  
ENSP00000261741	   4-­‐72	   732-­‐804	   30	   ENSMUSP00000001809	   13-­‐83	   101-­‐168	   33	  
ENSP00000261741	   4-­‐72	   834-­‐904	   30	   ENSMUSP00000001809	   13-­‐83	   193-­‐261	   33	  
ENSP00000261741	   298-­‐363	   404-­‐473	   15	   ENSMUSP00000001809	   13-­‐83	   296-­‐363	   35	  
ENSP00000261741	   298-­‐363	   589-­‐642	   9	   ENSMUSP00000001809	   101-­‐168	   193-­‐261	   45	  
ENSP00000261741	   298-­‐363	   732-­‐804	   18	   ENSMUSP00000001809	   101-­‐168	   296-­‐363	   41	  
ENSP00000261741	   298-­‐363	   834-­‐904	   27	   ENSMUSP00000001809	   193-­‐261	   296-­‐363	   52	  
ENSP00000261741	   404-­‐473	   589-­‐642	   29	   ENSMUSP00000066312	   93-­‐162	   226-­‐294	   28	  
ENSP00000261741	   404-­‐473	   732-­‐804	   32	   ENSMUSP00000066312	   93-­‐162	   516-­‐583	   39	  
ENSP00000261741	   404-­‐473	   834-­‐904	   24	   ENSMUSP00000066312	   226-­‐294	   516-­‐583	   47	  
ENSP00000261741	   589-­‐642	   732-­‐804	   29	   ENSMUSP00000008477	   27-­‐84	   153-­‐212	   17	  
ENSP00000261741	   589-­‐642	   834-­‐904	   35	   ENSMUSP00000066311	   5-­‐69	   156-­‐223	   30	  
ENSP00000261741	   732-­‐804	   834-­‐904	   25	   ENSMUSP00000066311	   5-­‐69	   285-­‐351	   16	  
ENSP00000271628	   15-­‐85	   102-­‐173	   36	   ENSMUSP00000066311	   5-­‐69	   403-­‐458	   23	  
ENSP00000364912	   8-­‐68	   339-­‐406	   19	   ENSMUSP00000066311	   5-­‐69	   760-­‐829	   26	  
ENSP00000364912	   8-­‐68	   440-­‐507	   24	   ENSMUSP00000066311	   156-­‐223	   285-­‐351	   23	  
ENSP00000364912	   8-­‐68	   535-­‐587	   24	   ENSMUSP00000066311	   156-­‐223	   403-­‐458	   28	  
ENSP00000364912	   339-­‐406	   440-­‐507	   14	   ENSMUSP00000066311	   156-­‐223	   760-­‐829	   23	  
ENSP00000364912	   339-­‐406	   535-­‐587	   22	   ENSMUSP00000066311	   285-­‐351	   403-­‐458	   19	  
ENSP00000364912	   440-­‐507	   535-­‐587	   26	   ENSMUSP00000066311	   285-­‐351	   760-­‐829	   10	  
ENSP00000322016	   88-­‐158	   185-­‐254	   41	   ENSMUSP00000066311	   403-­‐458	   760-­‐829	   30	  
ENSP00000322016	   88-­‐158	   443-­‐501	   11	   ENSMUSP00000084114	   151-­‐218	   235-­‐296	   38	  
ENSP00000322016	   185-­‐254	   443-­‐501	   8	   ENSMUSP00000088365	   113-­‐180	   230-­‐332	   5	  
ENSP00000246071	   27-­‐84	   153-­‐212	   17	   ENSMUSP00000093425	   9-­‐77	   108-­‐178	   27	  
ENSP00000221419	   120-­‐174	   211-­‐268	   27	   ENSMUSP00000093425	   9-­‐77	   216-­‐280	   36	  
ENSP00000221419	   120-­‐174	   400-­‐454	   12	   ENSMUSP00000093425	   108-­‐178	   216-­‐280	   32	  
ENSP00000221419	   211-­‐268	   400-­‐454	   18	   ENSMUSP00000003501	   41-­‐111	   127-­‐190	   37	  
ENSP00000352162	   41-­‐111	   127-­‐190	   37	   ENSMUSP00000003501	   41-­‐111	   286-­‐355	   30	  
ENSP00000352162	   41-­‐111	   286-­‐355	   30	   ENSMUSP00000003501	   127-­‐190	   286-­‐355	   28	  
ENSP00000352162	   127-­‐190	   286-­‐355	   28	   ENSMUSP00000105216	   155-­‐220	   252-­‐322	   19	  
ENSP00000348345	   14-­‐84	   113-­‐182	   42	   ENSMUSP00000105216	   155-­‐220	   452-­‐505	   7	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ENSP00000348345	   14-­‐84	   291-­‐358	   39	   ENSMUSP00000105216	   252-­‐322	   452-­‐505	   12	  
ENSP00000348345	   113-­‐182	   291-­‐358	   42	   ENSMUSP00000107403	   58-­‐118	   137-­‐201	   26	  
ENSP00000258962	   18-­‐85	   123-­‐184	   25	   ENSMUSP00000007993	   6-­‐69	   116-­‐184	   25	  
ENSP00000351409	   19-­‐84	   110-­‐175	   33	   ENSMUSP00000007993	   6-­‐69	   327-­‐385	   23	  
ENSP00000351409	   19-­‐84	   403-­‐472	   21	   ENSMUSP00000007993	   6-­‐69	   480-­‐559	   14	  
ENSP00000351409	   110-­‐175	   403-­‐472	   24	   ENSMUSP00000007993	   116-­‐184	   327-­‐385	   37	  
ENSP00000363745	   167-­‐231	   248-­‐312	   20	   ENSMUSP00000007993	   116-­‐184	   480-­‐559	   14	  
ENSP00000363745	   167-­‐231	   346-­‐407	   25	   ENSMUSP00000007993	   327-­‐385	   480-­‐559	   22	  
ENSP00000363745	   248-­‐312	   346-­‐407	   20	   ENSMUSP00000030623	   291-­‐355	   366-­‐425	   16	  
ENSP00000295470	   151-­‐218	   235-­‐296	   38	   ENSMUSP00000048450	   191-­‐222	   247-­‐271	   8	  
ENSP00000260956	   113-­‐178	   231-­‐334	   6	   ENSMUSP00000048450	   191-­‐222	   293-­‐362	   34	  
ENSP00000244020	   4-­‐64	   112-­‐177	   24	   ENSMUSP00000048450	   247-­‐271	   293-­‐362	   28	  
ENSP00000228284	   706-­‐774	   803-­‐871	   27	   ENSMUSP00000005643	   46-­‐111	   137-­‐202	   34	  
ENSP00000361949	   13-­‐83	   101-­‐168	   29	   ENSMUSP00000005643	   46-­‐111	   430-­‐499	   19	  
ENSP00000361949	   13-­‐83	   193-­‐261	   34	   ENSMUSP00000005643	   137-­‐202	   430-­‐499	   24	  
ENSP00000361949	   13-­‐83	   296-­‐363	   30	   ENSMUSP00000035199	   100-­‐171	   233-­‐308	   20	  
ENSP00000361949	   101-­‐168	   193-­‐261	   45	   ENSMUSP00000045048	   14-­‐84	   113-­‐182	   42	  
ENSP00000361949	   101-­‐168	   296-­‐363	   42	   ENSMUSP00000045048	   14-­‐84	   291-­‐358	   39	  
ENSP00000361949	   193-­‐261	   296-­‐363	   50	   ENSMUSP00000045048	   113-­‐182	   291-­‐358	   42	  
ENSP00000253363	   155-­‐220	   252-­‐322	   19	   ENSMUSP00000105233	   5-­‐69	   307-­‐372	   23	  
ENSP00000253363	   155-­‐220	   452-­‐505	   7	   ENSMUSP00000105233	   5-­‐69	   432-­‐501	   27	  
ENSP00000253363	   252-­‐322	   452-­‐505	   12	   ENSMUSP00000105233	   5-­‐69	   548-­‐613	   24	  
ENSP00000313007	   13-­‐83	   101-­‐168	   33	   ENSMUSP00000105233	   5-­‐69	   919-­‐988	   24	  
ENSP00000313007	   13-­‐83	   193-­‐261	   31	   ENSMUSP00000105233	   307-­‐372	   432-­‐501	   30	  
ENSP00000313007	   13-­‐83	   296-­‐363	   35	   ENSMUSP00000105233	   307-­‐372	   548-­‐613	   33	  
ENSP00000313007	   101-­‐168	   193-­‐261	   47	   ENSMUSP00000105233	   307-­‐372	   919-­‐988	   24	  
ENSP00000313007	   101-­‐168	   296-­‐363	   41	   ENSMUSP00000105233	   432-­‐501	   548-­‐613	   19	  
ENSP00000313007	   193-­‐261	   296-­‐363	   52	   ENSMUSP00000105233	   432-­‐501	   919-­‐988	   21	  
ENSP00000349428	   78-­‐131	   200-­‐258	   9	   ENSMUSP00000105233	   548-­‐613	   919-­‐988	   22	  
ENSP00000349428	   78-­‐131	   383-­‐435	   18	   ENSMUSP00000101413	   8-­‐68	   341-­‐408	   19	  
ENSP00000349428	   78-­‐131	   482-­‐544	   5	   ENSMUSP00000101413	   8-­‐68	   442-­‐509	   24	  
ENSP00000349428	   200-­‐258	   383-­‐435	   24	   ENSMUSP00000101413	   8-­‐68	   537-­‐589	   26	  
ENSP00000349428	   200-­‐258	   482-­‐544	   20	   ENSMUSP00000101413	   341-­‐408	   442-­‐509	   14	  
ENSP00000349428	   383-­‐435	   482-­‐544	   22	   ENSMUSP00000101413	   341-­‐408	   537-­‐589	   24	  
ENSP00000240185	   106-­‐171	   193-­‐241	   28	   ENSMUSP00000101413	   442-­‐509	   537-­‐589	   26	  
ENSP00000355089	   56-­‐123	   154-­‐216	   41	   ENSMUSP00000075709	   15-­‐85	   102-­‐173	   36	  
ENSP00000355089	   56-­‐123	   442-­‐472	   16	   ENSMUSP00000103947	   226-­‐295	   327-­‐399	   37	  
ENSP00000355089	   154-­‐216	   442-­‐472	   29	   ENSMUSP00000103947	   226-­‐295	   446-­‐518	   38	  
ENSP00000355565	   187-­‐218	   241-­‐267	   3	   ENSMUSP00000103947	   327-­‐399	   446-­‐518	   36	  
ENSP00000355565	   187-­‐218	   289-­‐358	   34	   ENSMUSP00000017065	   4-­‐64	   112-­‐177	   22	  
ENSP00000355565	   241-­‐267	   289-­‐358	   25	   ENSMUSP00000101833	   11-­‐96	   116-­‐186	   26	  
ENSP00000351168	   227-­‐296	   328-­‐400	   37	   ENSMUSP00000101833	   11-­‐96	   224-­‐288	   35	  
ENSP00000351168	   227-­‐296	   447-­‐519	   38	   ENSMUSP00000101833	   116-­‐186	   224-­‐288	   32	  
  
 
67 
  
 
ENSP00000351168	   328-­‐400	   447-­‐519	   36	   ENSMUSP00000098096	   136-­‐206	   233-­‐302	   41	  
ENSP00000341826	   16-­‐84	   107-­‐175	   34	   ENSMUSP00000098096	   136-­‐206	   491-­‐549	   13	  
ENSP00000358089	   11-­‐96	   116-­‐186	   26	   ENSMUSP00000098096	   233-­‐302	   491-­‐549	   11	  
ENSP00000358089	   11-­‐96	   224-­‐288	   35	   ENSMUSP00000102733	   70-­‐140	   156-­‐222	   38	  
ENSP00000358089	   116-­‐186	   224-­‐288	   32	   ENSMUSP00000102733	   70-­‐140	   308-­‐377	   31	  
ENSP00000382239	   5-­‐69	   157-­‐224	   30	   ENSMUSP00000102733	   156-­‐222	   308-­‐377	   26	  
ENSP00000382239	   5-­‐69	   286-­‐353	   24	   ENSMUSP00000038256	   4-­‐64	   81-­‐141	   44	  
ENSP00000382239	   5-­‐69	   402-­‐457	   23	   ENSMUSP00000107595	   37-­‐106	   128-­‐196	   36	  
ENSP00000382239	   5-­‐69	   928-­‐997	   20	   ENSMUSP00000078792	   18-­‐85	   123-­‐184	   25	  
ENSP00000382239	   157-­‐224	   286-­‐353	   26	   ENSMUSP00000019118	   706-­‐775	   803-­‐872	   27	  
ENSP00000382239	   157-­‐224	   402-­‐457	   28	   ENSMUSP00000079070	   13-­‐83	   101-­‐168	   29	  
ENSP00000382239	   157-­‐224	   928-­‐997	   22	   ENSMUSP00000079070	   13-­‐83	   193-­‐261	   34	  
ENSP00000382239	   286-­‐353	   402-­‐457	   14	   ENSMUSP00000079070	   13-­‐83	   296-­‐363	   30	  
ENSP00000382239	   286-­‐353	   928-­‐997	   8	   ENSMUSP00000079070	   101-­‐168	   193-­‐261	   44	  
ENSP00000382239	   402-­‐457	   928-­‐997	   30	   ENSMUSP00000079070	   101-­‐168	   296-­‐363	   42	  
ENSP00000310471	   4-­‐64	   81-­‐141	   44	   ENSMUSP00000079070	   193-­‐261	   296-­‐363	   48	  
ENSP00000307863	   151-­‐225	   261-­‐330	   18	   ENSMUSP00000059330	   12-­‐81	   93-­‐153	   27	  
ENSP00000307863	   151-­‐225	   400-­‐459	   11	   ENSMUSP00000101476	   167-­‐231	   248-­‐309	   22	  
ENSP00000307863	   261-­‐330	   400-­‐459	   18	   ENSMUSP00000101476	   167-­‐231	   343-­‐404	   25	  
ENSP00000313890	   159-­‐215	   339-­‐408	   14	   ENSMUSP00000101476	   248-­‐309	   343-­‐404	   20	  
ENSP00000313890	   159-­‐215	   420-­‐480	   8	   ENSMUSP00000038113	   106-­‐171	   193-­‐242	   24	  
ENSP00000313890	   339-­‐408	   420-­‐480	   27	   ENSMUSP00000031590	   4-­‐72	   297-­‐362	   12	  
ENSP00000282574	   9-­‐77	   108-­‐178	   27	   ENSMUSP00000031590	   4-­‐72	   402-­‐471	   24	  
ENSP00000282574	   9-­‐77	   216-­‐280	   36	   ENSMUSP00000031590	   4-­‐72	   587-­‐639	   18	  
ENSP00000282574	   108-­‐178	   216-­‐280	   32	   ENSMUSP00000031590	   4-­‐72	   724-­‐796	   27	  
ENSP00000343054	   100-­‐171	   233-­‐308	   20	   ENSMUSP00000031590	   4-­‐72	   826-­‐896	   31	  
ENSP00000376309	   37-­‐106	   128-­‐196	   36	   ENSMUSP00000031590	   297-­‐362	   402-­‐471	   4	  
ENSP00000349748	   299-­‐363	   374-­‐433	   16	   ENSMUSP00000031590	   297-­‐362	   587-­‐639	   9	  
ENSP00000233078	   12-­‐80	   115-­‐183	   31	   ENSMUSP00000031590	   297-­‐362	   724-­‐796	   21	  
ENSP00000363228	   5-­‐69	   307-­‐372	   23	   ENSMUSP00000031590	   297-­‐362	   826-­‐896	   27	  
ENSP00000363228	   5-­‐69	   432-­‐501	   26	   ENSMUSP00000031590	   402-­‐471	   587-­‐639	   28	  
ENSP00000363228	   5-­‐69	   547-­‐612	   24	   ENSMUSP00000031590	   402-­‐471	   724-­‐796	   30	  
ENSP00000363228	   5-­‐69	   859-­‐928	   24	   ENSMUSP00000031590	   402-­‐471	   826-­‐896	   25	  
ENSP00000363228	   307-­‐372	   432-­‐501	   31	   ENSMUSP00000031590	   587-­‐639	   724-­‐796	   28	  
ENSP00000363228	   307-­‐372	   547-­‐612	   33	   ENSMUSP00000031590	   587-­‐639	   826-­‐896	   37	  
ENSP00000363228	   307-­‐372	   859-­‐928	   25	   ENSMUSP00000031590	   724-­‐796	   826-­‐896	   25	  
ENSP00000363228	   432-­‐501	   547-­‐612	   22	   ENSMUSP00000111483	   56-­‐123	   153-­‐215	   41	  
ENSP00000363228	   432-­‐501	   859-­‐928	   21	   ENSMUSP00000111483	   56-­‐123	   422-­‐490	   22	  
ENSP00000363228	   547-­‐612	   859-­‐928	   22	   ENSMUSP00000111483	   153-­‐215	   422-­‐490	   25	  
ENSP00000223073	   6-­‐68	   116-­‐184	   26	   ENSMUSP00000093109	   77-­‐130	   199-­‐257	   9	  
ENSP00000223073	   6-­‐68	   337-­‐395	   25	   ENSMUSP00000093109	   77-­‐130	   381-­‐433	   7	  
ENSP00000223073	   6-­‐68	   490-­‐567	   14	   ENSMUSP00000093109	   77-­‐130	   480-­‐542	   5	  
ENSP00000223073	   116-­‐184	   337-­‐395	   37	   ENSMUSP00000093109	   199-­‐257	   381-­‐433	   24	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ENSP00000223073	   116-­‐184	   490-­‐567	   13	   ENSMUSP00000093109	   199-­‐257	   480-­‐542	   20	  
ENSP00000223073	   337-­‐395	   490-­‐567	   25	   ENSMUSP00000093109	   381-­‐433	   480-­‐542	   22	  
ENSP00000316950	   102-­‐171	   235-­‐303	   28	   ENSMUSP00000090470	   24-­‐91	   112-­‐178	   43	  
ENSP00000316950	   102-­‐171	   525-­‐592	   39	  
	   	   	   	  
ENSP00000316950	   235-­‐303	   525-­‐592	   44	  
	   	   	   	  FlyShared	   Fly	  RRM1	  vs	  RRM2	   Fly_Scores	   WormShared	   Worm	  RRM1	  vs	  RRM2	   Worm_Scores	  
FBpp0085916	   4-­‐74	   92-­‐160	   27	   CE18963	   5-­‐73	   177-­‐239	   14	  
FBpp0085916	   4-­‐74	   185-­‐249	   24	   CE18963	   5-­‐73	   281-­‐349	   28	  
FBpp0085916	   4-­‐74	   289-­‐357	   30	   CE18963	   5-­‐73	   501-­‐554	   14	  
FBpp0085916	   92-­‐160	   185-­‐249	   38	   CE18963	   5-­‐73	   643-­‐719	   13	  
FBpp0085916	   92-­‐160	   289-­‐357	   43	   CE18963	   5-­‐73	   750-­‐820	   23	  
FBpp0085916	   185-­‐249	   289-­‐357	   52	   CE18963	   177-­‐239	   281-­‐349	   11	  
FBpp0077781	   556-­‐626	   658-­‐724	   14	   CE18963	   177-­‐239	   501-­‐554	   11	  
FBpp0077781	   556-­‐626	   753-­‐804	   15	   CE18963	   177-­‐239	   643-­‐719	   17	  
FBpp0077781	   658-­‐724	   753-­‐804	   19	   CE18963	   177-­‐239	   750-­‐820	   11	  
FBpp0080905	   152-­‐223	   264-­‐366	   11	   CE18963	   281-­‐349	   501-­‐554	   14	  
FBpp0076875	   233-­‐297	   312-­‐378	   29	   CE18963	   281-­‐349	   643-­‐719	   26	  
FBpp0078974	   9-­‐77	   98-­‐165	   35	   CE18963	   281-­‐349	   750-­‐820	   21	  
FBpp0074012	   304-­‐368	   378-­‐441	   14	   CE18963	   501-­‐554	   643-­‐719	   11	  
FBpp0079471	   12-­‐70	   171-­‐227	   5	   CE18963	   501-­‐554	   750-­‐820	   22	  
FBpp0083366	   166-­‐231	   247-­‐308	   29	   CE18963	   643-­‐719	   750-­‐820	   25	  
FBpp0083366	   166-­‐231	   342-­‐403	   32	   CE26020	   7-­‐73	   125-­‐194	   32	  
FBpp0083366	   247-­‐308	   342-­‐403	   22	   CE26020	   7-­‐73	   473-­‐541	   43	  
FBpp0083976	   9-­‐76	   97-­‐167	   27	   CE26020	   125-­‐194	   473-­‐541	   36	  
FBpp0083976	   9-­‐76	   223-­‐287	   20	   CE20412	   34-­‐103	   122-­‐190	   27	  
FBpp0083976	   97-­‐167	   223-­‐287	   27	   CE20412	   34-­‐103	   215-­‐282	   25	  
FBpp0077324	   112-­‐182	   198-­‐270	   33	   CE20412	   34-­‐103	   319-­‐387	   31	  
FBpp0077324	   112-­‐182	   363-­‐432	   35	   CE20412	   122-­‐190	   215-­‐282	   33	  
FBpp0077324	   198-­‐270	   363-­‐432	   30	   CE20412	   122-­‐190	   319-­‐387	   40	  
FBpp0085681	   99-­‐156	   258-­‐314	   22	   CE20412	   215-­‐282	   319-­‐387	   47	  
FBpp0085681	   99-­‐156	   369-­‐429	   12	   CE29126	   174-­‐240	   274-­‐343	   8	  
FBpp0085681	   258-­‐314	   369-­‐429	   5	   CE38662	   31-­‐99	   112-­‐180	   31	  
FBpp0072706	   5-­‐65	   362-­‐423	   26	   CE27708	   48-­‐114	   137-­‐207	   31	  
FBpp0072706	   5-­‐65	   478-­‐546	   11	   CE27708	   48-­‐114	   243-­‐305	   31	  
FBpp0072706	   5-­‐65	   741-­‐773	   12	   CE27708	   137-­‐207	   243-­‐305	   28	  
FBpp0072706	   5-­‐65	   911-­‐981	   29	   CE24110	   5-­‐70	   876-­‐943	   16	  
FBpp0072706	   362-­‐423	   478-­‐546	   25	   CE03763	   5-­‐65	   131-­‐196	   19	  
FBpp0072706	   362-­‐423	   741-­‐773	   21	   CE07355	   28-­‐85	   145-­‐204	   10	  
FBpp0072706	   362-­‐423	   911-­‐981	   20	   CE08718	   112-­‐170	   230-­‐335	   22	  
FBpp0072706	   478-­‐546	   741-­‐773	   21	   CE00983	   44-­‐114	   130-­‐196	   31	  
FBpp0072706	   478-­‐546	   911-­‐981	   23	   CE00983	   44-­‐114	   376-­‐444	   31	  
FBpp0072706	   741-­‐773	   911-­‐981	   18	   CE00983	   130-­‐196	   376-­‐444	   31	  
FBpp0082724	   9-­‐75	   117-­‐178	   22	   CE03111	   14-­‐74	   165-­‐234	   4	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FBpp0087934	   114-­‐161	   316-­‐384	   8	   CE36388	   202-­‐266	   283-­‐350	   10	  
FBpp0087934	   114-­‐161	   398-­‐456	   25	   CE36388	   202-­‐266	   379-­‐440	   24	  
FBpp0087934	   316-­‐384	   398-­‐456	   25	   CE36388	   283-­‐350	   379-­‐440	   14	  
FBpp0072593	   132-­‐202	   229-­‐298	   32	   CE31214	   97-­‐165	   265-­‐333	   21	  
FBpp0072593	   132-­‐202	   560-­‐622	   14	   CE31214	   97-­‐165	   414-­‐484	   23	  
FBpp0072593	   229-­‐298	   560-­‐622	   6	   CE31214	   265-­‐333	   414-­‐484	   10	  
FBpp0088567	   109-­‐174	   194-­‐242	   26	   CE41585	   58-­‐122	   144-­‐208	   36	  
FBpp0082316	   26-­‐94	   117-­‐185	   30	   CE41585	   58-­‐122	   505-­‐575	   23	  
FBpp0081601	   59-­‐128	   234-­‐302	   24	   CE41585	   144-­‐208	   505-­‐575	   27	  
FBpp0081601	   59-­‐128	   565-­‐628	   28	   CE35148	   186-­‐246	   283-­‐351	   29	  
FBpp0081601	   234-­‐302	   565-­‐628	   14	   CE35148	   186-­‐246	   391-­‐451	   18	  
FBpp0085240	   257-­‐323	   422-­‐478	   5	   CE35148	   283-­‐351	   391-­‐451	   31	  
FBpp0085240	   257-­‐323	   612-­‐664	   11	   CE02231	   176-­‐242	   261-­‐328	   10	  
FBpp0085240	   257-­‐323	   714-­‐774	   11	   CE36374	   15-­‐85	   102-­‐172	   28	  
FBpp0085240	   422-­‐478	   612-­‐664	   24	   CE31089	   11-­‐77	   125-­‐186	   19	  
FBpp0085240	   422-­‐478	   714-­‐774	   8	   CE42671	   118-­‐181	   191-­‐251	   13	  
FBpp0085240	   612-­‐664	   714-­‐774	   16	   CE27339	   186-­‐260	   293-­‐361	   20	  
FBpp0076112	   4-­‐72	   254-­‐314	   11	   CE27339	   186-­‐260	   425-­‐481	   8	  
FBpp0076112	   4-­‐72	   366-­‐435	   24	   CE27339	   293-­‐361	   425-­‐481	   14	  
FBpp0076112	   4-­‐72	   571-­‐622	   9	   CE26949	   228-­‐300	   365-­‐421	   10	  
FBpp0076112	   4-­‐72	   681-­‐755	   15	   CE05167	   595-­‐660	   685-­‐753	   21	  
FBpp0076112	   4-­‐72	   787-­‐858	   24	   CE39251	   25-­‐93	   116-­‐184	   33	  
FBpp0076112	   254-­‐314	   366-­‐435	   19	   CE17724	   36-­‐99	   171-­‐230	   15	  
FBpp0076112	   254-­‐314	   571-­‐622	   3	   CE17724	   36-­‐99	   253-­‐311	   11	  
FBpp0076112	   254-­‐314	   681-­‐755	   9	   CE17724	   171-­‐230	   253-­‐311	   23	  
FBpp0076112	   254-­‐314	   787-­‐858	   21	   CE34752	   34-­‐96	   140-­‐197	   22	  
FBpp0076112	   366-­‐435	   571-­‐622	   30	   CE34752	   34-­‐96	   325-­‐379	   5	  
FBpp0076112	   366-­‐435	   681-­‐755	   27	   CE34752	   140-­‐197	   325-­‐379	   14	  
FBpp0076112	   366-­‐435	   787-­‐858	   25	   CE28911	   145-­‐231	   248-­‐317	   27	  
FBpp0076112	   571-­‐622	   681-­‐755	   11	   CE08369	   47-­‐116	   190-­‐258	   15	  
FBpp0076112	   571-­‐622	   787-­‐858	   23	   CE08369	   47-­‐116	   387-­‐449	   25	  
FBpp0076112	   681-­‐755	   787-­‐858	   19	   CE08369	   190-­‐258	   387-­‐449	   11	  
FBpp0088583	   239-­‐304	   337-­‐406	   21	   CE24366	   104-­‐174	   209-­‐278	   28	  
FBpp0088583	   239-­‐304	   511-­‐565	   10	   CE24366	   104-­‐174	   679-­‐735	   14	  
FBpp0088583	   337-­‐406	   511-­‐565	   18	   CE24366	   209-­‐278	   679-­‐735	   10	  
FBpp0088856	   51-­‐123	   149-­‐219	   42	   CE29337	   48-­‐115	   136-­‐202	   46	  
FBpp0088856	   51-­‐123	   483-­‐550	   29	   CE32618	   33-­‐68	   293-­‐335	   13	  
FBpp0088856	   149-­‐219	   483-­‐550	   32	   CE36103	   31-­‐97	   126-­‐188	   36	  
FBpp0076553	   9-­‐70	   88-­‐150	   54	   CE36103	   31-­‐97	   431-­‐500	   19	  
FBpp0082320	   58-­‐126	   138-­‐206	   31	   CE36103	   126-­‐188	   431-­‐500	   26	  
FBpp0070716	   9-­‐79	   144-­‐203	   21	   CE30508	   137-­‐193	   248-­‐306	   28	  
FBpp0082269	   6-­‐66	   117-­‐182	   18	   CE30508	   137-­‐193	   438-­‐493	   10	  
FBpp0074013	   95-­‐169	   209-­‐278	   17	   CE30508	   137-­‐193	   540-­‐600	   3	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FBpp0074013	   95-­‐169	   344-­‐399	   8	   CE30508	   248-­‐306	   438-­‐493	   28	  
FBpp0074013	   209-­‐278	   344-­‐399	   10	   CE30508	   248-­‐306	   540-­‐600	   15	  
FBpp0070859	   15-­‐85	   102-­‐172	   29	   CE30508	   438-­‐493	   540-­‐600	   7	  
FBpp0072239	   50-­‐118	   232-­‐299	   17	  
	   	   	   	  
FBpp0072239	   50-­‐118	   381-­‐449	   11	  
	   	   	   	  
FBpp0072239	   232-­‐299	   381-­‐449	   17	  
	   	   	   	  
FBpp0110257	   298-­‐364	   384-­‐448	   38	  
	   	   	   	  
FBpp0110257	   298-­‐364	   810-­‐880	   28	  
	   	   	   	  
FBpp0110257	   384-­‐448	   810-­‐880	   23	  
	   	   	   	  
FBpp0080510	   157-­‐235	   262-­‐329	   30	  
	   	   	   	  
FBpp0075557	   57-­‐119	   339-­‐408	   25	  
	   	   	   	  
FBpp0077631	   260-­‐326	   390-­‐468	   16	  
	   	   	   	  
FBpp0086479	   281-­‐350	   382-­‐458	   35	  
	   	   	   	  
FBpp0086479	   281-­‐350	   548-­‐619	   24	  
	   	   	   	  
FBpp0086479	   382-­‐458	   548-­‐619	   26	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Table S 2.4 DAZ orthologs identified in different species (InParanoid and manual Blast) 
 
	  
Chimpanzee	   Macaque	  
	  
	   InParanoid.H.sapiens-­‐P.troglodytes.tgz	   InParanoid.H.sapiens-­‐M.mulatta.tgz	  
	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	  
Specie
s	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	   Species	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
BOLL	  
Q8N9W6	  
(BOLL_HU
MAN)	  
12135	   587	  
H.sapi
ens	  
Q8N9
W6	   100%	   11313	   584	  
H.sapie
ns	  
Q8N9
W6	   100%	  
12135	   587	  
P.trogl
odytes	  
H2QJ
74	   100%	   11313	   584	  
M.mula
tta	  
F7HR
30	   100%	  
	   	  	  
	   	   	   	  
	  	  
	   	   	  
	  	  
DAZL	  
Q92904	  
(DAZL_HU
MAN)	  
11774	   609	  
H.sapi
ens	  
Q929
04	   100%	   10944	   605	  
H.sapie
ns	  
Q929
04	   100%	  
11774	   609	  
P.trogl
odytes	  
H2Q
M56	   100%	   10944	   605	  
M.mula
tta	  
F6WG
03	   100%	  
	   	  	  
	   	   	   	  
	  	  
	   	   	  
	  	  
DAZ3	  
Q9NR90	  
(DAZ3_HU
MAN)	  
Addition
al	  
sequenc
e	  search	   2,425	  
H.sapi
ens	  
Q9NR
90	   Length:	  510,	  
Identity:	  88.0%	  
E-­‐value:	  0.0	  
Addition
al	  
sequenc
e	  search	   1,658	  
H.sapie
ns	  
Q9NR
90	   Length:	  551,	  
Identity:	  82.0%	  
E-­‐value:	  0.0	  
P.trogl
odytes	  
H2RB
60	  
M.mula
tta	  
C0KZ
99	  
Addition
al	  
sequenc
e	  search	   2,114	  
H.sapi
ens	  
Q9NR
90	   Length:	  438,	  
Identity:	  82.0%	  
E-­‐value:	  0.0	  
Addition
al	  
sequenc
e	  search	   1,150	  
H.sapie
ns	  
Q9NR
90	   Length:	  559,	  
Identity:	  49.0%	  
E-­‐value:	  6.0×10-­‐149	  
P.trogl
odytes	  
H2RB
61	  
M.mula
tta	  
C0KZ
A0	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	   	  
	  	  
	   	   	  
	  	  
DAZ2	  
Q13117	  
(DAZ2_HU
MAN)	  
7204	   968	  
H.sapi
ens	  
Q131
17	   89%	  
Addition
al	  
sequenc
e	  search	   1,662	  
H.sapie
ns	  
Q131
17	   Length:	  551,	  
Identity:	  82.0%	  
E-­‐value:	  0.0	  7204	   968	  
P.trogl
odytes	  
H2RB
60	   100%	  
M.mula
tta	  
C0KZ
99	  
	  	   	  	   	  	   	  	   	  	  
Addition
al	  
sequenc
e	  search	   1139	  
H.sapie
ns	  
Q131
17	   Length:	  559,	  
Identity:	  46.0%	  
E-­‐value:	  3.0×10-­‐146	  	  	   	  	   	  	   	  	   	  	  
M.mula
tta	  
C0KZ
A0	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	   	  
	  	  
	   	   	  
	  	  
DAZ4	  
Q86SG3	  
(DAZ4_HU
MAN)	  
Addition
al	  
sequenc
e	  search	   2,797	  
H.sapi
ens	  
Q86S
G3	   Length:	  743,	  
Identity:	  91.0%	  
E-­‐value:	  0.0	  
Addition
al	  
sequenc
e	  search	   2,418	  
H.sapie
ns	  
Q86S
G3	   Length:	  551,	  
Identity:	  83.0%	  
E-­‐value:	  0.0	  
P.trogl
odytes	  
H2R5
R2	  
M.mula
tta	  
C0KZ
99	  
Addition
al	  
sequenc
e	  search	   2,054	  
H.sapi
ens	  
Q86S
G3	   Length:	  438,	  
Identity:	  88.0%	  
E-­‐value:	  0.0	  
	  	   	  	   	  	   	  	   	  	  
P.trogl
odytes	  
H2RB
61	   	  	   	  	   	  	   	  	   	  	  
Addition
al	  
sequenc
e	  search	   2,033	  
H.sapi
ens	  
Q86S
G3	   Length:	  414,	  
Identity:	  91.0%	  
E-­‐value:	  0.0	  
	  	   	  	   	  	   	  	   	  	  
P.trogl
odytes	  
H2RB
57	   	  	   	  	   	  	   	  	   	  	  
	  
	  	  
	   	   	   	  
	  	  
	   	   	  
	  	  
DAZ1	  
Q1RMF9	  
(Q1RMF9_
HUMAN)	  
Addition
al	  
sequenc
e	  search	   3605	  
H.sapi
ens	  
Q1R
MF9	   Length:	  743,	  
Identity:	  92.0%	  
E-­‐value:	  0.0	  
	  	   	  	   	  	   	  	   	  	  
P.trogl
odytes	  
H2R5
R2	   	   	  	   	  	   	  	   	  	   	  	  
  
 
72 
  
 
	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
Gorilla	   Chicken	  
	  
InParanoid.G.gorilla-­‐H.sapiens.tgz	   InParanoid.G.gallus-­‐H.sapiens.tgz	  
	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	  
Specie
s	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	   Species	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
BOLL	  
Q8N9W6	  
(BOLL_HU
MAN)	  
12345	   558	  
G.gorill
a	  
G3RC
N1	   100%	   8097	   429	   G.gallus	  
F1ND
D0	   100%	  
12345	   558	  
H.sapi
ens	  
Q8N9
W6	   100%	   8097	   429	  
H.sapie
ns	  
Q8N9
W6	   100%	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZL	  
Q92904	  
(DAZL_HU
MAN)	  
11581	   611	  
G.gorill
a	  
G3SGI
9	   100%	   8619	   388	  
	   	   	   	  
G.gallus	  
Q804
A9	   	   100%	  
11581	   611	  
H.sapi
ens	  
Q929
04	   100%	   8619	   388	  
	   	   	   	   	  
H.sapie
ns	  
Q929
04	   100%	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ3	  
Q9NR90	  
(DAZ3_HU
MAN)	  
Addition
al	  
sequenc
e	  search	   841	  
H.sapi
ens	  
Q9NR
90	   Length:	  295,	  
Identity:	  83.0%	  
E-­‐value:	  3.0×10-­‐106	  
	  	   	  	   	  	   	  	   	  	  
G.gorill
a	  
G3S8
R9	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	  
	  	   	  	  
	  	  
	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ2	  
Q13117	  
(DAZ2_HU
MAN)	  
Addition
al	  
sequenc
e	  search	   841	  
H.sapi
ens	  
Q131
17	   Length:	  295,	  
Identity:	  83.0%	  
E-­‐value:	  3.0×10-­‐105	  
	  	   	  	   	  	   	  	   	  	  
G.gorill
a	  
G3S8
R9	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	  
	  	   	  	  
	  	  
	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ4	  
Q86SG3	  
(DAZ4_HU
MAN)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ1	  
Q1RMF9	  
(Q1RMF9_
HUMAN)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
Zebrafish	   Frog	  
	  
InParanoid.D.rerio-­‐H.sapiens.tgz	   InParanoid.H.sapiens-­‐X.tropicalis.tgz	  
  
 
73 
  
 
	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	  
Specie
s	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
Ortholo
g_group	  
InPar
anoid	  
Best	  
Score	  
or	  
Blast	  
Score	   Species	  
Unipr
ot_ID	  
Bootstrap_support_
as_seed_ortholog	  
BOLL	  
Q8N9W6	  
(BOLL_HU
MAN)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZL	  
Q92904	  
(DAZL_HU
MAN)	  
11476	   155	   D.rerio	  
Q9YG
W7	   100%	   10148	   290	  
H.sapie
ns	  
Q929
04	   100%	  
11476	   155	  
H.sapi
ens	  
Q929
04	   99%	   10148	   290	  
X.tropic
alis	  
Q76C
Y5	   100%	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ3	  
Q9NR90	  
(DAZ3_HU
MAN)	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q131
17	   100%	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q9NR
90	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q86S
G3	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q9N
QZ3	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   12219	   88	  
X.tropic
alis	  
F6SK8
7	   100%	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ2	  
Q13117	  
(DAZ2_HU
MAN)	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q131
17	   100%	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q86S
G3	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q9N
QZ3	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
X.tropic
alis	  
F6SK8
7	   100%	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	   	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ4	  
Q86SG3	  
(DAZ4_HU
MAN)	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q131
17	   100%	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q9NR
90	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q86S
G3	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
H.sapie
ns	  
Q9N
QZ3	   	  	  
	  	   	  	   	  	   	  	   	  	   12219	   88	  
X.tropic
alis	  
F6SK8
7	   100%	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
	  	  
	   	   	  
	  	   	  	  
	   	   	  
	  	  
DAZ1	  
Q1RMF9	  
(Q1RMF9_
HUMAN)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
  
 
74 
  
 
 
 
 
CHAPTER 3  
 
TRANSCRIPTOME-WIDE IDENTIFICATION AND STUDY OF CANCER-SPECIFIC 
SPLICING EVENTS ACROSS MULTIPLE TUMORS2 
 
3.1 Overview 
 
Dysregulation of alternative splicing (AS) is one of molecular hallmarks of cancer, with 
splicing alteration of numerous genes in cancer patients. However, studying splicing mis-
regulation in cancer is complicated by large noise of tissues-specific splicing. To obtain a global 
picture of cancer-specific splicing, we analyzed transcriptome sequencing data from 1149 
patients in TCGA project, producing a core set of AS events significantly altered across multiple 
cancer types. These cancer-specific AS events are highly conserved, more likely to maintain 
protein reading frame, and mainly function in cell cycle, cell adhesion/migration, and insulin 
signaling pathway. Furthermore, these events can serve as new molecular biomarkers to 
distinguish cancer from normal tissues, to separate cancer subtypes, and to predict patient 
survival. We also found that most genes whose expression is closely associated with cancer-
specific splicing are key regulators of the cell cycle. This study uncovers a common set of 
                                                
2 This chapter previously appeared as an article in the Journal of Oncotarget. The original 
citation is as follow: Tsai YS, Dominguez D, Gomez SM, Wang Z. “Transcriptome-wide 
identification and study of cancer-specific splicing events across multiple tumor,” Oncotarget. 
(in press, Feb 2015) 
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cancer-specific AS events altered across multiple cancers, providing mechanistic insight into 
how splicing is mis-regulated in cancers.  
 
3.2 Introduction 
 
Most human genes undergo alternative splicing (AS) to produce multiple isoforms with different 
biological properties.  This process is tightly controlled across different tissues and 
developmental stages, and dysregulation of AS is closely associated with various human diseases 
including cancer [14, 15]. The extensive alteration of AS is considered to be one of the molecular 
hallmarks of cancer [83], and affects numerous genes that are critical for tumor pathogenesis and 
progression (e.g. apoptosis, angiogenesis, tumor metastasis) [84]. While most genetic mutations 
occur at a low frequency in cancer patients (with a few exceptions like TP53), many identified 
cancer-specific AS events were found in more than half of the tumor samples, suggesting a 
predominant role of splicing dysregulation in cancer [14, 84].  For example, CD44 is a key 
mediator of cell-cell and cell-matrix interactions, migration and invasion [85], and different 
splicing isoforms of CD44 have been linked with tumor evasion and met Figure astasis in many 
cancers [86-88].  Other well-documented cases include the apoptosis regulator Bcl-x, which can 
shift its splicing from pro-apoptotic into anti-apoptotic isoforms in cancers [89].  
 AS is generally regulated by multiple cis-acting splicing regulatory elements (SREs) that 
are specifically bound by trans-acting splicing factors to enhance or inhibit the use of nearby 
splice sites [23, 90]. The same splicing factor may either activate or inhibit splicing by binding to 
its cognate SREs in different pre-mRNA regions, which is commonly referred to as context 
dependent activity [18, 20, 21]. Various cellular signaling pathways, such as the MEK/ERK or c-
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Myc pathway [91-93], were found to control the expression level and activity of splicing factors, 
which in turn determine different splicing patterns in distinct tissues (reviewed in [90, 94]).  
Many splicing factors are involved in cancer pathogenesis through mediating AS of hundreds of 
genes [84]. For example, the splicing factor SRSF1 is found to act as a proto-oncogene to 
promote cell transformation [46], whereas the splicing suppressor RBM4 functions as a tumor 
suppressor to inhibit tumor progression[49]. These two antagonistic factors control a partially 
overlapping set of AS events that are involved in cell migration and apoptosis [49].  
 While the global change of splicing in cancers is being increasingly appreciated, the 
functional consequences and regulatory mechanisms of cancer-specific AS remain poorly 
understood. In addition, detailed analyses of cancer-associated splicing were previously focused 
on single tumor types or specific genes [95, 96], which is often dominated by the noise from 
tissue specific AS events.  Since cancer is a highly heterogeneous disease, the genetic variation 
between samples has made the identification of cancer-specific splicing isoforms difficult. 
Recent advance in The Cancer Genome Atlas (TCGA) project has provided tremendous amounts 
of sequencing data from the transcriptome of thousands of samples in different cancer types [8], 
making it possible for an unbiased identification and a further analysis of “cancer-specific” 
splicing events across different cancer types.   
 In this study, we performed a transcriptome-wide splicing comparison between thousands 
of tumor samples and paired normal controls to identify a large number of splicing events with 
altered splicing in cancer.  Most of these events were found to change in a single cancer type, 
and we further identified a core set of cancer-specific AS events across three different cancer 
types. The genes containing cancer-specific AS events are significantly enriched for functions in 
cell cycle, cell adhesion/migration, and insulin signaling pathway. Detailed analyses suggested 
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that cancer-specific cassette exons are more conserved among vertebrates and more likely to 
maintain the protein reading frame. The set of cancer-specific AS events can serve as reliable 
biomarkers to separate tumor from normal samples and to even distinguish different subtypes of 
breast cancer. Finally, we found that most genes whose expression is closely associated with 
cancer-specific splicing are also key regulators of cell cycle, providing a previously unknown 
link between cell cycle and splicing regulation in cancer cells.  
 
3.3 Results 
 
3.3.1 Identification of cancer-specific AS events common to multiple cancers.  
It is well known that splicing is controlled in a tissue specific manner with a global 
change of the splicing landscape between different tissues [10, 11]. Thus identification of AS 
events altered in cancer vs. normal cells is often complicated by the tissue types used. It remains 
unclear what portion of AS events are commonly mis-regulated across all cancer types vs. those 
specific to certain cancers. To identify cancer-specific AS events that are changed within and/or 
across multiple cancers, we used RNA-seq data collected through TCGA project [8]. The aligned 
RNA-seq reads were processed through the MISO pipeline to estimate ratios of different splicing 
isoforms for each annotated splicing event. For each AS event, we calculated the PSI (Percent 
Spliced In) values between all normal and tumor samples, and identified potential cancer-
specific AS events that are significantly altered in cancer vs. normal tissues (Figure 3.1A). 
For a reliable comparison, we selected three types of cancers that have sufficient number 
of paired normal samples from TCGA, including breast invasive carcinoma (BRCA), lung 
squamous cell carcinoma (LUSC) and liver hepatocellular carcinoma (LIHC). We focused on 
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four major modes of AS for more detailed analysis: skipped exon (SE), retained intron (RI), 
alternative 3’ splice site (A3SS) and alternative 5’ splice site (A5SS). In each cancer type, we 
identified AS events that satisfy the following criteria: (i) the AS event is detected in at least 10 
tumor samples and 10 normal samples; (ii) the distributions of PSI values of each event are 
significantly different between normal and tumor samples (p <0.05 by t-test); (iii) the mean 
difference of PSI values between normal and tumor samples is large than 0.1 (Figure 3.1B).  
For each cancer type, we identified several thousand AS events that have significant changes of 
the splicing isoforms (table 3.1). Most of these events are specific to a single cancer type, with 
lung cancer having more altered AS events compare to breast and liver cancers, probably due to 
the higher mutation rate in lung cancer [97].   
We considered the common events that changed in all three types of cancers as a core set 
of 163 cancer-specific AS events (Figure 3.1B and Supplementary Table S3.1). As a background 
control, we simulated the overlaps of AS events between different cancer types using 1000 
randomly selected datasets with matched size (see methods). In all four AS modes, the overlaps 
between simulated datasets are significantly smaller than those between real set, especially for 
the overlaps of all three cancers (Figure 3.1C). This result suggests that although each cancer 
type has tissue-specific set of splicing events, there are indeed a significant number of splicing 
events shared by multiple cancers. Strikingly, 10 of the genes that show cancer-specific AS are 
also frequently mutated in cancers vs. normal samples [98]. Such overlap is significantly more 
than the overlap expected by chance (p=10-6 by hypergeometric test), indicating that the function 
of these genes may be altered through either mutation or splicing changes to affect cancer 
progression. This result also suggests that, in addition to point mutations and copy number 
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variations, the alteration of splicing may serve as another important route to alter gene function 
in cancer. 
Splicing of most introns is regulated in a co-transcriptional fashion [94], thus a change in 
gene expression may affect AS outcomes of corresponding genes. We examined the genes 
containing cancer-specific AS events, and found that most of them (68%-90%) do not have 
significant change of expression levels between normal vs. tumor samples (Supplementary 
Figure S3.1A), suggesting that splicing of these events are not biased by their gene expression. In 
addition, we found that similar numbers of genes have increased vs. decreased PSI values, with 
exception of RI events that tend to have more retained introns (i.e. PSI increased) in cancers 
(Supplementary Figure S3.1B). Intron retention is a relatively less studied mode of AS in 
mammals and usually changes the coding frame and triggers nonsense mediated mRNA decay 
(NMD) [99]. Therefore an increase in intron retention may represent an important mechanism for 
protein inactivation in tumors. 
3.3.2 Consistent change of cancer-specific AS events across tumor types. 
 To determine if the cancer-specific AS events change consistently among different types 
of cancers, we compared the difference of PSI values between cancer and normal (ΔPSI) across 
three cancer types for each event (Figure 3.2A).  The majority (i.e. 85%) of these cancer-
specific AS events change consistently across different tumor types (i.e., with an increased or 
decreased PSI values in all three tumors) when comparing tumors to the cognate normal tissue, 
suggesting that the splicing change in these genes will likely generate similar functional 
consequences across different tumors. The remaining 15% of AS events, while being altered 
across all cancers, have different patterns of splicing changes depending on the cancer type. 
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Representative examples of cancer-specific AS events were arbitrarily selected to 
illustrate splicing changes between tumor and normal samples.  We chose one example from 
each AS mode and used colored lines to represent the ΔPSI between the paired tumor vs. the 
adjacent normal tissue (Figure 3.2B, upper panel). We found that there is large heterogeneity of 
ΔPSI between the paired cancer-normal samples. In some cases of breast cancer, both an increase 
and decrease in PSI were found among different patients, which might reflect differences 
between breast cancer subtypes. In addition, we also plotted the distribution of the PSI for the 
same examples in all normal and tumor samples, and found that the changes of PSI are consistent 
with those found in paired samples (white and gray boxes, bottom of Figure 3.2B).   
3.3.3 Biological functions of cancer-specific AS events. 
 We further examined the genes containing newly identified cancer-specific AS events, 
and found that many of these genes are known to play a key roles in different stages of tumor 
progression (Supplementary Table S3.1).  Most of these genes are functionally related to each 
other and form closely connected protein interaction networks (Figure 3.2C).  Based on the 
MCODE clustering algorithm [100], these genes can be clustered into three groups connected by 
several hub proteins (Figure 3.2C and Supplementary Table S3.2).  The largest group contains 
genes involved in cell cycle regulation (such as AURKB, CDCA5), with genes in the other two 
groups having functions in mediating cell adhesion/migration (e.g. CD44 and Collagens) and 
involved in the insulin signaling pathway (e.g. INSR, PPARG).  The functional clustering of 
genes with cancer-specific AS suggests that the regulation of AS in cancer plays important roles 
in key pathways related to cancer pathogenesis, including cell cycle and cell adhesion/migration.  
The association of insulin response pathway with splicing regulation in cancer has not been 
reported before, and its functional implication will be an interesting subject of future studies. 
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To further study the functional consequence of cancer-specific AS events in an unbiased 
fashion, we performed gene ontology (GO) analysis on genes containing cancer-specific AS 
events using the DAVID online tool (http://david.abcc.ncifcrf.gov/) [74, 101]. We found that the 
most enriched functional categories included cell adhesion, cell division, cell cycle and so on. 
(Figure 3.3A). We also did GO analysis on each individual cancer type and ranked enriched GO 
terms by their p-value (Supplementary Figure S3.2). The top enriched terms were cytoskeleton 
proteins and proteins associated with cell adhesion, ATP-binding, cell cycle.  
3.3.4 Sequence characteristics of cancer-specific AS events. 
 The skipped exon is the most common mode of AS among all identified cancer-specific 
AS events (Figure 3.1B), providing a sufficient amount of data for detailed sequence analyses. 
We first measured the length of all skipped exons, and found no obvious difference between the 
cancer-specific SEs, the SEs that are altered in a single cancer type, and all annotated SEs as 
control (Figure 3.3B).  We further examined if the lengths of these alternative exons can be 
divided by three, which is a good indication of how each AS event affects mRNA reading frame.  
We found that 42% of the alternative exons in control set of SEs are phase 0 exon (i.e. maintain 
their reading frame), while in the sets of SEs altered in single or multiple types of cancers, a 
notably increased fraction of exons maintain their reading frame (Figure 3.3C). In particular, 
53% of the SEs shared by all three cancers are phase 0 exons, significantly more than what is 
expected by chance (p=0.008 by fisher’s exact test).  Since disruption of reading frame often 
introduces premature stop codons that lead to NMD, the increased tendency of cancer-specific 
SEs to maintain reading frame suggests that these events tend to produce proteins with different 
functions rather than disrupting protein function via changing reading frame.  
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Alternative splicing is generally regulated by cis-acting SREs that function as splicing 
enhancers or silencers [18]. These SREs usually function in the nearby region of alternative 
splice sites, and thus the pre-mRNA regions within and adjacent to the alternative exons are 
more conserved than corresponding regions near the constitutive exons. When further examining 
the conservation of pre-mRNA regions near 124 cancer-specific SEs shared by three cancer 
types, we found that these exons tend to be highly conserved across 100 vertebrate species in the 
adjacent regions. Such sequence conservation is even higher than alternative exons that are 
spliced in a cancer-independent manner (Figure 3.3D, comparing black and grey lines), 
suggesting that cancer-specific alternative exons are under additional evolutionary constraints.  
This result is consistent with the notion that alternative splicing of cancer-associated genes are 
tightly controlled in normal cells across different species to mediate critical and highly conserved 
processes in cell growth.  
To further identify putative SREs that control cancer-specific SEs, we examined these 
highly conserved regulatory regions to measure whether there are enriched sequence motifs that 
could be potentially recognized by splicing factors (Supplementary Figure S3.3). Some of these 
motifs resemble the binding site of known splicing factor. For example, the AC-rich motifs are 
recognized by hnRNP L and the UG rich motifs resemble hnRNP H/F binding sites [21]. 
Consistently, the hnRNP H was shown to be up-regulated in certain cancer and control several 
cancer related splicing events [102, 103].  
3.3.5 Splicing of cancer-specific AS events are highly fluctuated.  
 The ratios between different splicing isoforms of the same gene are tightly regulated to 
ensure precise control of gene function.  In normal cells, splicing is usually controlled in a 
tissue-specific fashion with certain dominant isoforms in different tissues [10, 11]. However, 
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such dominance of certain tissue-specific isoforms is often absent in cancer cells. In another 
word, many splicing isoforms are found in the “wrong tissues”, leading to a more dispersed 
spectrum of AS. However such deregulation of AS in cancer has only been observed in an 
anecdotal fashion, and a thorough investigation with correct controls is lacking.  
To examine potential splicing deregulation in cancers, we directly test: (i) if the splicing 
of cancer-specific AS events have higher variability than control events, and (ii) if such 
variability is higher in cancer vs. normal samples. We calculated the standard deviation (SD) of 
PSI value for each AS event, which measures the amount of variation from the average. The SDs 
of cancer-specific AS events were compared to those of control AS events across both normal 
and tumor samples in each cancer type. Since the mean value of PSI dramatically affects its SD 
(Supplementary Figure S3.4, PSI values near 0 or 1 tend to have smaller SD), we randomly 
picked control AS events from the MISO database with PSI distribution matched to cancer-
specific AS events. The selection of such controls can eliminate potential biases caused by 
different PSI distribution between cancer-specific AS events vs. all other AS events.  
We found that all the cancer-associated AS events have higher PSI variation than controls 
in all three tissue types (Figure 3.3E, comparing 2 boxes at the right to the ones at left), 
suggesting that splicing of these events are indeed highly variable across different samples. In 
addition, when comparing the cancer-specific AS event in tumor sample with normal samples, 
those cancer-AS events still tend to have higher variability in tumors than in normal samples (p-
value: 1.2x10-17, 5.3x10-6 and 6.0x10-6 for BRCA, LIHC and LUSC respectively, Figure 3.3E). 
In each cancer type, we also plotted the distribution of PSI in histograms in supplementary figure 
S3.5 using both all AS events and the 163 cancer-specific events. This result is consistent with 
the popular hypothesis that the tissue specificity of AS in normal samples is disrupted in cancers, 
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probably due to extensive changes in the expression levels and/or activities of oncogenic splicing 
factors.  
3.3.6 Cancer-specific AS events as molecular biomarkers.  
 Identification of a core set of cancer-specific AS events makes it possible to use this 
relatively small dataset as a new molecular biomarker of cancers. To this end, we conducted 
principal component analysis (PCA) using the 163 cancer-specific AS events. For each tumor or 
normal sample, we generated a vector with 163 variables using the PSI values of cancer-specific 
AS events. We constructed a data matrix consist of all tumor and normal samples in each cancer 
type and further analyzed with PCA.  The first two principal components in PCA accounted for 
30%, 25% and 24% of the total variance for LIHC, LUSC and BRCA samples respectively 
(Supplementary Figure S3.6). The distribution of all samples was plotted using the first two 
principal components, which show a clear separation between cancer and normal samples 
(Figure 3.4A). All analyses showed a reliable separation of samples into two clusters (labeled 
with red and blue for tumor and normal samples respectively), suggesting that the 163 cancer-
specific AS can potentially serve as a reliable biomarker for cancer diagnosis.  
In addition, we combined all samples from three types of cancers and analyzed combined 
data with a similar PCA procedure. Consistent with our analyses of single cancer type, the cancer 
and normal samples can be reliably separated with the first two principal components (Figure 
3.4B, “C” for cancer and “N” for normal), indicating that cancer-specific AS events are useful 
molecular biomarkers to separate tumors from mixed samples.  In addition, the samples from 
different tissue types can be roughly separated (Figure 3.4B, with orange, green and black 
representing breast, lung and liver respectively). This result suggests that although the 163 AS 
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events are identified based on their altered splicing in multiple cancers, their splicing patterns 
still partially reflect tissue of origin.  
Breast cancer is a well-annotated cancer type in TCGA data and is classified into several 
subtypes based on histopathological criteria and expression of a core set of genes [104, 105].  
The breast cancer cells in different subtypes (Claudin-low, Basal-like, HER2-enriched, Luminial 
B and Luminal A) resemble cells in different stages of normal mammary development, which is 
well correlated with tumor progression (Figure 3.5A) [105]. Since our BRCA dataset has a large 
number of samples with well-annotated subtype categories, we sought to determine if the cancer-
specific AS events can be used to separate cancer subtypes. We conducted a similar PCA 
procedure using 818 breast samples that were independently classified into normal and four 
cancer subtypes by PAM50 [104]. By plotting all samples along the first two principal 
components, we found that different breast cancer subtypes tend to be clustered into different 
groups (Figure 3.5B). Certain subtypes of breast cancers, such as basal and luminal types, are 
particularly well separated. In addition, some normal samples that were misclassified as luminal 
A cancers by PAM50 were correctly distinguished using cancer-specific AS events, suggesting 
that the cancer-specific AS events can potentially serve as a cancer biomarker independent of 
current classification criteria using gene expression data. Although current separation by two 
PCA components is not very strong with some overlaps between subtypes, this analysis provided 
a proof-of-concept for splicing-based tumor classification. A more sophisticated statistical 
approach and analysis is needed to prove this. A representative example of cancer-specific AS 
events was selected to show that alteration of splicing patterns in the same gene could be 
different in distinct subtypes of breast cancer (Figure 3.5C), with the luminal A subtype having 
the largest variability between patients.  
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3.3.7 Ratio of different splicing variants can serve as predictor of cancer survival. 
 Until around 2000, the chance of survival for cancer patients was mainly predicted 
according to various histologic and clinical characteristics.  The advance of microarray 
technology led to more accurate profiling of gene expression in cancers, allowing prediction of 
cancer survival by the gene-expression signature of cancer [106, 107].  
The extensive splicing mis-regulation and frequent mutations of certain splicing factors 
in cancer have suggested that some AS events may directly affect tumor biogenesis and 
progression, however the consequence of splicing mis-regulation on patient survival remains 
unclear. The identification of cancer-specific AS events across a large number of patients makes 
it possible to test if splicing mis-regulation in certain genes can serve as a predictor of cancer 
prognosis.   
We directly test this possibility using TCGA dataset of breast cancer which has largest 
number of patients. We separated 727 BRCA patients according to the ratio of different splicing 
isoform for each cancer-specific AS event (i.e. patients with high vs. low PSI values), and 
examine if such classification is correlated with the overall survival of BRCA patients using 
Kaplan-Meier analysis. We found that five of cancer-specific AS events indeed can be used as 
predictor of tumor survival (log rank p<0.05), with two examples shown in figure 3.5D.  The 
first example, WBP1 (WW domain binding protein 1), is a binding partner of WWOX tumor 
suppressor that is frequently mutated in breast cancer [108]. We found that increased retention of 
intron 3 in WBP1 is associated with poor prognosis (Figure 3.5D). The second example, 
GPR116, is an adhesion G-protein-coupled receptor that promotes breast cancer metastasis 
[109]. The inclusion of an alternative exon at end of GPR116 will generate a non-canonical 
isoform (isoform 2) with a different C-terminal cytoplasmic domain that may change its ability 
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to interact with downstream signaling. We found that the increased production of isoform 2 is 
associated with poor prognosis. Taken together, our data show that, for the first time, the splicing 
ratio of some human genes in cancers is associated with cancer survival, suggesting the 
possibility to use gene splicing as a new molecular signature to predict cancer prognosis. 
3.3.8 Possible regulators of cancer-specific AS. 
 AS is generally controlled by various trans-acting splicing factors that specifically 
recognize cis-acting SREs in pre-mRNA. The level and activity of splicing factors usually vary 
in different cells, leading to the distinct AS patterns in corresponding cell types. Since splicing 
factors are often controlled by their co-expressed and functionally interacted proteins in different 
cellular signaling pathways [84], the splicing profile in certain cells may be significantly 
correlated with the expression of genes that play regulatory roles in AS. Therefore, given a large 
set of mRNA-seq data across different samples, a global analysis of correlations between AS 
patterns and expression of all genes may reveal regulatory relationships.  
To explore possible regulatory mechanisms of cancer-specific AS, we systematically 
calculated the correlation between the PSI value of the 163 cancer-specific AS events and the 
expression of all detectable genes (Figure 3.6A). We found that the set of cancer-specific AS 
events are indeed significantly correlated with expression of many genes, among which are 304 
genes highly correlated with more than 30 cancer-specific AS events. This set of genes are either 
positively or negatively correlated with the PSI values of many cancer-specific AS events, and 
thus may reflect potential regulatory pathways for the associated AS events.  
We further conducted GO analysis on genes significantly associated with cancer-specific 
AS events, and found that the vast majority of them function in multiple pathways related to cell 
cycle regulation (Figure 3.6B). However, the functional category of RNA-binding is not 
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significantly enriched in the set of genes associated with cancer-specific AS. We were a little 
surprised by the small number of correlated splicing factors. However, splicing factor activities 
can also be regulated in the level of protein modification, and indeed we found that the 
phosphorylation of several splicing factors is cell cycle dependent (Dominguez at al, unpublished 
data). This result suggests that the activity of splicing factors may be controlled in a cell cycle 
dependent manner (e.g., through protein phosphorylation), and thus cell cycle proteins can 
indirectly affect splicing in tumor cells.   
In addition, we analyzed protein-protein interaction among the genes correlated with 
cancer-specific AS using the STRING database. We found that 173 out of the 304 genes are 
highly connected with each other, and surprisingly the two largest clusters in the interaction 
network consist predominantly of genes that mediate the two major cell cycle checkpoints (i.e. 
checkpoint for G1-S and G2-M transition, Figure 3.6C). The genes in the largest cluster 
remarkably form a complete graph with 32 nodes, of which each connects with all others to 
function in kinetochore formation, cell division and mitosis (red cluster in Figure 3.6C). The 
second biggest group has 18 genes that are mostly involved in DNA replication. Even the smaller 
clusters have cell cycle related functions such as P53 signaling, M phase, DNA repair, and 
condensin complex. Such a high degree of correlation between cell cycle regulation and cancer-
specific splicing has not been previously reported but has profound implication in how AS is 
controlled in multiple cancers.   
3.3.9 Cancer-specific AS events common to 13 cancers 
After the completion of three cancer comparisons, we then expanded our study to a more 
sophisticated list of cancers which includes BLCA (Bladder Urothelial Carcinoma), BRCA 
(Breast invasive carcinoma), COAD (Colon adenocarcinoma), HNSC (Head and Neck squamous 
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cell carcinoma), KICH (Kidney Chromophobe), KIRC (Kidney renal clear cell carcinoma), 
KIRP (Kidney renal papillary cell carcinoma), LIHC (Liver hepatocellular carcinoma), LUAD 
(Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), PRAD (prostate 
adenocarcinoma), THCA (Thyroid carcinoma) and UCEC (Uterine Corpus Endometrial 
Carcinoma). Same analysis pipeline was used but with a more stringent read coverage criteria. 
We required every splicing event to have at least 20 reads coverage and at least 5 reads 
supporting one of the two isoforms, which allow us to eliminate some false-positive splicing 
events. The number of cancer-specific AS events in each individual cancer are shown in figure 
3.7A. Again, most of these events are specific to a single cancer type, with UCEC, COAD and 
LUSC having more altered AS events compare to the rest. We then compared every pair of 
cancers to see whether there are some cancers have similar AS profiles (Figure 3.7B). We found 
among all the cancer pairs, HNSC and LUSC have the highest similarity, which is consistent 
with the finding in [98] that these two types of cancer also have similar mutation profiles. 
Finally, we searched for AS events that were changed in multiple cancer types. Interestingly, 
there are 161 AS events altered among at least eight types of cancer (Figure 3.7C). The genes 
containing these events are enriched in regulation of cell motion, muscel cell differentiation, 
cytoskeleton and etc (Figure 3.7D). In addition, 23 out of the 161 AS events are altered among 
more than 10 types of cancer (Figure 3.7C): ASAP2, SLK, NUMB, ADD3, EXOC7, NIN, RPS24, 
GAB1, CCDC50, LRRFIP2, MYH11, TNC, MBNL1, TUBA1A, HERC2P3, PRICKLE4, PILRB, 
RBM6, CDK10, ATG16L2, MYO15B, TUBA1A and PPCS. Many of these genes are know to play 
an important role in some cancers. For example, a cancer-specific transcript of MYH11 in AML 
was reported in many studies [110, 111]. In addition, cancer-specific isoform of SLK, NUMB and 
ADD3 were also found in non-small cell lung cancer [112]. All these studies identified the 
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cancer-specific AS in one type of cancer. In our study, we used high-throughtput sequencing data 
to identify these AS event and confirm they are not only specific to one type of cancer, but also 
change among a lot of cancers.  
 
3.4 Discussion 
Here we performed a systematic identification and analysis of cancer-specific AS events 
using thousands of patient samples from TCGA data. To increase the statistical power of our 
analyses, we selected three types of cancers that have a relatively large number of paired normal 
controls. These tissue types are sufficiently different to enable us to filter out tissue-specific 
splicing, as most identified AS events are altered in only a single type of cancer (Figure 3.1B). 
The AS events significantly altered in all three cancer types include many genes whose splicing 
was known to play critical roles in cancer development, such as the CD44 [88], NUMB [113, 
114], and FN1 [115]. These genes probably represent a core set of cancer-specific AS events that 
affect key pathways in cancer progression. 
On the other hand, several AS events that have well-known roles in cancer development 
were not identified by our procedure, probably due to the high stringency used in our filters.  
For example, our set of cancer-specific AS does not include Bcl-x, whose splicing is known to 
control cell apoptosis in multiple tumors [89] and can be used as a potential therapeutic target 
[116, 117]. However the ΔPSI of Bcl-x is not large enough to pass the thresholds in our pipeline, 
and we expect that additional cancer-specific AS events can be identified when the criteria are 
relaxed. We also require the AS events to be detected in ~30% of normal liver samples (10 out of 
36, see table 1), which may cause some uncommon events to be omitted in our pipeline.  
 Although most cancer-specific AS events are involved in cellular pathways critical to cell 
growth and migration, they may not directly drive the initial stages of tumorigenesis, as we could 
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not detect obvious mutations near the splice sites of these alternatively spliced exons.  Instead 
we speculate that they are more likely to be a result of mis-regulated splicing factors that 
potentially change splicing of many pre-mRNA targets.  Consistently, several splicing factors 
were found to be mutated or significantly changed in expression between cancers and normal 
tissue, including SRSF1, QK1, RBM4, RBM5/6/10, and hnRNP A2 [46, 47, 49, 113, 114].  
These results imply that cancer-specific AS events will be more useful as cancer biomarkers, 
whereas the splicing factors may better serve as potential therapeutic targets to restore mis-
regulated splicing in cancer.  
 To study potential regulatory mechanisms for the cancer-specific AS events, we used an 
association study to identify genes whose expression is correlated with these events across 
thousands of tumor and normal samples. This large dataset size enables a statistically reliable 
identification of genes that directly or indirectly regulate AS. Such analyses only identified a 
small number of putative splicing factors including hnRNP L and snRPA1 (Figure 3.6C, marked 
at the bottom). We speculate that this is due to the large heterogeneity among tumor samples, as 
the known cancer-related splicing factors are found to be altered in only a subset of tumor 
samples.  Remarkably, the majority of genes whose expression is associated with cancer-
specific AS events are those involved in cell cycle regulation, revealing an unknown link 
between cell cycle and splicing regulation. An unbiased clustering of these associated genes 
recapitulated two major cell cycle checkpoints (i.e., G1 to S and G2 to M transition) and several 
main control pathways for cell cycle progression (e.g., DNA repair and P53 signaling).  
Although the reason of such high correlation is not clear, there are several interesting 
implications and predictions. For example, this result may suggest that genes controlling cell 
cycle progression also play a central regulatory role in pre-mRNA splicing and processing.  
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Since cancer cells undergo fast growth and division compared to normal cells, there may be an 
increasing pressure for cancer cells to transcribe and splice certain genes at a high rate in some 
cell cycle stages. Because most introns are spliced co-transcriptionally, the increased 
transcription rate may directly affect AS of a certain set of genes in cancer. There may also be 
epigenetic factors that bridge the regulation of cell cycle with alternative splicing. A careful 
examination of this link requires integration of the changes in various epigenetic markers and 
transcription factors with splicing alteration, which will be an important direction for future 
investigation. Another interesting implication is that AS may be temporally regulated during the 
cell cycle. Although periodic gene transcription during cell cycle is well documented [118], there 
are limited reports on temporal regulation of splicing at different cell cycle stages. Our result 
implies that such a regulation mode is likely to exist and may even be a major mechanism 
responsible for cancer-specific AS.  
 In summary, this study generated a common set of cancer-specific AS events across 
different cancer types, which can be used as novel cancer biomarkers. We provided a detailed 
picture of unique features for these AS events and mechanistic insights on how splicing is mis-
regulated in cancer.  Because dysregulation of splicing in cancer can often serve as a cancer 
progression indicator, the identification of a core set of cancer-specific AS events will likely help 
early cancer detection and thus improve the chance of cure. Finally, this relative small set of AS 
events will facilitate direct discovery of key regulators that are responsible for splicing 
dysregulation in cancers and thus can potentially be used as new therapeutic targets. 
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3.5 Materials and Methods 
 
3.5.1 Data acquisition and sequence processing. 
 Pair-ended RNA-seq data were acquired from the TCGA consortium, with all reads being 
pair-ended (length: 50, 48, and 48 for breast, lung, and liver cancer respectively). Each sample 
has an average of >150 million reads. The reads were aligned to the human genome version hg19 
with MapSplice V2.0 [119], and the gene expression values were estimated using the RSEM 
pipeline [120] and normalized to the upper quartile of all expressed genes [121].   
To analyze AS events on a genomic scale, we used the MISO event-centric pipeline [122] 
with the hg19 v2.0 annotation to calculate the inclusion ratio of all annotated AS isoforms 
(http://genes.mit.edu/burgelab/miso/annotations/ver2/miso_annotations_hg19_v2.zip). Further 
analyses were carried out for four major modes of AS: skipped exon (SE), retained intron (RI), 
alternative 3’ splice site (A3SS) and alternative 5’ splice site (A5SS). Based on the coverage of 
different splicing isoforms, each AS event was assigned with a PSI (Percent Spliced In) value 
ranging from 0 to 1. To qualify as a valid AS events, we require that both isoforms are detectable 
in at least 10 normal samples and 10 tumor samples for each cancer type. 
3.5.2 Determination of AS events shared between cancer types. 
 To examine the statistical significance for the number of AS events that are in common 
between different cancers, 1000 simulated datasets were generated by randomly selecting a 
control set of AS events with matched size in each cancer type (number of AS events for lung, 
liver and breast cancer respectively: SE: 3111, 1308, 1804; RI: 378, 109, 201; A3SS: 614, 317, 
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331; A5SS: 533, 244, 290). We then computed the number of events that were common across 
multiple cancer types. In each AS mode (SE, RI, A3SS and A5SS), we generated 1000 simulated 
datasets and calculate the mean overlaps between different cancers, which were then compared 
to the overlaps of real data using rank test. 
3.5.3 Analyses of protein-protein-interaction among cancer-specific AS events. 
The genes containing cancer-specific AS events (or genes whose expression is associated 
with cancer-specific AS events) were obtained and submitted to the STRING database [123, 124] 
(http://string-db.org/) for protein-protein interactions (PPI) analysis. We used the combined score 
of 0.4 as a cutoff and included five white nodes for network continuity. We used Cytoscape 
[125] to visualize the PPI network and the MCODE algorithm [100] to identify highly connected 
clusters within the network. See supplementary Table S3.2 and S3.3 for detailed parameters. 
3.5.4 Calculation of evolutionary score.  
Sequence evolutionary score was downloaded from UCSC phastCons100 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/phastCons100way/) [126]. Based on multiple 
sequence alignments of 100 vertebrate species, each nucleotide was given an evolutionary 
conservation score ranging from 0 to 1. Highly conserved regions are assigned with a higher 
score. PhastCons estimates the probability that each nucleotide belongs to a conserved element 
based on multiple alignments using a hidden Markov model. For each SE event, we extracted 
sequences from different regions near the alternative exon to calculate average conservation 
score in a sliding window of 8 nt across all cancer-specific SE events and control events. 
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3.5.5 Motif enrichment analysis. 
To analyze the enriched sequence motifs near the splice sites of the 163 cancer-specific 
AS events, we first obtained nucleotide sequences from three splicing regulatory regions: 
upstream intron (300 nt), exon and downstream intron (300 nt) as shown in Figure S3.3. When 
obtaining the sequences, we excluded the first 25 nucleotides right upstream of the skipped exon, 
the first 10 nucleotides right downstream of the skipped exon and the first and the last two 
nucleotides within the exon. We then calculated the frequency and Z-score of all 5-nt “words” 
near the alternative exons of the 163 sequences in three regulatory regions using methods 
described in [127]. All 5-mers with Z-score larger than 2.5 were then clustered by sequence 
similarity and multiply aligned by using CLUSTALW to identify candidate motifs. At a cutoff 
dissimilarity score of 2.65, 2.7 and 2.7, we obtained 5, 7 and 5 clusters of at least four sequences 
in each cluster for upstream intron, exon and downstream intron respectively. Finally, we plotted 
the consensus sequence for each cluster for all three regulatory regions (Figure S 3.3). 
3.5.6 Principal Component analysis (PCA). 
PCA is a data analysis technique commonly applied for dimension reduction, exploratory 
analysis and feature selection. PSI values of the 163 cancer-specific AS events were used to form 
the data vector for PCA. For each cancer type, the PSI vectors across all normal and tumor 
samples were then combined and used as the input data matrix to perform PCA using the 
prcomp() function in R. We also conducted PCA by combining the PSI values across all samples 
from three cancer types. The distributions of normal and cancer samples across the first two 
components were plotted. 
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3.5.7 Survival analysis for breast cancer patients. 
We obtained the overall survival data of breast cancer patients from the UCSC Cancer 
Browser (727 patients). If a patient deceased (event happened), the “days_to_death” was used as 
the time variable; if a patient is still living, the time variable is the maximum of 
“days_to_last_known_alive” and “days_to_last_followup”. The patient samples were split into 
two groups according to the top or bottom quartile of PSI values for each of the 163 cancer-
specific events. The resulted two patient groups are compared for their probability of survival 
using a Kaplan-Meier survival plot and the log rank P values are calculated. This process was 
repeated for every cancer-specific event.  
3.5.8 Correlation between gene expression and AS.  
Correlations between genes and AS events were calculated using two matrices. The first 
matrix consists of the PSI values of 163 cancer-specific AS events across 1319 cancer and 
normal samples. Another matrix contains the expression level of every gene across 1319 
samples. We computed the spearman rank correlation, ρ (rho), between every two vectors from 
the two matrices using cor.test() in R. Each pair with |ρ| >=0.4 and p<=0.005 was considered as a 
highly correlated event-gene pair. We considered genes that are highly correlated with more than 
30 cancer-specific AS events as potential regulators through a direct or indirect regulation. We 
then used STRING database [123, 124] (http://string-db.org/) to extract PPIs between these 
potential regulators (304 genes), and Cytoscape and MCODE to visualize and cluster the 
interaction networks. 
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Table 3.1 Summary of cancer dataset 
Tumor Type No. of 
normal 
samples 
No. of 
tumor 
samples 
Total 
mapped 
Reads  
No. of AS 
events 
detected  
No. of AS events 
changed in cancer 
vs. normal 
BRCA 
(breast cancer) 
91 727 1.3E+11 
 
65,152 2,626 
LIHC 
(liver cancer) 
36 74 1.6E+10 
 
70,342 1,978 
LUSC 
(lung cancer) 
43 348 6.4E+10 70,637 4,636 
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Figure 3.1 Identification of AS events altered in cancers.  
(A) Analysis pipeline to identify AS events that are differentially spliced in cancer vs. normal 
tissues.  (B) Venn diagram of differentially spliced AS events that are specific to one or 
multiple types of cancers in four different AS modes (SE, RI, A3SS and A5SS). (C) Numbers of 
AS events overlapped in the simulated dataset (white boxes) and the real dataset (gray boxes). 
We randomly selected the matched number of AS events from all the detectable AS events for 
each cancer and then calculated the overlaps. This procedure was repeated 1000 times, and the 
mean and range of numbers of overlapped events are shown. 
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Figure 3.2 Examples of cancer-specific AS events.  
(A) Changes of splicing across different cancer types.  For all cancer-specific AS events, the 
differences of mean PSI values between cancer and normal samples were calculated. We plotted 
the percent of AS events with PSI changed in same direction among all cancers (purple) or in 
different directions for one specific type of cancer (BRCA, LUSC or LIHC). (B) Change of 
splicing in selected examples of cancer-specific AS events. The PSI values of paired samples are 
marked on the left (normal) and right (tumor) panel in each ladder plot with a colored line 
linking two PSI values. Blue lines represent AS events with increased PSIs in tumor, whereas red 
lines represent events with decreased PSIs and grey lines represent events with negligible change 
of PSI (<=0.05).  Box plots in the bottom are comparisons between all normal samples (white 
boxes) and all tumor samples (grey boxes). (C) PPI networks of genes containing cancer-specific 
AS events. The networks have 3 highly connected clusters defined by MCODE (color coded in 
pink, yellow and green). The hub proteins interacting with multiple clusters were coded with 
multiple colors. Three genes that are also frequently mutated in tumors were marked by red 
circles. The most enriched function/GO-term was labeled next to each cluster. 
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Figure 3.3 Molecular features of AS events changed in cancers.  
(A) The genes containing 163 cancer-specific AS events were analyzed by gene ontology, and 
the significantly enriched (p<0.005) GO terms are plotted. (B) Box plots of the length of 
alterative exons in the SE events from the MISO database, the SE events that were changed in 
LIHC, LUSC, BRCA, and the SE events altered in all cancers (from the left to the right). 
Asterisks indicate significant increase of phase 0 exon (P<0.05 by Fisher's exact test). (C) 
Percent of skipped exons in each exon phase. Exons are classified into phase 0, 1, and 2 
depending on the reminders when dividing their length by 3. Phase 0 (white boxes): events 
without frame-shift; Phase1 and 2 (black and gray boxes): events with frame-shift. The order is 
same as (B). (D) Sequence conservation near the cancer-specific skipped exons and all skipped 
exons. Black line represents average conservation score from the 124 cancer-specific SE events; 
grey line represents average conservation score from all the SE events in MISO database 
(control). (E) We compared the distribution of PSI standard deviation between control AS (left) 
and AS events that change in each cancer (right). We also compared those between normal 
(white box) and tumor samples (grey box). 
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Figure 3.4 PCA analysis using cancer-specific AS events.  
(A) PCA analysis of the 110 liver tissue samples (LIHC: 36 normal and 74 tumor), 391 lung 
tissue samples (LUSC: 43 normal and 348 tumor) and 818 breast tissue (BRCA: 91 normal and 
727 tumor) using the 163 cancer-specific AS events. Tumor samples are in red circles and 
normal samples are in blue circles. (B) PCA analysis of samples from all three tissues using the 
163 cancer-specific AS events. Samples were color-coded as its origin tissue. The cancer 
samples are labeled as “C” and the normal samples are labeled as “N”.
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Figure 3.5 Using cancer-specific AS events to separate breast cancer subtypes.  
(A) An overview of four different breast cancer subtypes in tumor developments. (B) PCA 
analysis of the 818 breast tissue using the 163 cancer-specific AS events. Different BRCA 
samples were labeled according to each subtype as classified by PAM50. (C) An example SE 
event where the different BRCA subtypes have different splicing patterns. The ladder plots were 
generated as described in figure 3.2B. (D) Two examples of cancer-specific AS events whose 
PSI value can be used to predict survival of breast cancer patients. 
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Figure 3.6 Genes associated with cancer-specific AS events.  
(A) Flow chart of identifying possible regulators of cancer-specific AS. (B) Gene ontology 
analysis of the 304 genes that are highly correlated with the 163 tumor AS events. (Spearman 
rank correlation >=0.4 across 1319 samples, p-value<0.005, and correlated with more than 30 
out of the 163 tumor AS).  (C) PPI networks of genes that are highly correlated with the 163 
cancer-specific AS events. Color-coded proteins are clustered by MCODE. Light purple-colored 
nodes were proteins that were not clustered into any group by MCODE. The most enriched 
function/GO-term was labeled next to each cluster. The genes involved in RNA binding and 
splicing regulation are also indicated at the bottom.  
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Figure 3.7 Cancer-specific AS events among 13 cancer types.  
(A) Cancer-specific AS events in each individual cancer type and in each splicing mode (as color 
specified). (B) Heatmap of similarity between every paired cancer. The similarity was measured 
as the percentage of AS events altered in both cancers (normalized to the leftmost cancer type in 
each row). (C) Number of AS events altered among at least 10, 9 and 8 types of cancer. (D) Gene 
ontology analysis of the genes contacting cancer-specific AS events that are altered among at 
least eight types of cancer (161 AS events). 
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3.6 Supplementary Material 
 
Figure S 3.1 The percentage of genes change in both expression level and splicing and the 
splicing isoform change in four AS modes.  
(A) For the genes containing cancer-specific AS (white circle) in each cancer type, a small 
fraction also showed significant changes in expression level between tumor and normal samples 
(grey circle). We used the following threshold for expression changes: the expression levels of 
each gene have to change by at least two fold between cancers vs normal with p-value <= 0.005. 
(B) The change of PSI values between paired tumor and normal samples were plotted in each 
cancer type and in all three cancers separately. ΔPSI was calculated as the PSI value in cancer 
sample minus the PSI value in paired normal control. Each dot represents a paired of cancer and 
normal sample.   
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Figure S 3.2 Gene ontology analysis of AS events altered in three cancer types: BRCA (A), 
LIHC (b) and LUSC (C).  
We obtained the list of genes containing AS events that change significantly in their PSI values 
between tumor and normal samples in breast, liver and lung cancer datasets, and listed the highly 
enriched GO terms with p-value less than 0.005 using DAVID gene ontology tool. The x-axis is 
the –log (P) of the enriched GO term.  
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Figure S 3.3 Enriched motifs near cancer-specific skipped exons.   
The pentamers significantly enriched in each pre-mRNA region were identified and clustered 
into different groups according sequence similarity. The consensus motif in each group was 
represented with pictogram. Upstream intron: 300 nucleotides upstream of the skipped exon. The 
enriched Exon region: the whole exon sequences were used except the first and the last two 
nucleotides. Downstream intron: 300 nucleotides downstream of the skipped exon. The regions 
overlapping with splice sites (the first 10 nt and the last 25 nt of intorns) were excluded to avoid 
strong splicing signals. 
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Figure S 3.4 Scatter plots of the standard deviation of PSI vs. mean of PSI.   
For each AS event, the PSI values and the standard deviation of PSI were plotted among all 
samples in breast, liver and lung cancer datasets.  The distribution of all AS events (left) were 
compared to the AS events that significantly change between tumor and normal (right), and the 
control set was selected from all AS events with matched distribution of PSI values. 
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 Cancer-specific events in BRCA Cancer-specific events in LIHC Cancer-specific events in LUSC 
 
Figure S 3.5. Histograms of the standard deviation of PSI for all AS events (top) or for 163 
cancer-specific AS events (bottom).  
The normal and tumor samples (in BRCA, LIHC and LUSC cancer) are plotted in different 
colors, and we found that for both types of AS events, the SD of PSI is larger (right-skewed) in 
tumor samples, suggesting that splicing in tumors are more dispersed. See also Fig 3E.  
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Figure S 3.6. The proportion of variance explained by the first ten principal components.  
Variances of the first 10 PCA compoents are shown in black boxes and the cumulative 
proportions of them are shown in red lines. 
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Table S 3.1 162 Cancer-specific AS events and their average PSI values in three types of 
normal and tumor samples 
 
	   Mean	  of	  PSI	   	   	  
SE	   BRCA	  
normal	  
BRCA	  
tumor	  
LUSC	  
normal	  
LUSC	  
tumor	  
LIHC	  
normal	  
LIHC	  
tumor	   ENSG	  ID	  
Gene	  
Name	  
chr10:34663802:34663930:-­‐
@chr10:34661426:34661464:-­‐
@chr10:34648999:34649187:-­‐	   0.56	   0.43	   0.59	   0.42	   0.63	   0.49	  
ENSG00000148498	  
PARD3	  
chr17:76210761:76210870:+@chr17:76218909:7
6219073:+@chr17:76219546:76221716:+	   0.21	   0.03	   0.16	   0.02	   0.30	   0.06	   ENSG00000089685	  
BIRC5	  
chr8:82630417:82630459:-­‐
@chr8:82629484:82629523:-­‐
@chr8:82627222:82627349:-­‐	   0.75	   0.62	   0.76	   0.59	   0.46	   0.57	  
ENSG00000104231	  
ZFAND1	  
chr6:45881965:45882146:-­‐
@chr6:45881515:45881549:-­‐
@chr6:45866190:45870992:-­‐	   0.07	   0.25	   0.02	   0.24	   0.45	   0.35	  
ENSG00000112782	  
CLIC5	  
chr17:5329291:5329402:+@chr17:5329556:5329
619:+@chr17:5335862:5336340:+	   0.63	   0.49	   0.72	   0.52	   0.68	   0.52	   ENSG00000129197	  
RPAIN	  
chr8:26721604:26722922:-­‐
@chr8:26627798:26628183:-­‐
@chr8:26613913:26614296:-­‐	   0.79	   0.59	   0.80	   0.61	   0.95	   0.76	  
ENSG00000120907	  
ADRA1A	  
chr6:39877579:39877699:-­‐
@chr6:39876816:39876878:-­‐
@chr6:39872034:39874893:-­‐	   0.80	   0.67	   0.82	   0.72	   0.84	   0.71	  
ENSG00000124615	  
MOCS1	  
chr15:60688350:60688626:-­‐
@chr15:60685237:60685639:-­‐
@chr15:60678227:60678285:-­‐	   0.45	   0.29	   0.34	   0.18	   0.37	   0.23	  
ENSG00000182718	  
ANXA2	  
chr9:131036129:131036251:-­‐
@chr9:131035064:131035144:-­‐
@chr9:131030699:131030803:-­‐	   0.67	   0.36	   0.72	   0.49	   0.65	   0.51	  
ENSG00000167110	  
GOLGA2	  
chr11:64850836:64850871:-­‐
@chr11:64846825:64847259:-­‐
@chr11:64835960:64836073:-­‐	   0.63	   0.83	   0.65	   0.88	   0.54	   0.74	  
ENSG00000146670	  
CDCA5	  
chr5:126112853:126112944:+@chr5:126113053:
126113559:+@chr5:126140468:126140624:+	   0.63	   0.78	   0.72	   0.84	   0.68	   0.78	   ENSG00000113368	  
LMNB1	  
chr11:65307716:65307853:-­‐
@chr11:65307484:65307624:-­‐
@chr11:65307191:65307352:-­‐	   0.40	   0.28	   0.43	   0.24	   0.50	   0.35	  
ENSG00000168056	  
LTBP3	  
chr6:131199244:131199390:-­‐
@chr6:131193511:131193678:-­‐
@chr6:131191468:131191521:-­‐	   0.06	   0.23	   0.09	   0.28	   0.41	   0.30	  
ENSG00000079819	  
EPB41L2	  
chr18:3131373:3131494:-­‐
@chr18:3129230:3129517:-­‐
@chr18:3126699:3126895:-­‐	   0.08	   0.20	   0.11	   0.58	   0.20	   0.42	  
ENSG00000101605	  
MYOM1	  
chr3:58817412:58817615:-­‐
@chr3:58792121:58792182:-­‐
@chr3:58739496:58739590:-­‐	   0.49	   0.63	   0.55	   0.73	   0.51	   0.65	  
ENSG00000163689	  
C3orf67	  
chr4:38869354:38869455:+@chr4:38870019:388
70167:+@chr4:38879692:38880047:+	   0.22	   0.33	   0.22	   0.35	   0.23	   0.36	   ENSG00000197712	  
FAM114A
1	  
chr11:85339622:85339732:+@chr11:85342189:8
5342360:+@chr11:85342731:85342852:+	   0.64	   0.40	   0.69	   0.56	   0.69	   0.59	   ENSG00000171204	  
TMEM126
B	  
chr6:46823711:46823795:-­‐
@chr6:46822452:46822518:-­‐
@chr6:46820242:46821808:-­‐	   0.23	   0.36	   0.07	   0.26	   0.08	   0.32	  
ENSG00000069122	  
GPR116	  
chr3:194134488:194134568:-­‐
@chr3:194132928:194133017:-­‐
@chr3:194123403:194126845:-­‐	   0.79	   0.60	   0.82	   0.67	   0.68	   0.57	  
ENSG00000133657	  
ATP13A3	  
chr10:111890121:111890244:+@chr10:1118920
63:111892158:+@chr10:111893084:111895323:
+	   0.30	   0.41	   0.28	   0.60	   0.16	   0.26	  
ENSG00000148700	  
ADD3	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chr14:100842597:100842680:-­‐
@chr14:100841620:100841740:-­‐
@chr14:100835424:100835595:-­‐	   0.42	   0.28	   0.62	   0.42	   0.67	   0.40	  
ENSG00000140105	  
WARS	  
chr3:98241386:98241910:-­‐
@chr3:98240497:98240562:-­‐
@chr3:98239977:98240286:-­‐	   0.10	   0.25	   0.10	   0.28	   0.36	   0.48	  
ENSG00000080822,
ENSG00000080819	  
CLDND1	  
chr9:21994820:21995300:-­‐
@chr9:21993881:21994052:-­‐
@chr9:21970901:21971207:-­‐	   0.40	   0.29	   0.35	   0.20	   0.43	   0.23	  
ENSG00000147889	  
CDKN2A	  
chr17:74090495:74090662:-­‐
@chr17:74086410:74086478:-­‐
@chr17:74085256:74085401:-­‐	   0.20	   0.45	   0.20	   0.31	   0.44	   0.29	  
ENSG00000182473	  
EXOC7	  
chr19:1358393:1358463:+@chr19:1358587:1358
699:+@chr19:1360135:1361031:+	   0.07	   0.22	   0.10	   0.26	   0.13	   0.23	   ENSG00000160953	  
MUM1	  
chr20:37076109:37076266:+@chr20:37076573:3
7076736:+@chr20:37077305:37077373:+	   0.36	   0.24	   0.38	   0.16	   0.33	   0.15	   ENSG00000174365	  
SNHG11	  
chr8:26721604:26722922:-­‐
@chr8:26716549:26716722:-­‐
@chr8:26605667:26606265:-­‐	   0.28	   0.46	   0.25	   0.46	   0.06	   0.29	  
ENSG00000120907	  
ADRA1A	  
chr10:79796952:79797062:+@chr10:79799959:7
9799983:+@chr10:79800373:79800473:+	   0.94	   0.75	   0.85	   0.55	   0.72	   0.51	   ENSG00000138326	  
RPS24	  
chr10:103902802:103902855:+@chr10:1039040
07:103904064:+@chr10:103908129:103908278:
+	   0.70	   0.56	   0.73	   0.55	   0.65	   0.53	  
ENSG00000148840	  
PPRC1	  
chr7:103123320:103123418:-­‐
@chr7:103113449:103113453:-­‐
@chr7:103112231:103113355:-­‐	   0.15	   0.33	   0.24	   0.39	   0.05	   0.16	  
ENSG00000189056	  
RELN	  
chr1:160109683:160109774:+@chr1:160110441:
160110564:+@chr1:160111084:160113374:+	   0.03	   0.22	   0.08	   0.32	   0.36	   0.25	   ENSG00000018625	  
ATP1A2	  
chr1:155170491:155170617:+@chr1:155172914:
155173062:+@chr1:155174826:155175286:+	   0.13	   0.28	   0.37	   0.25	   0.40	   0.28	   ENSG00000231064	  
RP11-­‐
263K19.4	  
chr2:3605976:3606588:+@chr2:3607038:360731
9:+@chr2:3608907:3609340:+	   0.38	   0.50	   0.40	   0.54	   0.20	   0.40	   ENSG00000234171	  
RNASEH1-­‐
AS1	  
chr14:73749067:73749213:-­‐
@chr14:73745989:73746132:-­‐
@chr14:73741918:73744001:-­‐	   0.19	   0.48	   0.07	   0.35	   0.16	   0.32	  
ENSG00000133961	  
NUMB	  
chr10:79796952:79797062:+@chr10:79799962:7
9799982:+@chr10:79800373:79800473:+	   0.82	   0.43	   0.63	   0.30	   0.53	   0.27	   ENSG00000138326	  
RPS24	  
chr3:24338717:24338862:-­‐
@chr3:24270429:24270492:-­‐
@chr3:24231565:24231825:-­‐	   0.87	   0.72	   0.70	   0.59	   0.63	   0.74	  
ENSG00000151090	  
THRB	  
chr16:46727005:46727094:+@chr16:46729474:4
6729586:+@chr16:46729929:46729997:+	   0.66	   0.82	   0.66	   0.88	   0.62	   0.73	   ENSG00000091651	  
ORC6	  
chr7:129710349:129710649:+@chr7:129736761:
129736847:+@chr7:129756285:129756506:+	   0.53	   0.64	   0.45	   0.59	   0.53	   0.63	   ENSG00000128607	  
KLHDC10	  
chr15:91512754:91512853:-­‐
@chr15:91512309:91512350:-­‐
@chr15:91509268:91510432:-­‐	   0.22	   0.10	   0.25	   0.12	   0.39	   0.21	  
ENSG00000198901	  
PRC1	  
chr3:98241386:98241910:-­‐
@chr3:98240497:98240540:-­‐
@chr3:98239977:98240286:-­‐	   0.14	   0.30	   0.13	   0.32	   0.39	   0.52	  
ENSG00000080822,
ENSG00000080819	  
CLDND1	  
chr17:79865430:79865474:-­‐
@chr17:79865080:79865133:-­‐
@chr17:79864636:79864774:-­‐	   0.42	   0.52	   0.50	   0.62	   0.53	   0.39	  
ENSG00000185813	  
PCYT2	  
chr2:216238045:216238134:-­‐
@chr2:216236832:216237023:-­‐
@chr2:216236632:216236738:-­‐	   0.69	   0.80	   0.70	   0.90	   0.72	   0.87	  
ENSG00000115414	  
FN1	  
chr2:175351601:175351816:-­‐
@chr2:175347738:175347886:-­‐
@chr2:175346225:175346715:-­‐	   0.30	   0.48	   0.44	   0.56	   0.44	   0.58	  
ENSG00000163328	  
GPR155	  
chr2:238303230:238303847:-­‐
@chr2:238296225:238296827:-­‐
@chr2:238289558:238290142:-­‐	   0.23	   0.60	   0.79	   0.63	   0.48	   0.32	  
ENSG00000163359	  
COL6A3	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chr13:76378425:76378677:+@chr13:76383290:7
6383319:+@chr13:76391297:76391414:+	   0.58	   0.48	   0.86	   0.59	   0.69	   0.54	   ENSG00000136153	  
LMO7	  
chr3:37136283:37136399:-­‐
@chr3:37132958:37133029:-­‐
@chr3:37125127:37125297:-­‐	   0.69	   0.30	   0.80	   0.64	   0.77	   0.56	  
ENSG00000093167	  
LRRFIP2	  
chr12:123694603:123694709:-­‐
@chr12:123687797:123687922:-­‐
@chr12:123687171:123687631:-­‐	   0.34	   0.50	   0.39	   0.57	   0.40	   0.54	  
ENSG00000051825	  
MPHOSPH
9	  
chr7:30618847:30618930:-­‐
@chr7:30618622:30618744:-­‐
@chr7:30617111:30617707:-­‐	   0.58	   0.30	   0.50	   0.27	   0.34	   0.23	  
ENSG00000196295	  
AC005154
.6	  
chr1:171196790:171196927:-­‐
@chr1:171173030:171173127:-­‐
@chr1:171168386:171168654:-­‐	   0.97	   0.77	   0.99	   0.83	   0.67	   0.53	  
ENSG00000225243,
ENSG00000231424	  
RP1-­‐
127D3.4	  
chr7:30793347:30793554:+@chr7:30805961:308
06177:+@chr7:30818048:30818167:+	   0.13	   0.31	   0.02	   0.27	   0.16	   0.34	   ENSG00000254959	  
INMT-­‐
FAM188B	  
chr11:35211382:35211519:+@chr11:35232793:3
5232996:+@chr11:35236399:35236461:+	   0.67	   0.80	   0.48	   0.83	   0.31	   0.42	   ENSG00000026508	  
CD44	  
chr5:122181160:122181388:+@chr5:122226722:
122226820:+@chr5:122272429:122272512:+	   0.32	   0.20	   0.22	   0.33	   0.40	   0.28	   ENSG00000064652	  
SNX24	  
chr9:139304780:139305054:-­‐
@chr9:139304542:139304691:-­‐
@chr9:139302278:139302390:-­‐	   0.44	   0.55	   0.46	   0.58	   0.41	   0.51	  
ENSG00000165689	  
SDCCAG3	  
chr3:180630234:180630524:+@chr3:180632440:
180632783:+@chr3:180651122:180651174:+	   0.46	   0.28	   0.47	   0.37	   0.49	   0.35	   ENSG00000114416	  
FXR1	  
chr17:65870933:65871136:+@chr17:65871672:6
5871860:+@chr17:65882244:65882432:+	   0.73	   0.36	   0.73	   0.40	   0.65	   0.44	   ENSG00000171634	  
BPTF	  
chr11:120195838:120196077:+@chr11:1201978
31:120198349:+@chr11:120200686:120204388:
+	   0.63	   0.76	   0.64	   0.85	   0.59	   0.75	  
ENSG00000181264	  
TMEM136	  
chr15:41624113:41624179:-­‐
@chr15:41611856:41611978:-­‐
@chr15:41605471:41605552:-­‐	   0.64	   0.81	   0.64	   0.85	   0.59	   0.77	  
ENSG00000104147	  
OIP5	  
chr16:69166387:69166493:-­‐
@chr16:69154956:69155073:-­‐
@chr16:69151912:69154552:-­‐	   0.69	   0.56	   0.75	   0.63	   0.58	   0.48	  
ENSG00000168802	  
CHTF8	  
chr16:69155339:69155396:-­‐
@chr16:69154956:69155073:-­‐
@chr16:69151912:69154552:-­‐	   0.66	   0.54	   0.69	   0.58	   0.57	   0.46	  
ENSG00000168802	  
CHTF8	  
chr8:145738025:145738154:-­‐
@chr8:145737775:145737944:-­‐
@chr8:145737527:145737707:-­‐	   0.82	   0.92	   0.82	   0.94	   0.76	   0.89	  
ENSG00000160957	  
RECQL4	  
chr14:100842597:100842680:-­‐
@chr14:100841620:100841687:-­‐
@chr14:100835424:100835595:-­‐	   0.49	   0.34	   0.69	   0.48	   0.71	   0.45	  
ENSG00000140105	  
WARS	  
chr20:44442076:44442103:+@chr20:44443023:4
4443109:+@chr20:44444180:44444384:+	   0.82	   0.96	   0.82	   0.98	   0.69	   0.92	   ENSG00000175063	  
UBE2C	  
chr3:160166514:160166583:-­‐
@chr3:160165520:160165630:-­‐
@chr3:160153291:160156974:-­‐	   0.19	   0.05	   0.21	   0.05	   0.41	   0.29	  
ENSG00000213186,
ENSG00000248710	  
TRIM59	  
chr8:26721604:26722922:-­‐
@chr8:26716549:26716722:-­‐
@chr8:26613913:26614296:-­‐	   0.26	   0.45	   0.21	   0.43	   0.05	   0.26	  
ENSG00000120907	  
ADRA1A	  
chr1:78963559:78963629:+@chr1:78997898:789
98038:+@chr1:79002091:79006386:+	   0.15	   0.31	   0.22	   0.36	   0.39	   0.21	   ENSG00000122420	  
PTGFR	  
chr3:152163071:152163328:+@chr3:152164493:
152164546:+@chr3:152165409:152165562:+	   0.20	   0.44	   0.13	   0.46	   0.19	   0.39	   ENSG00000152601	  
MBNL1	  
chr19:7152737:7152938:-­‐
@chr19:7150508:7150543:-­‐
@chr19:7142827:7143101:-­‐	   0.63	   0.30	   0.53	   0.38	   0.77	   0.61	  
ENSG00000171105	  
INSR	  
chr6:168311964:168312169:+@chr6:168314083:
168314103:+@chr6:168314848:168314993:+	   0.43	   0.23	   0.66	   0.53	   0.42	   0.22	   ENSG00000130396	  
MLLT4	  
chr15:101827113:101827215:-­‐
@chr15:101826419:101826498:-­‐ 0.60	   0.83	   0.74	   0.89	   0.66	   0.78	   ENSG00000131876	  
SNRPA1	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@chr15:101825931:101826006:-­‐	  
chr12:53677842:53677951:+@chr12:53679708:5
3680696:+@chr12:53681756:53682125:+	   0.73	   0.86	   0.70	   0.83	   0.51	   0.71	   ENSG00000135476	  
ESPL1	  
chr20:44442076:44442103:+@chr20:44444180:4
4444384:+@chr20:44444493:44444552:+	   0.65	   0.88	   0.68	   0.91	   0.60	   0.79	   ENSG00000175063	  
UBE2C	  
chr14:102698872:102699045:-­‐
@chr14:102691432:102692745:-­‐
@chr14:102690837:102691131:-­‐	   0.75	   0.63	   0.70	   0.58	   0.57	   0.46	  
ENSG00000080823	  
MOK	  
chr10:79796952:79797062:+@chr10:79799962:7
9799983:+@chr10:79800373:79800473:+	   0.96	   0.79	   0.89	   0.62	   0.80	   0.58	   ENSG00000138326	  
RPS24	  
chr5:131705401:131706057:+@chr5:131714070:
131719993:+@chr5:131721020:131721191:+	   0.75	   0.59	   0.57	   0.42	   0.40	   0.30	   ENSG00000197375	  
SLC22A5	  
chr20:50418818:50419048:-­‐
@chr20:50407872:50408891:-­‐
@chr20:50405400:50405680:-­‐	   0.62	   0.73	   0.59	   0.75	   0.61	   0.73	  
ENSG00000101115	  
SALL4	  
chr13:50007454:50007529:-­‐
@chr13:49975269:49975406:-­‐
@chr13:49956936:49957077:-­‐	   0.65	   0.46	   0.51	   0.32	   0.40	   0.17	  
ENSG00000102547	  
CAB39L	  
chr14:100842597:100842680:-­‐
@chr14:100841620:100841743:-­‐
@chr14:100835424:100835595:-­‐	   0.41	   0.28	   0.61	   0.41	   0.68	   0.40	  
ENSG00000140105	  
WARS	  
chr4:338124:338219:+@chr4:366453:366796:+
@chr4:376884:377760:+	   0.81	   0.67	   0.75	   0.65	   0.59	   0.41	   ENSG00000131127	  
ZNF141	  
chr14:73753818:73754022:-­‐
@chr14:73749067:73749213:-­‐
@chr14:73741918:73744001:-­‐	   0.80	   0.52	   0.89	   0.69	   0.67	   0.49	  
ENSG00000133961	  
NUMB	  
chr2:63206323:63206470:+@chr2:63215066:632
15173:+@chr2:63217851:63217975:+	   0.26	   0.54	   0.31	   0.63	   0.22	   0.40	   ENSG00000115504	  
EHBP1	  
chr10:70287003:70287280:-­‐
@chr10:70276841:70277022:-­‐
@chr10:70276508:70276600:-­‐	   0.23	   0.47	   0.42	   0.53	   0.33	   0.53	  
ENSG00000122912	  
SLC25A16	  
chrX:108939373:108939425:-­‐
@chrX:108928656:108928673:-­‐
@chrX:108926365:108926895:-­‐	   0.24	   0.36	   0.15	   0.33	   0.37	   0.26	  
ENSG00000068366	  
ACSL4	  
chr15:44673004:44673174:+@chr15:44695085:4
4695252:+@chr15:44705534:44707959:+	   0.54	   0.42	   0.54	   0.42	   0.53	   0.39	   ENSG00000166734	  
CASC4	  
chr10:12191851:12191960:+@chr10:12197777:1
2197930:+@chr10:12198906:12199066:+	   0.39	   0.61	   0.45	   0.61	   0.48	   0.65	   ENSG00000065665	  
SEC61A2	  
chr1:143910078:143910155:-­‐
@chr1:143906012:143906136:-­‐
@chr1:143896452:143897641:-­‐	   0.57	   0.72	   0.61	   0.79	   0.46	   0.62	  
ENSG00000215784	  
FAM72D	  
chr20:50418818:50419048:-­‐
@chr20:50406561:50408891:-­‐
@chr20:50405400:50405680:-­‐	   0.68	   0.81	   0.66	   0.82	   0.67	   0.79	  
ENSG00000101115	  
SALL4	  
chr3:98241386:98241910:-­‐
@chr3:98240497:98240547:-­‐
@chr3:98239977:98240286:-­‐	   0.12	   0.28	   0.13	   0.32	   0.38	   0.50	  
ENSG00000080822,
ENSG00000080819	  
CLDND1	  
chr9:21994820:21995300:-­‐
@chr9:21993881:21994067:-­‐
@chr9:21970901:21971207:-­‐	   0.38	   0.28	   0.34	   0.19	   0.36	   0.23	  
ENSG00000147889	  
CDKN2A	  
chr8:95479633:95479783:-­‐
@chr8:95470496:95470664:-­‐
@chr8:95423349:95423543:-­‐	   0.70	   0.86	   0.65	   0.87	   0.55	   0.68	  
ENSG00000197275	  
RAD54B	  
chr1:78958357:78959226:+@chr1:78963559:789
63629:+@chr1:79002091:79006386:+	   0.11	   0.30	   0.15	   0.34	   0.39	   0.20	   ENSG00000122420	  
PTGFR	  
chr6:30294131:30294927:-­‐
@chr6:30282046:30282259:-­‐
@chr6:30263909:30264014:-­‐	   0.58	   0.69	   0.44	   0.66	   0.43	   0.53	  
ENSG00000231074	  
HCG18	  
chr8:67579787:67579936:+@chr8:67589877:675
90189:+@chr8:67591956:67592259:+	   0.44	   0.59	   0.43	   0.61	   0.48	   0.62	   ENSG00000213865	  
C8orf44	  
chr4:56749989:56750094:+@chr4:56755054:567
55098:+@chr4:56756389:56756552:+	   0.41	   0.74	   0.14	   0.61	   0.34	   0.51	   ENSG00000090989	  
EXOC1	  
chr17:62747925:62748074:-­‐
0.30	   0.14	   0.34	   0.11	   0.27	   0.16	   ENSG00000215769	  
hsa-­‐mir-­‐
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@chr17:62746712:62746841:-­‐
@chr17:62745780:62746126:-­‐	  
6080	  
chr7:102185153:102185223:-­‐
@chr7:102183972:102184108:-­‐
@chr7:102181948:102182109:-­‐	   0.71	   0.83	   0.79	   0.94	   0.68	   0.78	  
ENSG00000168255,
ENSG00000228049	  
POLR2J3	  
chr20:44463598:44463755:+@chr20:44469087:4
4469097:+@chr20:44469278:44471914:+	   0.40	   0.23	   0.36	   0.25	   0.40	   0.28	   ENSG00000124104	  
SNX21	  
chr14:50116983:50117159:-­‐
@chr14:50114011:50114078:-­‐
@chr14:50110270:50110388:-­‐	   0.71	   0.83	   0.68	   0.85	   0.70	   0.82	  
ENSG00000100479	  
POLE2	  
chr3:12330436:12330633:+@chr3:12353879:123
53952:+@chr3:12421203:12421430:+	   0.92	   0.70	   0.93	   0.77	   0.69	   0.80	   ENSG00000132170	  
PPARG	  
chr5:122181160:122181388:+@chr5:122189369:
122189462:+@chr5:122272429:122272512:+	   0.31	   0.20	   0.19	   0.33	   0.39	   0.28	   ENSG00000064652	  
SNX24	  
chr9:19336268:19336412:+@chr9:19336684:193
36830:+@chr9:19340990:19341112:+	   0.67	   0.82	   0.64	   0.79	   0.59	   0.74	   ENSG00000137145	  
DENND4C	  
chr14:100842597:100842680:-­‐
@chr14:100841620:100841883:-­‐
@chr14:100835424:100835595:-­‐	   0.30	   0.19	   0.46	   0.28	   0.57	   0.30	  
ENSG00000140105	  
WARS	  
chr11:62623484:62623853:+@chr11:62639049:6
2639141:+@chr11:62648491:62648919:+	   0.49	   0.67	   0.12	   0.48	   0.25	   0.52	   ENSG00000168003	  
SLC3A2	  
chr11:113142482:113142598:+@chr11:1131436
55:113143770:+@chr11:113145989:113149158:
+	   0.05	   0.24	   0.11	   0.24	   0.17	   0.31	  
ENSG00000149294	  
NCAM1	  
chr17:8213556:8213661:+@chr17:8214146:8214
181:+@chr17:8215309:8215958:+	   0.07	   0.17	   0.06	   0.30	   0.40	   0.28	   ENSG00000198844	  
ARHGEF1
5	  
chr22:31495731:31495882:+@chr22:31496871:3
1496939:+@chr22:31500302:31500610:+	   0.76	   0.92	   0.67	   0.91	   0.73	   0.84	  
ENSG00000183963,
ENSG00000100330	  
SMTN	  
chr7:102185153:102185223:-­‐
@chr7:102183972:102184149:-­‐
@chr7:102181948:102182109:-­‐	   0.72	   0.84	   0.79	   0.94	   0.67	   0.79	  
ENSG00000168255,
ENSG00000228049	  
POLR2J3	  
chr8:26721604:26722922:-­‐
@chr8:26627798:26628183:-­‐
@chr8:26605667:26606265:-­‐	   0.82	   0.59	   0.83	   0.60	   0.94	   0.78	  
ENSG00000120907	  
ADRA1A	  
chr1:53387225:53387591:-­‐
@chr1:53379567:53379767:-­‐
@chr1:53377395:53377462:-­‐	   0.72	   0.59	   0.51	   0.66	   0.20	   0.38	  
ENSG00000121310	  
ECHDC2	  
chr6:138768138:138768330:-­‐
@chr6:138763120:138763251:-­‐
@chr6:138751530:138754817:-­‐	   0.22	   0.47	   0.24	   0.36	   0.40	   0.54	  
ENSG00000135540	  
NHSL1	  
chr5:148619322:148619451:+@chr5:148622054:
148622101:+@chr5:148624444:148624578:+	   0.69	   0.49	   0.77	   0.56	   0.75	   0.61	   ENSG00000173210	  
ABLIM3	  
chr1:9801152:9801314:-­‐
@chr1:9797556:9797612:-­‐
@chr1:9795943:9796100:-­‐	   0.51	   0.19	   0.45	   0.34	   0.51	   0.36	  
ENSG00000171603	  
CLSTN1	  
chr4:88898211:88898249:+@chr4:88901198:889
01278:+@chr4:88901545:88901586:+	   0.75	   0.86	   0.71	   0.89	   0.65	   0.87	   ENSG00000118785	  
SPP1	  
chr3:123452534:123453069:-­‐
@chr3:123451743:123451949:-­‐
@chr3:123444791:123444925:-­‐	   0.69	   0.56	   0.71	   0.51	   0.56	   0.42	  
ENSG00000065534	  
MYLK	  
chr2:173362703:173362828:+@chr2:173366500:
173366629:+@chr2:173368819:173371181:+	   0.69	   0.44	   0.56	   0.74	   0.32	   0.21	   ENSG00000091409	  
ITGA6	  
chr6:33366065:33366164:+@chr6:33368169:333
68291:+@chr6:33371091:33371144:+	   0.34	   0.10	   0.35	   0.13	   0.50	   0.19	   ENSG00000237649	  
KIFC1	  
chrX:154255055:154255215:-­‐
@chrX:154250685:154250771:-­‐
@chrX:154227754:154227875:-­‐	   0.65	   0.40	   0.72	   0.42	   0.55	   0.44	  
ENSG00000185010	  
F8	  
chr7:79088163:79088315:+@chr7:79088723:790
88769:+@chr7:79088852:79096783:+	   0.04	   0.15	   0.04	   0.19	   0.09	   0.28	   ENSG00000234456	  
MAGI2-­‐
AS3	  
chr3:12328867:12329174:+@chr3:12353879:123
53952:+@chr3:12421203:12421430:+	   0.96	   0.74	   0.96	   0.79	   0.72	   0.84	   ENSG00000132170	  
PPARG	  
chr7:102185153:102185223:-­‐
@chr7:102183972:102184144:-­‐
@chr7:102181948:102182109:-­‐	   0.72	   0.84	   0.78	   0.94	   0.68	   0.78	  
ENSG00000168255,
ENSG00000228049	  
POLR2J3	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chr15:91512754:91512853:-­‐
@chr15:91512309:91512350:-­‐
@chr15:91509280:91509883:-­‐	   0.19	   0.04	   0.21	   0.04	   0.39	   0.11	  
ENSG00000198901	  
PRC1	  
chr1:2433551:2433848:+@chr1:2435056:243508
2:+@chr1:2435361:2436964:+	   0.24	   0.40	   0.39	   0.19	   0.48	   0.34	   ENSG00000149527	  
PLCH2	  
chr3:37396592:37396678:+@chr3:37402734:374
02796:+@chr3:37407571:37408370:+	   0.40	   0.71	   0.29	   0.51	   0.43	   0.55	   ENSG00000144674	  
GOLGA4	  
chr12:49580394:49580616:-­‐
@chr12:49580093:49580241:-­‐
@chr12:49578578:49579773:-­‐	   0.92	   0.75	   0.89	   0.67	   0.56	   0.40	  
ENSG00000167552	  
TUBA1A	  
chr1:110213909:110214004:+@chr1:110214095:
110214205:+@chr1:110217369:110217908:+	   0.86	   0.70	   0.86	   0.73	   0.33	   0.52	   ENSG00000213366	  
GSTM2	  
RI	  
	   	   	   	   	   	  
	  
	  
chr2:74686565:74686679:+@chr2:74686770:746
86872:+	   0.48	   0.62	   0.49	   0.69	   0.46	   0.64	   ENSG00000239779	  
WBP1	  
chr21:45751897:45751726:-­‐
@chr21:45750799:45750346:-­‐	   0.39	   0.50	   0.34	   0.49	   0.16	   0.26	   ENSG00000160226	  
C21orf2	  
chr3:132298402:132298336:-­‐
@chr3:132297725:132297640:-­‐	   0.43	   0.53	   0.45	   0.62	   0.09	   0.25	   ENSG00000240303	  
ACAD11	  
chr1:28907158:28907072:-­‐
@chr1:28906493:28906045:-­‐	   0.39	   0.25	   0.50	   0.32	   0.43	   0.31	   ENSG00000197989	  
SNHG12	  
chr19:10446652:10446347:-­‐
@chr19:10446029:10445742:-­‐	   0.20	   0.40	   0.07	   0.22	   0.11	   0.38	   ENSG00000076662	  
ICAM3	  
chr9:139753661:139753769:+@chr9:139754338:
139754516:+	   0.12	   0.32	   0.25	   0.45	   0.04	   0.16	   ENSG00000177943	  
MAMDC4	  
chr2:74686565:74686689:+@chr2:74686770:746
86872:+	   0.35	   0.52	   0.38	   0.62	   0.39	   0.55	   ENSG00000239779	  
WBP1	  
chr3:52005908:52005828:-­‐
@chr3:52005714:52005476:-­‐	   0.28	   0.49	   0.32	   0.61	   0.18	   0.33	   ENSG00000114779	  
ABHD14B	  
chr1:161146896:161146702:-­‐
@chr1:161146369:161146224:-­‐	   0.55	   0.31	   0.48	   0.37	   0.53	   0.34	   ENSG00000158850	  
B4GALT3	  
chr1:28907158:28906937:-­‐
@chr1:28906493:28906045:-­‐	   0.58	   0.43	   0.66	   0.53	   0.63	   0.46	   ENSG00000197989	  
SNHG12	  
A3SS	  
	   	   	   	   	   	  
	  
	  
chr8:67364188:67364340:+@chr8:67365945|67
366294:67366392:+	   0.29	   0.50	   0.38	   0.64	   0.11	   0.28	   ENSG00000147576	  
ADHFE1	  
chr16:1843638:1843734:-­‐
@chr16:1842402|1842516:1840414:-­‐	   0.39	   0.27	   0.18	   0.39	   0.02	   0.14	   ENSG00000099769	  
IGFALS	  
chr19:19144419:19144822:+@chr19:19153520|
19153525:19153686:+	   0.67	   0.78	   0.66	   0.81	   0.59	   0.70	   ENSG00000105676	  
ARMC6	  
chr12:53343499:53343608:-­‐
@chr12:53343362|53343369:53343240:-­‐	   0.60	   0.75	   0.71	   0.57	   0.76	   0.64	   ENSG00000170421	  
KRT8	  
chr17:27045140:27045286:-­‐
@chr17:27044611|27044665:27044231:-­‐	   0.51	   0.62	   0.50	   0.64	   0.53	   0.67	   ENSG00000109113	  
RAB34	  
chr6:44095376:44095415:+@chr6:44102157|44
102298:44102480:+	   0.31	   0.17	   0.08	   0.19	   0.28	   0.16	   ENSG00000137216	  
TMEM63B	  
chr2:74685527:74685798:+@chr2:74686565|74
686605:74686689:+	   0.52	   0.40	   0.46	   0.29	   0.36	   0.24	  
ENSG00000115274,
ENSG00000239779	  
INO80B	  
chr1:63872733:63872797:+@chr1:63876811|63
876817:63877002:+	   0.22	   0.11	   0.31	   0.19	   0.38	   0.21	   ENSG00000088035	  
ALG6	  
chr16:3024001:3024158:-­‐
@chr16:3023216|3023254:3023139:-­‐	   0.41	   0.19	   0.44	   0.16	   0.45	   0.24	   ENSG00000127564	  
PKMYT1	  
chr16:3024001:3024158:-­‐
@chr16:3023216|3023446:3023139:-­‐	   0.81	   0.67	   0.81	   0.54	   0.76	   0.62	   ENSG00000127564	  
PKMYT1	  
chr12:49580394:49580616:-­‐
@chr12:49580197|49580241:49580093:-­‐	   0.99	   0.85	   0.97	   0.52	   0.56	   0.44	   ENSG00000167552	  
TUBA1A	  
chr3:136676707:136677043:+@chr3:136699173
|136699308:136699434:+	   0.34	   0.44	   0.39	   0.23	   0.29	   0.41	   ENSG00000174564	  
IL20RB	  
chr9:137717638:137717750:+@chr9:137721822
|137721954:137722022:+	   0.42	   0.64	   0.43	   0.71	   0.46	   0.59	   ENSG00000130635	  
COL5A1	  
chr17:27045140:27045286:-­‐
@chr17:27044611|27044638:27044231:-­‐	   0.45	   0.56	   0.48	   0.63	   0.49	   0.62	   ENSG00000109113	  
RAB34	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chr7:100488790:100488959:-­‐
@chr7:100487956|100488709:100487615:-­‐	   0.43	   0.60	   0.39	   0.52	   0.30	   0.47	   ENSG00000087085	  
ACHE	  
A5SS	  
	   	   	   	   	   	  
	  
	  
chr1:169559440:169559385|169559386:-­‐
@chr1:169558090:169558699:-­‐	   0.81	   0.68	   0.89	   0.65	   0.65	   0.55	   ENSG00000174175	  
SELP	  
chr21:44293801:44293661|44293713:-­‐
@chr21:44283550:44283706:-­‐	   0.68	   0.81	   0.72	   0.86	   0.74	   0.85	   ENSG00000160193	  
WDR4	  
chr19:58055951:58055019|58055605:-­‐
@chr19:58053208:58054611:-­‐	   0.43	   0.57	   0.42	   0.55	   0.43	   0.53	  
ENSG00000105132,
ENSG00000251369	  
ZNF550	  
chr17:26925653:26925483|26925528:-­‐
@chr17:26919000:26920084:-­‐	   0.23	   0.06	   0.25	   0.06	   0.25	   0.10	  
ENSG00000076382,
ENSG00000258472	  
SPAG5	  
chr8:124360513:124360423|124360427:-­‐
@chr8:124359332:124359646:-­‐	   0.81	   0.93	   0.76	   0.92	   0.76	   0.87	   ENSG00000156802	  
ATAD2	  
chr12:124812179:124811955|124812093:-­‐
@chr12:124810737:124810916:-­‐	   0.54	   0.78	   0.42	   0.65	   0.64	   0.75	   ENSG00000196498	  
NCOR2	  
chr1:42922173:42922299|42922744:+@chr1:42
922918:42923021:+	   0.28	   0.52	   0.43	   0.65	   0.44	   0.56	   ENSG00000127125	  
PPCS	  
chr16:15802698:15802659|15802660:-­‐
@chr16:15796992:15797980:-­‐	   0.03	   0.33	   0.01	   0.29	   0.29	   0.41	   ENSG00000133392	  
MYH11	  
chr19:38806445:38806357|38806387:-­‐
@chr19:38800045:38800283:-­‐	   0.36	   0.48	   0.45	   0.62	   0.53	   0.79	   ENSG00000167645	  
YIF1B	  
chr9:137721822:137721890|137722022:+@chr9
:137726817:137727050:+	   0.18	   0.06	   0.17	   0.05	   0.21	   0.09	   ENSG00000130635	  
COL5A1	  
chr12:4665519:4665668|4665716:+@chr12:466
8023:4669213:+	   0.18	   0.07	   0.16	   0.06	   0.30	   0.14	   ENSG00000111247	  
RAD51AP
1	  
chr6:34204650:34204738|34204740:+@chr6:34
208514:34208659:+	   0.54	   0.69	   0.62	   0.92	   0.49	   0.67	   ENSG00000137309	  
HMGA1	  
chr16:1733510:1733593|1733621:+@chr16:173
5440:1735588:+	   0.21	   0.09	   0.30	   0.14	   0.32	   0.21	  
ENSG00000206053,
ENSG00000261732	  
HN1L	  
chr16:16315688:16315470|16315506:-­‐
@chr16:16313679:16313804:-­‐	   0.46	   0.59	   0.43	   0.58	   0.19	   0.40	   ENSG00000091262	  
ABCC6	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Table S 3.2 MCODE Cluster Results of corresponding proteins of cancer-specific AS  
Cluster	   Score	  (Density*#Nodes)	  Nodes	  Edges	   Node	  IDs	  
1	   9.28	   26	   116	  
POLE2,	  MYLK,	  LMNB1,	  FN1,	  CDCA8,	  ORC6L,	  RAD51AP1,	  SPAG5,	  PRC1,	  
UBE2C,	  TUBA1A,	  CDKN2A,	  ESPL1,	  OIP5,	  AURKB,	  PKMYT1,	  TRIM59,	  
MPHOSPH9,	  BIRC5,	  RAD54B,	  ATAD2,	  RECQL4,	  CDCA5,	  INCENP,	  RELN,	  
KIFC1	  
2	   4	   14	   26	   FN1,	  SELP,	  ICAM3,	  KRT8,	  SPP1,	  COL5A1,	  COL6A3,	  CD44,	  NCAM1,	  CDKN2A,	  SLC3A2,	  RELN,	  ANXA2,	  ITGA6	  
3	   4	   10	   18	   HMGA1,	  PPARG,	  INSR,	  FN1,	  PTPN1,	  PPRC1,	  THRB,	  NCOR2,	  IRS1,	  ANXA2	  
  
*Parameters:  
Network Scoring: 
Include Loops: false 
Degree Cutoff: 2 
Cluster Finding: 
Node Score Cutoff: 0.2 
Haircut: false   
Fluff: true   
Fluff Density Cutoff: 0.1    
K-Core: 2   
Max. Depth from Seed: 100  
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Table S 3.3 MCODE Cluster Results of proteins that are highly correlated with the cancer-
specific AS  
Cluster	   Score	  (Density*#Nodes)	  Nodes	  Edges	   Node	  IDs	  
1	   32	   32	   496	  
CENPO,	  SPC25,	  NDC80,	  AURKB,	  CENPH,	  MLF1IP,	  ERCC6L,	  CENPE,	  SPC24,	  
BUB1B,	  ZWILCH,	  ZWINT,	  CENPK,	  CENPL,	  KIF18A,	  SGOL2,	  BIRC5,	  NUF2,	  
BUB1,	  CENPA,	  SGOL1,	  SKA1,	  INCENP,	  CDCA8,	  KIF2C,	  CDC20,	  CENPN,	  CASC5,	  
CENPI,	  CENPM,	  PLK1,	  CENPF	  
2	   13.529	   18	   115	   MCM6,	  CLSPN,	  CDT1,	  POLE2,	  POLA2,	  MCM10,	  CDC6,	  PRIM2,	  MCM4,	  DBF4,	  MCM7,	  CDC45,	  ORC1L,	  CDC7,	  ORC6L,	  CHEK1,	  CCNB1,	  MCM2	  
3	   5	   5	   10	   CCNE1,	  TYMS,	  E2F1,	  PCNA,	  RRM2	  
4	   5	   5	   10	   UBE2T,	  FANCA,	  FANCB,	  FANCD2,	  FANCI	  
5	   4	   4	   6	   KIF4A,	  SKA3,	  AURKA,	  PRC1	  
6	   4	   4	   6	   NCAPG,	  NCAPH,	  NCAPD2,	  SMC4	  
7	   3	   3	   3	   HJURP,	  OIP5,	  RUVBL1	  
8	   3	   3	   3	   UBE2C,	  PSMD2,	  PTTG1	  
9	   3	   3	   3	   RFC4,	  TIMELESS,	  RFC2	  
10	   3	   7	   9	   MND1,	  CDK1,	  RAD51,	  PKMYT1,	  CDC25A,	  CDK4,	  CCNE2	  
11	   3	   3	   3	   POLR2H,	  SNRPA1,	  HNRNPL	  
  
*Parameters: 
Network Scoring: 
Include Loops: false 
Degree Cutoff: 2 
Cluster Finding: 
Node Score Cutoff: 0.2 
Haircut: true   
Fluff: false   
K-Core: 2   
Max. Depth from Seed: 100 
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CHAPTER 4  
 
 
GLOBAL INTRON RETENTION IN HUMAN KIDNEY TUMORS CORRELATES 
WITH PATIENT SURVIVAL3  
 
4.1 Overview 
The identification of molecular traits that drive clinical outcomes is critical to a complete 
understanding of cancer and the development of effective therapeutics. Gene regulatory networks 
are well-established predictors of patient survival and drug response. However, most current 
analyses have focused almost exclusively on examining mRNA levels, making it unclear if other 
gene regulatory mechanisms like alternative splicing (AS) are clinically informative molecular 
traits. We carried out a comprehensive analysis of the clear-cell renal carcinoma (ccRCC) 
transcriptome and uncovered widespread changes in alternative splicing. A significant increase 
in global intron retention in tumor vs. matched normal kidney emerged as the predominant 
abnormality. Variability in global intron retention levels was observed across tumors, that is, 
some tumors generally splice out introns better than others. We define a novel class of renal 
tumors based on global intron retention (IR-class). While the IR-class does not associated with 
known genetic alterations, they do correlate with previously identified kidney cancer subtypes, 
have significantly shorter overall survival and exhibit high expression of non-coding RNAs and 
                                                
3 This work is currently under preparation as a manuscript to the Cancer Research journal.  
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key splicing regulators. Further analysis revealed that intron retention-based classifications are 
specific to kidney cancers and not other tumor types. This work demonstrates that intron 
retention patterns are molecular traits with predictive power in kidney tissues, and that these 
tumors have co-opted the splicing landscape to alter pathways that provide an advantage to 
tumors. 
 
4.2 Introduction 
Generally, the choice of splice sites within a pre-mRNA is regulated by cis-acting 
sequence elements that interact with trans-acting protein factors that promote or inhibit 
recruitment of the splicing machinery. This process is tightly regulated during development, 
differentiation, circadian rhythms, and varies dramatically across different tissues [10, 11]. Mis-
regulated AS has been observed in wide range of human cancers [14, 15, 128], however the 
consequence on patient survival and tumor biology remains unclear. Known drivers of these AS 
alterations include changes in the expression level of specific splicing factors including the 
proto-oncogene SRSF1 or the tumor suppressor RBM4, which promote or inhibit a “cancer 
state” via splicing regulation [46, 49]. While some tumors harbor genetic alterations in splicing 
factors like U2AF and SF3B [129-132], these mutations account for only a small fraction of 
genetic alterations across tumors, whereas emerging evidence suggests that many tumors have 
altered splicing.  
ccRCC is the most prevalent type of kidney cancer, and is considered a heterogeneous 
disease with incompletely understood molecular pathogenesis. Genetic alterations in 
chromosome 3p leading to bi-allelic loss of VHL are the most common feature of ccRCC [133, 
134]. Secondary alterations in SETD2, PBRM1 and BAP1 have also emerged as frequent 
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recurrent mutations which reside in the same genetic locus [135-137]. These proteins, as well as 
general chromatin features, have been implicated in splicing regulation [138]. Previous, studies 
have shown a correlation between SETD2 loss and aberrant splicing in tumors and cell lines with 
defects in intron retention being the most affected [138]. Furthermore, mutations in various 
splicing factors were identified in ccRCC by whole genome sequencing [134], however their 
consequence on the splicing landscape is not known. Together these data suggest that mis-
regulation of AS in ccRCC could be an alteration underlying its pathogenesis. Here we report 
widespread alterations of AS in ccRCC and define a class of tumors with high global intron 
retention (IR-class). These intron-based classifications appear to be specific to ccRCC, and not 
other tumor types including breast, lung and liver cancers.  
 
4.3 Results 
4.3.1 Intron retention is widespread in kidney tumors 
Through analysis in the previous chapter (3.3.9), we noticed that kidney cancer has a 
widespread splicing mis-regulation, especially in the intron retention category. A thorough 
transcriptome analysis was then applied to the ccRCC (i.e. KIRC in the TCGA data). About five 
hundred kidney tumors and 72 normal paired samples were analyzed by the MISO pipeline to 
measure the skipped exons (SE), retained introns (RI), alternative 3’ (A3SS) and 5’splice sites 
(A5SS) [122] (See 3.5.1 for details). In total over 15,000 splicing events were analyzed. Over a 
thousand events were altered between normal and tumor tissues (Figure 3.7). The most striking 
splicing change was a statistically significant increase in about 2/3 retained introns analyzed. To 
make sure this phenomenon is specific to retained introns and kidney cancer only, we compared 
the results with the other three types of splicing and other types of cancer. We did not see the 
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significant increase or decrease in other types of splicing (i.e. they changed in both directions, 
both inclusion and skipping of exons. Figure 4.1A). We also compared it with breast and lung 
cancer and found no significant increase in retained intron in these two types of cancer (Figure 
4.1B). We also examined the levels of global intron retention in non-transformed normal kidney 
and compared this to tumor kidney and found kidney cancer showed much higher variability in 
intron retention compared to the normal kidney (Figure 4.1C), indicating that the widespread 
intron retention may be a feature of kidney tumors.  
4.3.2 Some kidney tumors express significant more retained introns than the others 
Remarkably, we noted that some tumors exhibited pervasive intron retention, meaning 
many detected introns in single tumor were co-retained. To further examine such common intron 
retentions in some kidney tumors, we stratified tumors by calculating a retention score, which is 
the mean PSI value of all 3190 detected introns. Based on the retention scores, 124 cases (top 
quartile) were defined as having high intron retentions and 373 cases were defined as having 
normal intron retentions (within the distribution of normal kidney retention scores). We refer 
them as HIR (High Intron Retention) and NIR (Normal Intron Retention) classes, respectively 
(Figure 4.2A). We also classified all detected retained intron events into four subgroups using 
correlation analysis. For every RI event, we calculated a Spearman’s rank correlation between its 
PSI values and the average PSI values across all tumors (Figure 4.2A, right color bar). We 
identified a set of 858 retained introns that were highly co-regulated across tumors (Spearman’s 
ρ >.75), while only a small fraction (30%) of introns showed little or no co-regulation 
(Spearman’s | ρ | < 0.2). We also found that the length of the introns of those highly co-regulated 
events are longer than those of events with low or no correlation (P = 2e-16 and 7e-14 when 
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comparing ‘high positive’ to ‘positive’ and ‘high positive’ to ‘no correlation’ respectively, 
Figure 4.2B), consistent with the fact that longer introns are generally more retained [139].  
Furthermore, genes harboring these highly co-regulated introns were highly enriched for 
RNA processing and protein degradation functions (Figure 4.2C) when we conducted a 
functional enrichment analysis by he DAVID annotation tool (http://david.abcc.ncifcrf.gov/) 
[74]. This may imply a non-random selection of these genes. 
To further identify putative SREs that may control these highly co-regulated introns, we 
examined their regulatory regions to measure whether there are enriched sequence motifs that 
could be potentially recognized by known splicing factors (Figure 4.2D). We found that motifs 
that have been previously shown to regulate splicing from an intronic position were identified in 
these co-regulated introns. These include a CTTC motif, which is similar to the previously 
published intronic splicing silencer (ISS group C) [20] as well as a G-rich motif, which is similar 
to the intronic splicing enhancer (ISE group D) [21].  
4.3.3 High intron retention is not correlated with any known mutations, but correlated with 
a recently defined subclass in kidney cancer and expression levels of some genes 
To determine if any of the common mutations found in kidney cancer correlated with 
intron retention levels, we then analyzed prevalence of specific mutations in the HIR class 
including VHL, PBRM1, SETD2, KDM5C, BAP1, PTEN, MTOR, TP53 and PIK3CA (Figure 
4.3A). Surprisingly no specific mutations correlated with a global increase in intron retention as 
the percentage of the observed HIR classes with these mutations are similar to what is expected 
(Figure 4.3B). This indicates that the major drivers of these phenotypes may be related to gene 
expression changes. Kidney tumors were previously classified as M1-M4 class using mRNA 
expression, with the M2 and M3 being the most aggressive tumor subtype [140]. Our HIR class 
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is mostly composed of the M2 tumors (~60%) and it is significant more than expected (Figure 
4.3C, P =0.0001), while the NIR class is comprised of the M1-M3 classes. These data indicate 
that, widespread changes in the mRNA expression may drive the retention phenotype.  
Furthermore, when comparing gene expression differences between the HIR and NIR 
class, we identified 388 transcripts that are expressed at significantly higher levels in the HIR 
class (cutoff of P < 9.0e-5 and greater than 2-fold expression change, Figure 4.3A bottom). Some 
regulators of AS, including the CLK1 kinase, which has been shown to regulate intron retention, 
was found within these differentially expressed genes (Figure 4.3D). Interestingly, a significant 
increase in some long non-coding RNAs (lncRNAs), such as MALAT1 (P < 4.2e-48) and NEAT1 
(P < 1.9e-53) was also observed in the HIR class (Figure 4.3D). Some reports have indicated that 
MALAT1 may regulate alternative splicing and cell cycle control, while other studies have 
shown no difference in the splicing of exons. HIR tumors represent a highly specific context 
wherein these lncRNAs may be promoting tumorigenesis through alternative splicing.  
Finally, when we look at the overlap between the genes whose expression levels altered 
between HIR and NIR (388 genes) and genes containing the highly co-regulated introns (588 
genes), there were only 26 genes overlaps (Figure 4.3E). This indicates that in kidney cancer, 
aberrant gene regulation via mRNA levels and splicing are affecting nearly mutually exclusive 
genes sets. This mutual exclusivity is an emerging theme in various biological settings including 
disease states. 
4.3.4 Intron retention in kidney cancer is highly correlated with patient survival 
Given the substantial increase of global intron retention in these tumors we determined if 
these changes would bear any significance on patient survival. Strikingly, we found that HIR 
tumors had a significantly shorter median overall survival as compared to NIR tumors (Figure 
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4.4A, P=0.0004). To the best of our knowledge this is the first analysis of patient survival based 
on global splicing patterns. These data are also consistent with tumors of M2 class being most 
aggressive. However, even when this analysis was carried out with HIR tumors that were not of 
the M2 class, a significant survival difference was still observed, indicating that HIR represents a 
new molecular classification. Furthermore, no such difference in survival was seen in other 
tumor types when the same classifications based on intron retention were attempted in liver, lung 
and breast cancers (Figure 4.4B-D). 
Genes whose expression levels can predict patient survival in kidney have been 
previously published [140]. We set out to perform a similar analysis using splicing PSI values for 
over 40,000 splicing events using the same RNA-sequencing data from the same tumors (Figure 
4.4E). We identified over 1,100 (P <0.005 and FDR = 5) splicing events whose pattern was 
predictive of patient survival in kidney tumors, the majority of these events were retained introns 
(898 total events), but cassette exons and alternative 5’ and 3’ splice sites were also identified 
(Figure 4.4F). Given that intron retention is not as common as other alternative splicing types, 
but still emerged as the most powerful and prevalent predictor, is both highly significant (P = 
Fisher’s exact test) and indicative of the role of intron spicing in kidney cancer progression. This 
finding was not seen in breast, lung and liver cancer since only 34, 80 and 40 introns, 
respectively, correlated with patient survival (Figure 4.4G). Consistent with the observation that 
global intron retention leads to poor survival, we found that typically high levels of specific 
introns correlated with poor survival. However, a small set of introns correlated with better 
survival. These data suggest that for some genes less retention is observed in more aggressive 
tumors, albeit at much lower frequency.  
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Intron retention is the least understood form of alternative splicing, but is the one most 
likely to have drastic consequences on mRNA stability and protein production by activation of 
the nonsense mediated decay pathway (NMD), which leads to the degradation of the mRNA 
[99].  
We selected the genes whose retained introns most significantly correlated with median 
survival differences and performed gene ontology analysis (~500 genes) using DAVID online 
tool. The most enriched terms was alternative splicing, atp-binding, mutagenesis and etc. (Figure 
4.4H ). This result provides evidence that mis-spliced genes are not being randomly affected, 
rather they belong to specific classes of genes.   
 
4.4 Discussion 
  Our work marks the first comprehensive analysis of alternative splicing and patient 
survival. We reveal a previously unappreciated layer of mis-regulated gene expression and more 
specifically intron retention. Splicing alterations across human tumors are being increasingly 
uncovered due to the advent RNA-sequencing. The Cancer Genome Atlas network has provided 
a powerful resource for the identification of mis-regulated features. Other examples of RNA-
processing defects in tumors have emerged including alternative polyadenalytion and 3’UTR 
usage[141, 142], which is known to affect translation and micro-RNA mediated gene 
suppression. We predict that, RNA processing is equally mis-regulated as are mRNA levels and 
that measurement of specific RNA processing events (i.e. splicing or alternative 
polyadenylation) in human tumors will have predictive value in patient survival and drug 
response. Ultimately, combing alternative splicing, poly-adenylation and RNA abundance will 
help paint a more accurate portrait of the tumor transcriptome that can be used for meaningful 
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tumor classifications. Given that these RNA processing pathways affect mostly non-overlapping 
genes it is likely that combining these types of analysis will significantly increase the number of 
genes that are mis-regulated in cancer. Additionally mis-regulation of lncRNA and mircoRNA 
expression are altered in cancer [143-145], putting forth the possibility that most of the 
transcribed genome is altered in some fashion in human cancers.    
 
4.5 Materials and Methods 
4.5.1 Kidney tumor classification using retention score and splicing event correlation 
analysis 
For every tumor sample we calculated its retention score by taking the average PSI values 
of all detected RI events (3190 events in KIRC). Therefore, the higher the retention score, the 
more retained introns it has. We also used the same method to compute the retention score for 
other types of cancer for analysis. 
Correlations between all detected RI events and the average PSI values were calculated 
using spearman rank correlation. Each of the 3190 detected RI events has a vector of PSI values 
among all kidney tumors. Another vector is composed of the average PSI values (retention score 
mentioned above) among all kidney tumors. We computed the spearman rank correlation, ρ 
(rho), between these two vectors and repeated this procedure for every detected RI events. RI 
events with ρ ≥ 0.75 were classified as “high positive”, events with 0.4 ≤ ρ < 0.75 were classified 
as “positive”, events with 0.2 ≤ ρ < 0.4 were classified as “weak positive”, and the rest, ρ < 0.2, 
were classified as “no correlation or negative”. 
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4.5.2 Motif enrichment analysis 
To analyze the enriched sequence motifs near the splice sites of the 868 high positive 
correlated retained intron events, we first obtained nucleotide sequences from two splicing 
regulatory regions: upstream intron (300 bp downstream the 5’SS) and downstream intron (300 
bp upstream the 3’SS) as shown in Figure 4.2D. When obtaining the sequences, we excluded the 
first 10 nucleotides right downstream of the upstream exon and the first 25 nucleotides right 
upstream of the downstream exon because these regions overlap with the splice signal motifs. 
We then calculated the frequency and Z-score of all 6-nt “words” near the splice sites of the 868 
high positive correlated retained introns in two regulatory regions using methods described in 
[127]. All 6-mers with Z-score larger than 3 were then clustered by sequence similarity and 
multiply aligned by using CLUSTALW to identify candidate motifs. At a cutoff dissimilarity 
score of 2.5, we obtained 6 and 5 clusters of at least five sequences in each cluster for upstream 
intron and downstream intron respectively. Finally, we plotted the consensus sequence for each 
cluster for the two regulatory regions (Figure 4.2D). 
4.5.3 Survival analysis for kidney, liver, lung and breast cancer patients. 
We obtained the overall survival data of cancer patients from the UCSC Cancer Browser 
for all four types of cancer. For figure 4.4A-D, the patient samples were split into two groups 
according to their retention scores (see method 4.5.1): HIR (above the third quartile) and NIR 
(below the third quartile). The resulted two patient groups were compared for their probability of 
survival using a Kaplan-Meier survival analysis and the log rank P values were calculated. This 
process was repeated for all four types of cancer. For figure 4.4E-G, samples were separated into 
two groups according to each event’s PSI value: high PSI (above the third quartile) and low PSI 
(below the third quartile). Then we tested if there is a significant difference of their probability of 
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survival between the two groups using the Kaplan-Meier survival analysis and the log rank P 
values were calculated. It the log rank P < 0.005, we considered the event has potential 
prediction power for patients survival. We repeated this procedure for all four types of splicing 
event in kidney cancer and for all RI events in other types of cancer. 
In the parameter setting, if a patient deceased (event happened), the “days_to_death” was 
used as the time variable; if a patient is still living, the time variable is the maximum of 
“days_to_last_known_alive” and “days_to_last_followup”.  
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Figure 4.1 Comparing AS variability among normal vs. tumor in KIRC and other cancers. 
(A) Boxplots of average PSI values of all AS events between normal (blue) vs. tumor (red) in 
kidney cancer in four different types of AS. Each circle represents a sample and its average psi 
value across all AS events minus the median of the average PSI values in normal KIRC. The 
insert shows the average PSI distribution of RIs shift between normal samples (blue) and tumor 
samples (red). (B) Boxplots of average PSI values of all RI events between normal (blue) vs. 
tumor (red) in breast, liver and kidney cancer. Each circle represents a sample and its average psi 
value across all retained intron events minus the median of the average psi values in normal 
tissue. (C) Boxplots of standard deviation of PSIs among all detected RIs in kidney tumors (red 
box) and in normal kidney tissues (white box)  
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Figure 4.2 Intron retention is widespread in kidney cancers 
(A) Heatmap of PSI values of the 3190 retained intron events in 497 kidney cancer samples (Red 
to blue: high to low; the value was subtracted by the mean and normalized to the row standard 
deviation). The average psi values across 3190 events in each sample were plotted on top of the 
heatmap. Tumors were sorted by their retention score (i.e. average PSI value) in columns (from 
left to right: lower score to higher score) and the top quartile was classified as HIR class and the 
rest were NIR class. Retained intron events was sorted by their correlation to the average PSI in 
rows (from top to bottom: higher correlation to lower correlation) and they are clustered into four 
groups according to their Spearman's rank correlation coefficient ρ with different color labeled 
on the right. (B) The length distribution of retained introns in the three sub-groups: high positive, 
positive and no correlation or negative (from top to bottom). (C) Enriched gene ontology terms 
of genes containing the 868 high positive correlated retained intron events. (D) Enriched 
sequence motifs near the splice sites of the 868 high positive correlated retained intron events.    
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Figure 4.3 Mutation profiles of kidney cancer in the two defined classes and genes up-
regulated in the HIR class 
(A) Heatmap of PSI values of the 868 highly co-regulated intron retention events in 497 kidney 
tumors (Red to blue: high to low; the value was subtracted by the mean and normalized to the 
row standard deviation). The 497 kidney tumors were grouped into two classes first: NIR (light 
brown) and HIR (darker brown), and then clustered into four subgroups: M1-M4 cancer classes 
(cyan, slateblue, red and gray), and finally sorted by the retention score (from black to white: 
higher to lower score). The frequently mutated genes were labeled in different color boxes 
according to their mutation types in each tumor sample if existing. The bottom heatmaps are 
transcripts that are highly up-regulated in the HIR class. (B) The percentage of observed (grey) 
and expected (black) samples in HIR class with each frequently mutated genes. (C) The 
percentage of samples in HIR class that are classified in M1-M4 classes as observed (grey) and 
as expected (black). (D) Box plot of four example genes that are highly up-regulated in the HIR 
class compared with the NIR class and normal tissue. (E) Venn diagram of the overlapping genes 
among genes containing the highly co-regulated RIs and genes that are highly up-regulated in the 
HIR class. 
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Figure 4.4 Using retention score as a predictor for patient survival 
(A) The kidney tumor samples were separated into two groups according to their retention score: 
HIR and NIR classes. The group with higher score (i.e. more retained intron, HIR class) has 
significant shorter survival (median survival years: 4.45) than the group with lower score (i.e. 
less retained intron, NIR class, median survival years: 7.57) as shown in the Kaplan–Meier plot 
(p-value=0.0004). Same analyses were repeated for liver tumors (B), lung tumors (C) and breast 
tumors (D). (E) The flow chart of identifying potential predictor (i.e. AS event) for patient 
survival. Samples were separated into two groups according to each event’s PSI value: high PSI 
(above the third quartile) and low PSI (below the third quartile). Then we tested if there is a 
significant difference between the two survival curves using the log rank test (p<0.005). (F) We 
repeated this procedure for every splicing event in kidney cancer and plotted the number of 
events with potential prediction power (i.e. significant difference between the two survival 
curves). (G) Same as (F), but repeated in retained intron events in other types of cancer. (H) 
Enriched gene ontology terms of genes containing RI events that are most significantly 
correlated with median survival differences. 
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CHAPTER 5  
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This study was set out to explore RNA binding proteins, alternative splicing, and their 
connection and mis-regulation in cancers. The main findings are chapter specific and we 
summarized them according to the respective chapters below. 
  
5.1 Work summary/Important findings 
In the part 1 of our study (chapter 2), using genome-wide sequence analysis of the 
proteins containing RNA recognition motif (RRM), we have found extensive RRM duplications 
in RNA binding proteins. This unexpected finding suggested a new model for the evolution of 
RNA binding proteins and provided important implications on their function. The analyses of 
various annotated genomes suggest that the number of proteins with canonical RBDs has 
expanded significantly in mammals. In addition, the number of proteins with multiple RNA 
binding domains has also increased. In the study, we seek to study the mechanism and functional 
consequence of such expansion. The novel and important points of this study are: 1) The RRMs 
within same RBP are more similar than what would be expected in random pairs. Such increased 
similarity was maintained even after various shuffles. 2) The sibling RRM pairs have even 
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higher sequence similarity in species-specific RBPs compared to the ancient RBPs shared by 
multiple species. Together these observations suggest an extensive RRM duplication in many 
mammalian proteins. 3) We presented two examples of RRM duplication: a recent RRM 
duplication found only in some primates and an ancient duplication shared from yeast to human. 
4) The RBPs with different similarities between their sibling RRMs belong to distinct functional 
groups. 5) The RBP sequences outside the RNA binding domain are enriched with distinct low 
complexity domains that may be involved in protein interaction. In summary, this comprehensive 
study helps us better understand the evolution of RBPs and its functional implication. 
We then move forward to study alternative splicing in cancer (chapter 3). With a 
systematic analysis of alternative splicing (AS) in cancer using the TCGA data, we have made a 
significant step forward in revealing the identity and function of alternative splicing events 
altered across multiple cancers. Prevalent splicing alteration is one molecular hallmark of cancer. 
However, previous analyses of cancer-associated splicing were focused on specific genes or 
single tumor type, which is often dominated by the noise from tissue specific splicing events. In 
the study we performed a transcriptome-wide splicing comparison between thousands of samples 
in three different cancer types and performed detailed analyses of the function and regulation of 
cancer-specific AS events. The novel and important points of this study are: 1) A core set of 163 
cancer-specific AS events are identified, which is commonly found in multiple cancer types of 
different tissue origins. 2) Genes containing cancer-specific AS events are enriched for functions 
of cell cycle regulation, cell adhesion/migration, and insulin signaling pathway. 3) The cancer-
specific AS events are more conserved and more likely to maintain reading frame to produce 
different protein isoforms with distinct functions. 4) The newly identified splicing events can be 
used as molecular biomarkers to distinguish tumors from normal samples, to separate different 
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cancer subtypes, and to predict cancer survival. 5) The genes whose expression is closely 
associated with cancer-specific AS events are mostly key regulators of cell cycle progression, 
revealing an unknown link between the cell cycle and alternative splicing in cancer. In addition 
to providing a global picture of cancer-specific AS, this comprehensive study helps us to better 
understand the functional consequence of and mechanism of splicing mis-regulation in cancer. 
Through the analysis of 13 cancers, an interesting finding of retained introns in kidney 
cancer was identified, which leads to another extended study in chapter 4. With detailed 
sequence analysis, we found that some kidney tumors harbor a significant more retained introns 
in their mRNA transcripts. When further investigating other types of cancer, we did not find such 
elevation in intron retention, implying the phenomenon is specific to kidney cancer. The novel 
and important points of this work are: 1) Kidney tumors express a global intron retention which 
is specific to kidney cancers. 2) Kidney tumors with increased intron retention are more likely to 
have poor prognosis. We found those tumors have significant overlaps with recently defined 
kidney cancer subtype, M2, which is one of the most aggressive subtypes. 3) There is no clear 
link between such high intron retention and known cancer mutations through our statistical 
analysis. However, high gene expression of some lncRNAs and splicing factors are correlated 
with these elevated retained introns. 4) Intron retention in kidney cancer is highly correlated with 
patient survival, implying that global splicing patterns could be used as a predictor in kidney 
cancer progression. Together we have shown that intron retention patterns are molecular traits 
with predictive power in kidney tissues and that these tumors have adopted the splicing 
landscape to alter pathways that provide an advantage to tumors. 
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5.2 Weaknesses/limitations of the study and future direction 
At this point, we have summarized the most important details and findings from previous 
chapters, and it is necessary to discuss the weakness of our studies and limitations of the 
approaches we used. Additionally, it is important to emphasize and outline the future work that 
needs to be done in extending the research described. The main points are chapter specific and 
we described them according to the respective chapters below. 
5.2.1 Weaknesses/limitations in chapter 2 and future works 
In chapter 2, we found extensive RRM duplications in RBPs, and describe a potential 
model for their evolution. However, our study only covers about half of the RBPs in human. 
Although RRM-containing RBP is the largest group, in terms of protein number, among all 
human RBPs, there are still other RNA binding domains/motifs playing important roles in 
alternative splicing regulation, such as RS domains in serine-arginine (SR) proteins which are 
often the functional sequence interacting with other proteins and K homology (KH) domains in 
hnRNP proteins which can function in RNA recognition. We chose RRM domains because it is 
the most prevalent domain, however it will only make our study more completed when we 
include other RBDs that play important roles in the splicing regulation. 
In the end of chapter 2, we have provided important implications of functional correlation 
of the domain duplication and our results suggest that multiple RRMs allow a protein to bind 
RNA with higher sequence specificity and/or affinity than those RBPs with a single binding 
domain. In the future work, we would like to identify RNA binding targets of the RBPs we are 
interested in (e.g. Splicing factors). Now, with the availability of many crosslinking 
immunoprecipitation (CLIP)-seq data, which have revealed transcriptome-wide binding sites of 
RBPs at the single-nucleotide level. We can use them to identify the RBP binding targets at a 
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high-throughput manner. A recently published work has constructed a public available database, 
CLIPdb, which combines results from about 400 CLIP-seq datasets [146]. We will use data from 
the CLIPdb to explore the potential binding targets of our interested splicing factors.  
5.2.2 Weaknesses/limitations in chapter 3 and future works 
In chapter 3, we used MISO as our splicing annotation tools when analyzing RNA-seq 
data, however there are some limitations in our analyzing pipeline. First, only the annotated 
splicing events included in the MISO annotation database will be identified, those novel splicing 
events in the sample will never been detected. Future work in this part of the study will be trying 
different statistical models to detect differential transcription, which do not depend on a pre-
defined annotation database. For example both FDM [147] and EBseq [148] identify differential 
expressed splicing isorforms in an RNA-seq experiment. Using these methods we expect to 
identify many more novel splicing events that were not included in the MISO annotation 
database in the cancer samples. Secondly, we have analyzed the SE, RI, A3SS and A5SS 
splicing events among the cancer samples, but there are also alternative first exon (AFE), 
alternative last exon (ALE), tandem un-translated region (TandemUTR) and mutually exclusive 
exons (MXE) events that are also important, especially the TandemUTR events that have been 
shown to affect translation in tumor cells [141, 142]. Therefore including those types of splicing 
events in our study can help us identify more potential interesting splicing change in cancers. 
Finally, in our study, we have chose a filtering criteria to identify cancer-specific AS events that 
we think it’s good for the purpose of this study. However there is always no perfect filtering, in 
terms of balancing the sensitivity and specificity. In our results, there are still some known 
splicing events not picked up by our method due to the stringent requirement we have setup. In 
the future work, we will tune our filtering criteria to increase the sensitivity for some low 
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abundant cancer-specific events. 
5.2.3 Weaknesses/limitations in chapter 4 and future works 
In chapter 4, we have shown that intron retentions are widespread in kidney cancer and it 
is highly correlated with patient survival. However we only analyzed kidney tumor RNA-seq 
data with the annotated MISO database which includes only the known retained introns. It is fair 
to speculate that this phenomenon could happen globally in the splicing machinery and many 
other previously undetected introns are also retained in kidney cancer. Future work in this part of 
the study will be focusing on checking whether the intron retentions actually happen more than 
what we have found. In addition, we would like to further investigate the 388 transcripts that are 
highly expressed in the HIR class. We have shown that there are some splicing factors and 
lncRNAs within the highly expressed transcripts. For some of them, we would like to do 
experiments to test the connection between their gene expression level and intron retention rate 
in kidney cancer cell. 
Characterization of cancer splicing and how it is regulated is still far from complete. The 
work we presented here has provided a start point and some clues that how splicing alteration 
link to tumors. Together, our studies advance the understanding of splicing dysregulation in 
cancer in multiple aspects. Though much work will be needed, our works have provided many 
insights for cancer diagnosis and therapy. 
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